Mesoblast Limited (MESO) 20-F30 Aug 232023 FY Annual report (foreign)Financial data

Company Profile

Document and Entity Information

Document and Entity Information	12 Months Ended
Document and Entity Information	Jun. 30, 2023 shares
Document Information [Line Items]
Document Type	20-F
Amendment Flag	false
Document Period End Date	Jun. 30, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	FY
Trading Symbol	MESO
Entity Registrant Name	MESOBLAST LTD
Entity Central Index Key	0001345099
Current Fiscal Year End Date	--06-30
Title of 12(b) Security	American Depositary Shares, each representing five Ordinary Shares
Security Exchange Name	NASDAQ
Entity File Number	001-37626
Entity Incorporation, State or Country Code	C3
Entity Address Address Line1	Level 38
Entity Address Address Line2	55 Collins Street
Entity Address City Or Town	Melbourne
Entity Address Postal Zip Code	3000
Document Annual Report	true
Document Transition Report	false
Document Registration Statement	false
Document Shell Company Report	false
ICFR Auditor Attestation Flag	true
Document Accounting Standard	International Financial Reporting Standards
Entity Address Country	AU
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding	814,204,825
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Interactive Data Current	Yes
Auditor Firm ID	1379
Auditor Name	PricewaterhouseCoopers
Auditor Location	Melbourne, Australia
Document Financial Statement Error Correction [Flag]	false
Business Contact
Document Information [Line Items]
Entity Address Address Line1	Level 38
Entity Address Address Line2	55 Collins Street
Entity Address City Or Town	Melbourne
Entity Address Postal Zip Code	3000
Contact Personnel Name	Silviu Itescu
City Area Code	+61 (3)
Local Phone Number	9639 6036
Contact Personnel Fax Number	+61 (3) 9639 6030
Entity Address Country	AU

Consolidated Income Statement

Consolidated Income Statement - USD ($) $ in Thousands	12 Months Ended
Consolidated Income Statement - USD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Profit or loss [abstract]
Revenue	$ 7,501	$ 10,211	$ 7,434
Research & development	(27,189)	(32,815)	(53,012)
Manufacturing commercialization	(27,733)	(30,757)	(32,719)
Management and administration	(25,374)	(27,210)	(30,867)
Fair value remeasurement of contingent consideration	8,771	913	18,687
Fair value remeasurement of warrant liability	(2,205)	5,896	0
Other operating income and expenses	4,250	(536)	1,561
Finance costs	(20,122)	(17,288)	(10,714)
Loss before income tax	(82,101)	(91,586)	(99,630)
Income tax benefit/(expense)	212	239	819
Loss attributable to the owners of Mesoblast Limited	$ (81,889)	$ (91,347)	$ (98,811)
Losses per share from continuing operations attributable to the ordinary equity holders of the Group:
Basic - losses per share (in dollars per share)	$ (0.1108)	$ (0.1408)	$ (0.1633)
Diluted - losses per share (in dollars per share)	$ (0.1108)	$ (0.1408)	$ (0.1633)

Consolidated Statement of Compr

Consolidated Statement of Comprehensive Income - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Statement of comprehensive income [abstract]
Loss for the period	$ (81,889)	$ (91,347)	$ (98,811)
Items that may be reclassified to profit and loss
Exchange differences on translation of foreign operations	(573)	91	(1,524)
Items that will not be reclassified to profit and loss
Financial assets at fair value through other comprehensive income	(1)	(322)	209
Other comprehensive (loss)/income for the period, net of tax	(574)	(231)	(1,315)
Total comprehensive losses attributable to the owners of Mesoblast Limited	$ (82,463)	$ (91,578)	$ (100,126)

Consolidated Statement of Chang

Consolidated Statement of Changes in Equity - USD ($) $ in Thousands	Total	Issued Capital	Share Option Reserve	Investment Revaluation Reserve	Foreign Currency Translation Reserve	Warrant Reserve	Retained Earnings/ (accumulated losses)
Beginning balance at Jun. 30, 2020	$ 549,326	$ 1,051,450	$ 85,330	$ (429)	$ (38,267)		$ (548,758)
Loss for the period	(98,811)						(98,811)
Other comprehensive income/(loss)	(1,315)			209	(1,524)
Total comprehensive income/(loss) for the period	(100,126)			209	(1,524)		(98,811)
Transactions with owners in their capacity as owners:
Contributions of equity net of transaction costs	106,809	106,809
Transactions with owners in their capacity as owners	106,809	106,809
Tax credited / (debited) to equity	(91)		(91)
Transfer of exercised options		4,894	(4,894)
Fair value of share-based payments	12,510		12,510
Issuance of warrants	12,969					$ 12,969
Increase (decrease) in equity	25,388	4,894	7,525			12,969
Ending balance at Jun. 30, 2021	581,397	1,163,153	92,855	(220)	(39,791)	12,969	(647,569)
Loss for the period	(91,347)						(91,347)
Other comprehensive income/(loss)	(231)			(322)	91
Total comprehensive income/(loss) for the period	(91,578)			(322)	91		(91,347)
Transactions with owners in their capacity as owners:
Contributions of equity net of transaction costs	1,928	1,928
Transactions with owners in their capacity as owners	1,928	1,928
Tax credited / (debited) to equity	(239)		(239)
Transfer of exercised options		228	(228)
Fair value of share-based payments	5,536		5,536
Increase (decrease) in equity	5,297	228	5,069			0
Ending balance at Jun. 30, 2022	497,044	1,165,309	97,924	(542)	(39,700)	12,969	(738,916)
Loss for the period	(81,889)						(81,889)
Other comprehensive income/(loss)	(574)			(1)	(573)
Total comprehensive income/(loss) for the period	(82,463)			(1)	(573)		(81,889)
Transactions with owners in their capacity as owners:
Contributions of equity net of transaction costs	83,814	83,814
Transactions with owners in their capacity as owners	83,814	83,814
Tax credited / (debited) to equity	(212)		(212)
Fair value of share-based payments	3,655		3,655
Increase (decrease) in equity	3,443	0	3,443
Ending balance at Jun. 30, 2023	$ 501,838	$ 1,249,123	$ 101,367	$ (543)	$ (40,273)	$ 12,969	$ (820,805)

Consolidated Balance Sheet

Consolidated Balance Sheet - USD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022
Current Assets
Cash & cash equivalents	$ 71,318	$ 60,447
Trade & other receivables	6,998	4,403
Prepayments	3,342	4,987
Total Current Assets	81,658	69,837
Non-Current Assets
Property, plant and equipment	1,357	2,045
Right-of-use assets	5,134	7,920
Financial assets at fair value through other comprehensive income	1,757	1,758
Other non-current assets	2,326	1,930
Intangible assets	577,183	578,652
Total Non-Current Assets	587,757	592,305
Total Assets	669,415	662,142
Current Liabilities
Trade and other payables	20,145	23,079
Provisions	6,399	17,906
Borrowings	5,952	5,017
Lease liabilities	4,060	3,186
Warrant liability	5,426	2,185
Total Current Liabilities	41,982	51,373
Non-Current Liabilities
Provisions	16,612	12,523
Non-current borrowings	102,811	91,617
Lease liabilities	3,672	7,085
Deferred consideration	2,500	2,500
Total Non-Current Liabilities	125,595	113,725
Total Liabilities	167,577	165,098
Net Assets	501,838	497,044
Equity
Issued Capital	1,249,123	1,165,309
Reserves	73,520	70,651
Accumulated losses	(820,805)	(738,916)
Total Equity	$ 501,838	$ 497,044

Consolidated Statement of Cash

Consolidated Statement of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities
Commercialization revenue received	$ 7,480	$ 9,980	$ 6,121
Government grants and tax incentives received	1,118	24	68
Payments to suppliers and employees (inclusive of goods and services tax)	(72,683)	(75,769)	(106,920)
Interest received	796	7	17
Income taxes received /(paid)	20	(24)	(35)
Net cash (outflows) in operating activities	(63,269)	(65,782)	(100,749)
Cash flows from investing activities
Investment in fixed assets	(264)	(157)	(1,647)
Receipts from investment in sublease	120	0	0
Payments for licenses	(50)	(75)	0
Net cash (outflows) in investing activities	(194)	(232)	(1,647)
Cash flows from financing activities
Proceeds from borrowings	0	51,919	0
Repayment of borrowings	0	(55,458)	0
Payment of transaction costs from borrowings	(574)	(5,527)	(13)
Interest and other costs of finance paid	(6,014)	(6,084)	(5,932)
Proceeds from issue of shares	88,635	209	106,268
Proceeds from issue of warrants	0	8,081	12,969
Payments for share issue costs	(4,889)	(222)	(1,827)
Payments for lease liabilities	(2,656)	(2,788)	(2,931)
Net cash inflows/(outflows) by financing activities	74,502	(9,870)	108,534
Net increase/(decrease) in cash and cash equivalents	11,039	(75,884)	6,138
Cash and cash equivalents at beginning of period	60,447	136,881	129,328
FX (loss)/gain on the translation of foreign bank accounts	(168)	(550)	1,415
Cash and cash equivalents at end of period	$ 71,318	$ 60,447	$ 136,881

Basis of preparation

Basis of preparation	12 Months Ended
Basis of preparation	Jun. 30, 2023
Basis Of Preparation [Abstract]
Basis of preparation	Basis of preparation The general purpose financial statements of Mesoblast Limited and its subsidiaries have been prepared in accordance with International Financial Reporting Standards, as issued by the International Accounting Standards Board and Australian equivalent International Financial Reporting Standards, as issued by the Australian Accounting Standards Board. Mesoblast Limited is a for-profit entity for the purpose of preparing the financial statements. Certain comparative amounts have been reclassified to facilitate comparison to the current period. There was no material impact to the financial statements. The financial statements cover Mesoblast Limited and its subsidiaries. The financial statements were authorized for issue by the board of directors on August 31, 2023. The directors have the power to amend and reissue the financial statements. (i) Going concern The Group has continued its focus on maintaining tight control of net cash usage for operating activities, which was $63.3 million for the year ended June 30, 2023. As of June 30, 2023, the Group held total cash reserves of $71.3 million. The Group is implementing various cost containment and deferment strategies, including the reprioritization of projects and operational streamlining to manage net operating cash usage. In August 2023, the FDA provided a complete response to the Group's BLA resubmission for remestemcel-L for the treatment of pediatric SR-aGVHD and requires more data to support marketing approval, including potency assay or clinical data. In line with the Group's overall commercial strategy to progress to adult populations, the Group intends to conduct a targeted, controlled study in the highest-risk adults with the greatest mortality. In conjunction with implementing cost containment and deferment strategies, additional inflows from royalty monetization, capital markets, strategic partnerships or product specific financing will be required to meet the Group's projected expenditure consistent with the Group's business strategy over at least the next 12 months. As a result of these matters, there is material uncertainty related to events or conditions that may cast significant doubt (or raise substantial doubt as contemplated by Public Company Accounting Oversight Board (“PCAOB”) standards) on the Group’s ability to continue as a going concern and, therefore, that the Group may be unable to realize its assets and discharge its liabilities in the normal course of business. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. (ii) Historical cost convention These financial statements have been prepared under the historical cost convention, as modified by the revaluation of financial assets at fair value through other comprehensive income and financial assets and liabilities (including derivative instruments) at fair value through profit or loss, certain classes of property, plant and equipment and investment property. (iii) New and amended standards adopted by the Group There were no new or amended standards adopted by the Group in the year ended June 30, 2023. These financial statements follow the same accounting policies as compared to the June 30, 2022 consolidated financial statements and related notes as filed with the Australian Securities Exchange and the Securities and Exchange Commission. (iv) New accounting standards and interpretations not yet adopted by the Group There were no new accounting standards and interpretations not yet adopted by the Group for the June 30, 2023 reporting period that are expected to materially impact the Group. (v) Use of estimates The preparation of these consolidated financial statements requires the Group to make estimates and judgments that affect the reported amounts of assets, liabilities, income and expenses and related disclosures. On an ongoing basis, the Group evaluates its significant accounting policies and estimates. Estimates are based on historical experience and on various market-specific and other relevant assumptions that the Group believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities. (vi) Impact of after effects of COVID-19 and geopolitical instability Estimates are assessed each period and updated to reflect current information, such as the economic considerations related to the after effects of the COVID-19 pandemic could have on the Group’s significant accounting estimates. The Group is having to account for the after effects of the COVID-19 pandemic on healthcare network, which have been and may continue to be impacted by the pandemic with respect to patient care, operations/staffing, financials, and health and safety protocols. These impacts change the way that Mesoblast will have to engage with the relevant collaborators. Due to the effects of the COVID-19 pandemic, and recent geopolitical instability, countries in which the Group has operations have experienced some challenges in the ability of the Group’s suppliers and contractors to source, supply or acquire raw materials or components needed for its manufacturing process and supply chain. As a result, the manufacturing and commercialization of remestemcel-L and other product candidates could be adversely affected.

Significant changes in the curr

Significant changes in the current reporting period	12 Months Ended
Significant changes in the current reporting period	Jun. 30, 2023
Disclosure Of Significant Changes In Current Reporting Period [Abstract]
Significant changes in the current reporting period	Significant changes in the current reporting period (i) Significant events The financial position and performance of the Group was affected by the following events during the year ended June 30, 2023: • On April 25, 2023, the Group completed a global private placement primarily to existing major shareholders raising approximately $40.0 million, net of transaction costs. • In January 2023, the Group resubmitted to the FDA the Biologics License Application ("BLA") for approval of remestemcel-L in the treatment of children with SR-aGVHD and in March 2023, the FDA accepted the Company's BLA resubmission and set a Prescription Drug User Fee Act ("PDUFA") goal date of August 2, 2023. In August 2023, the FDA provided a complete response to the Group's BLA resubmission for remestemcel-L for the treatment of pediatric SR-aGVHD and requires more data to support marketing approval, including potency assay or clinical data. In line with the Group's overall commercial strategy to progress to adult populations, the Group intends to conduct a targeted, controlled study in the highest-risk adults with the greatest mortality. Assumptions associated with SR-aGVHD are included within the impairment assessment of Osiris MSC products within in-process research and development, contingent consideration, pre-launch inventory and the NovaQuest borrowings on the consolidated balance sheet and forecast net operating cash usage. The Group has assessed and included the impact of the FDA's complete response to the Group's BLA resubmission for remestemcel-L for the treatment of pediatric SR-aGVHD in these areas. Refer to Note 15 for more information. • In December 2022, the Group amended the terms of the loan agreement with Oaktree and in connection with the loan amendment, Oaktree was granted warrants to purchase 455,000 American Depositary Shares (ADSs) at $3.70 per ADS, a 15% premium to the 30-day VWAP. The Group determined that an obligation to issue the warrants had arisen from the time the debt facility was signed; consequently, a liability for the warrants was recognized in December 2022. The warrants were legally issued on March 8, 2023 and may be exercised within 7 years of issuance. Refer to Note 5(g)(vi) for more details on warrants issued.

Loss before income tax

Loss before income tax	12 Months Ended
Loss before income tax	Jun. 30, 2023
Disclosure Of Loss Before Income Tax [Abstract]
Loss before income tax	Loss before income tax Year Ended June 30, (in U.S. dollars, in thousands) Note 2023 2022 2021 Revenue Commercialization revenue 7,501 9,039 7,434 Milestone revenue — 1,172 — Total Revenue 7,501 10,211 7,434 Clinical trial and research & development (8,771) (10,483) (18,569) Manufacturing production & development (25,468) (28,884) (31,590) Employee benefits Salaries and employee benefits (17,197) (18,997) (26,804) Defined contribution superannuation expenses (384) (402) (379) Equity settled share-based payment transactions (1) (3,655) (5,536) (12,510) Total Employee benefits (21,236) (24,935) (39,693) Depreciation and amortization of non-current assets Plant and equipment depreciation (953) (1,144) (1,016) Right of use asset depreciation (1,661) (1,717) (1,691) Intellectual property amortization (1,493) (1,519) (1,557) Total Depreciation and amortization of non-current assets (4,107) (4,380) (4,264) Other Management & administration expenses Overheads & administration (10,104) (10,157) (7,757) Consultancy (3,922) (3,751) (5,386) Legal, patent and other professional fees (3,695) (5,571) (6,950) Intellectual property expenses (excluding the amount amortized above) (2,993) (2,621) (2,389) Total Other Management & administration expenses (20,714) (22,100) (22,482) Fair value remeasurement of contingent consideration Remeasurement of contingent consideration 5(g)(iii) 8,771 913 18,687 Total Fair value remeasurement of contingent consideration 8,771 913 18,687 Fair value remeasurement of warrant liability Remeasurement of warrant liability 5(g)(vi) (2,205) 5,896 — Total Fair value remeasurement of warrant liability (2,205) 5,896 — Other operating income and expenses Research and development tax incentive income (2) 3,506 — — Interest income 831 3 22 Foreign exchange (losses)/gains (163) (536) 1,471 Derecognition of right-of-use asset 76 — — Foreign withholding tax paid — (3) — Government grant revenue — — 68 Total Other operating income and expenses 4,250 (536) 1,561 Finance (costs)/gains Remeasurement of borrowing arrangements (678) (382) 5,225 Interest expense (19,444) (16,906) (15,939) Total Finance costs (20,122) (17,288) (10,714) Total loss before income tax (82,101) (91,586) (99,630) (1) Share-based payment transactions For the years ended June 30, 2023, 2022 and 2021, share-based payment transactions have been reflected in the Consolidated Statement of Comprehensive Income functional expense categories as follows: Year Ended June 30, (in U.S. dollars) 2023 2022 2021 Research and development 1,669,514 3,547,182 7,782,330 Manufacturing and commercialization (1,136) 378,096 547,998 Management and administration 1,986,968 1,610,567 4,179,416 Equity settled share-based payment transactions 3,655,346 5,535,845 12,509,744 (2) Research and development tax incentive The Group's research and development activities are eligible under the Australian government's Innovation Australia Research and Development Tax Incentive program for research and development activities conducted in relation to qualifying research that meets the regulatory criteria. Management has assessed these activities and expenditures to determine which costs are likely to be eligible under the incentive scheme. The Group assesses, on an annual basis, the quantum of previous research and development tax claims and on-going eligibility to claim this tax incentive in Australia.

Income tax benefit_(expense)

Income tax benefit/(expense)	12 Months Ended
Income tax benefit/(expense)	Jun. 30, 2023
Major components of tax expense (income) [abstract]
Income tax benefit/(expense)	Income tax benefit/(expense) Year Ended June 30, (in U.S. dollars, in thousands) 2023 2022 2021 (a) Reconciliation of income tax to prima facie tax payable Loss from continuing operations before income tax (82,101) (91,586) (99,630) Tax benefit at the Australian tax rate of 30% (2022: 30%, 2021: 30%) (24,630) (27,476) (29,889) Tax effect of amounts which are not deductible/(exempt) in calculating taxable income: Share-based payments expense 1,089 1,588 2,836 Research and development tax concessions (730) (869) (894) Foreign exchange translation gains/(losses) 501 159 313 Contingent consideration (2,631) (274) (5,606) Other sundry items 695 (2,036) 121 Subtotal (25,706) (28,908) (33,119) Adjustments for current tax of prior periods 274 (923) (1) Differences in overseas tax rates 8,537 8,407 13,218 Tax benefit not recognized 16,683 21,185 19,083 Change in tax rate on Deferred tax assets (1) — (8,326) (482) Change in tax rate on Deferred tax liability (1) — 8,326 482 Income tax benefit attributable to loss before income tax (212) (239) (819) (1) On June 30, 2022, there was a change in the expected tax rate applicable on future taxable profits in Singapore. The Group was expecting to benefit from concessionary tax rates (tax holiday) in Singapore under the tax incentives granted to the Group by the Singapore Economic Development Board, however at June 30, 2022 the Group had not met the conditions under the agreement to access the concessionary tax rates and therefore have recognized a change in the expected tax rate in Singapore to reflect the statutory tax rate of 17%. The Group is in current discussions with the Singapore Economic Development Board to amend the conditions of the incentive agreement and access these concessionary tax rates in the future. Year Ended June 30, (in U.S. dollars, in thousands) 2023 2022 2021 (b) Income tax (benefit)/expense Current tax Current tax — — — Total current tax (benefit)/expense — — — Deferred tax (Increase)/decrease in deferred tax assets 38 (8,317) (1,158) (Decrease)/increase in deferred tax liabilities (250) 8,078 339 Total deferred tax (benefit)/expense (212) (239) (819) Income tax (benefit)/expense (212) (239) (819) Deferred tax assets have been brought to account only to the extent that it is foreseeable that they are recoverable against future tax liabilities. Deferred tax assets are recognized for unused tax losses to the extent that it is probable that future taxable profit will be available against which the unused tax losses can be utilized. Deferred tax assets are offset against taxable temporary differences (deferred tax liabilities) when the deferred tax balances relate to the same tax jurisdiction in accordance with our accounting policy. Deferred taxes are measured at the rate in which they are expected to settle within the respective jurisdictions, which can change based on factors such as new legislation or timing of utilization and reversal of associated assets and liabilities. Year Ended June 30, (in U.S. dollars, in thousands) 2023 2022 2021 (c) Amounts that would be recognized directly in equity if brought to account Aggregate current and deferred tax arising in the reporting period and not recognized in net loss or other comprehensive income but which would have been directly applied to equity had it been brought to account: Current tax recorded in equity (if brought to account) (1,716) (142) (525) Deferred tax recorded in equity (if brought to account) 839 715 905 (877) 573 380 Year Ended June 30, (in U.S. dollars, in thousands) 2023 2022 2021 (d) Amounts recognized directly in equity Aggregate current and deferred tax arising in the reporting period and not recognized in net loss or other comprehensive income but debited/credited to equity Current tax recorded in equity — — — Deferred tax recorded in equity 212 239 91 212 239 91 Year Ended June 30, (in U.S. dollars, in thousands) 2023 2022 2021 (e) Deferred tax assets not brought to account Unused tax losses Potential tax benefit at local tax rates 125,728 111,283 77,738 Other temporary differences Potential tax benefit at local tax rates 12,318 11,046 7,424 Other tax credits Potential tax benefit at local tax rates 3,220 3,220 3,220 141,266 125,549 88,382 The Group has not brought to account $553.0 million (2022: $477.8 million, 2021: $424.9 million) of gross tax losses, which includes the benefit arising from tax losses in overseas countries. As of June 30, 2023 $553.0 million of tax losses not brought to account have an indefinite life. Gross tax losses of $44.5 million recognized as deferred tax asset expire within a range of 9 to 15 years. The benefits of unused tax losses will only be brought to account when it is probable that they will be realized. This benefit of tax losses will only be obtained if: • the Group derives future assessable income of a nature and an amount sufficient to enable the benefit from the deductions for the losses to be realized; • the Group continues to comply with the conditions for deductibility imposed by tax legislation; and • no changes in tax legislation adversely affect the Group in realizing the benefit from the deductions for the losses.

Financial assets and liabilitie

Financial assets and liabilities	12 Months Ended
Financial assets and liabilities	Jun. 30, 2023
Disclosure Of Financial Assets And Liabilities [Abstract]
Financial assets and liabilities	Financial assets and liabilities This note provides information about the Group's financial instruments, including: • an overview of all financial instruments held by the Group; • specific information about each type of financial instrument; • accounting policies; and • information used to determine the fair value of the instruments, including judgments and estimation uncertainty involved. The Group holds the following financial instruments: Financial assets Notes Assets at FVOCI (1) Assets at FVTPL (2) Assets at Total As of June 30, 2023 Cash & cash equivalents 5(a) — — 71,318 71,318 Trade & other receivables 5(b) — — 6,998 6,998 Financial assets at fair value through other comprehensive income 5(c) 1,757 — — 1,757 Other non-current assets 5(d) — — 2,326 2,326 1,757 — 80,642 82,399 As of June 30, 2022 Cash & cash equivalents 5(a) — — 60,447 60,447 Trade & other receivables 5(b) — — 4,403 4,403 Financial assets at fair value through other comprehensive income 5(c) 1,758 — — 1,758 Other non-current assets 5(d) — — 1,930 1,930 1,758 — 66,780 68,538 (1) Fair value through other comprehensive income (2) Fair value through profit or loss Financial liabilities Notes Liabilities at FVOCI (1) Liabilities at FVTPL (2) Liabilities at Total As of June 30, 2023 Trade and other payables 5(e) — — 20,145 20,145 Borrowings 5(f) — — 108,763 108,763 Contingent consideration 5(g)(iii) — 17,199 — 17,199 Warrant liability 5(g)(vi) — 5,426 — 5,426 — 22,625 128,908 151,533 As of June 30, 2022 Trade and other payables 5(e) — — 23,079 23,079 Borrowings 5(f) — — 96,634 96,634 Contingent consideration 5(g)(iii) — 23,284 — 23,284 Warrant liability 5(g)(vi) — 2,185 — 2,185 — 25,469 119,713 145,182 (1) Fair value through other comprehensive income (2) Fair value through profit or loss The Group’s exposure to various risks associated with the financial instruments is discussed in Note 10. The maximum exposure to credit risk at the end of the reporting period is the carrying amount of each class of financial assets mentioned above. a. Cash and cash equivalents As of June 30, (in U.S. dollars, in thousands) 2023 2022 Cash at bank 70,920 60,034 Deposits at call (1) 398 413 71,318 60,447 (1) As of June 30, 2023 and June 30, 2022, interest-bearing deposits at call include amounts of $0.4 million and $0.4 million, respectively, held as security and restricted for use. (i) Classification as cash equivalents Term deposits are presented as cash equivalents if they have a maturity of three months or less from the date of acquisition. b. Trade and other receivables and prepayments (i) Trade and other receivables As of June 30, (in U.S. dollars, in thousands) 2023 2022 Trade debtors 2,276 2,224 Tax incentives recoverable 2,363 — Foreign withholding tax recoverable 471 471 U.S. Tax credits 1,473 1,473 Net investment in sublease 195 — Interest receivables 18 — Other recoverable taxes (Goods and services tax and value-added tax) 202 235 Trade and other receivables 6,998 4,403 (ii) Prepayments As of June 30, (in U.S. dollars, in thousands) 2023 2022 Clinical trial research and development expenditure 950 1,313 Prepaid insurance and subscriptions 2,025 2,420 Other 367 1,254 Prepayments 3,342 4,987 (iii) Classification as trade and other receivables Trade receivables and other receivables represent the principal amounts due at balance date less, where applicable, any provision for expected credit losses. The Group uses the simplified approach to measuring expected credit losses, which uses a lifetime expected credit loss allowance. Debts which are known to be uncollectible are written off in the consolidated income statement. All trade receivables and other receivables, with the exception of the net investment in sublease, are recognized at the value of the amounts receivable, as they are due for settlement within 60 days and therefore do not require remeasurement. The net investment in sublease is recognized at the present value of minimum lease payments receivable over the remaining life of the lease. (iv) Fair values of trade and other receivables Due to the short-term nature of the current receivables, their carrying amount is assumed to be the same as their fair value. (v) Impairment and risk exposure Information about the impairment of trade and other receivables, their credit quality and the Group’s exposure to credit risk, foreign currency risk and interest rate risk can be found in Note 10(a) and (b). c. Financial assets at fair value through other comprehensive income Financial assets at fair value through other comprehensive income include the following classes of financial assets: As of June 30, (in U.S. dollars, in thousands) 2023 2022 Unlisted securities: Equity securities 1,757 1,758 1,757 1,758 (i) Classification of financial assets at fair value through other comprehensive income Financial assets at fair value through other comprehensive income comprises equity securities which are not held for trading, and which the Group has irrevocably elected at initial recognition to recognize in this category. These are strategic investments and the Group considers this classification to be more relevant. The financial assets are presented as non-current assets unless they mature, or management intends to dispose of them within 12 months of the end of the reporting period. (ii) Impairment indicators for financial assets at fair value through other comprehensive income Impairment losses (and reversal of impairment losses) on equity investments measured at FVOCI are not reported separately from other changes in fair value. See Note 23(m)(iv) for further details about the Group’s impairment policies for financial assets. (iii) Amounts recognized in other comprehensive income For the years ended June 30, 2023, 2022 and 2021, the Group recognized in statement of comprehensive income a nil gain/loss, a loss of $0.3 million and a gain of $0.2 million respectively, for change in fair value of the financial assets through other comprehensive income. (iv) Fair value, impairment and risk exposure Information about the methods and assumptions used in determining fair value is provided in Note 5(g). None of the financial assets through other comprehensive income are either past due or impaired. All financial assets at fair value through other comprehensive income are denominated in US$. d. Other non-current assets As of June 30, (in U.S. dollars, in thousands) 2023 2022 Bank guarantee 481 500 Net investment in sublease 414 — Letter of credit 1,179 1,178 Security deposit 252 252 2,326 1,930 (i) Classification of financial assets as other non-current assets Bank guarantee These funds are held in an account named Mesoblast Limited at National Australia Bank according to the terms of a Bank Guarantee which is security for the sublease agreement for our occupancy of Level 38, 55 Collins Street, Melbourne, Victoria, Australia. The Bank Guarantee is security for the full and faithful performance and observance by the subtenant of the terms, covenants and conditions of the sublease. The Bank Guarantee continues in force until it is released by the lessor. Letter of credit These funds held in an account named Mesoblast, Inc. at the Bank of America according to the terms of an irrevocable standby letter of credit which is security for the sublease agreement for our occupancy of 505 Fifth Avenue, New York, New York, United States of America. The letter of credit is security for the full and faithful performance and observance by the subtenant of the terms, covenants and conditions of the sublease. The letter of credit is deemed to automatically extend without amendment for a period of one year at each anniversary. (ii) Impairment and risk exposure Information about the impairment of other non-current assets and their credit quality and the Group’s exposure to credit risk can be found in Note 10(b). e. Trade and other payables As of June 30, (in U.S. dollars, in thousands) 2023 2022 Trade payables and other payables 20,145 23,079 Trade and other payables 20,145 23,079 The carrying amounts of trade and other payables are assumed to be the same as their fair values, due to their short-term nature. f. Borrowings As of June 30, (in U.S. dollars, in thousands) 2023 2022 Borrowings Secured liabilities: Borrowing arrangements 81,919 81,919 Less: transaction costs (8,740) (8,247) Amortization of carrying amount, net of payments made 35,584 22,962 108,763 96,634 As of June 30, (in U.S. dollars, in thousands) 2023 2022 Borrowings Current Borrowings - NovaQuest 336 372 Borrowings - Oaktree 5,616 4,645 5,952 5,017 Non-current Borrowings - NovaQuest 55,739 47,898 Borrowings - Oaktree 47,072 43,719 102,811 91,617 108,763 96,634 (i) Borrowing arrangements Funds associated with Oaktree Capital Management, L.P. (“Oaktree”) In November 2021, the Group entered into a $90.0 million five-year senior debt facility provided by funds associated with Oaktree. The Group drew the first tranche of $60.0 million on closing. The conditions required to draw down the additional $30.0 million tranche have not been met. The facility has a three-year interest only period, at a fixed rate of 9.75% per annum, after which time 40% of the principal amortizes over two years and a final payment is due no later than November 2026. The facility also allows the Group to make quarterly payments of interest at a rate of 8.0% per annum for the first two years, and the unpaid interest portion (1.75% per annum) will be added to the outstanding loan balance and currently accrues further interest at a fixed rate of 9.75% per annum. On November 19, 2021, Oaktree were granted warrants to purchase 1,769,669 American Depositary Shares (“ADSs”) at US$7.26 per ADS, a 15% premium to the 30-day VWAP. The Group determined that an obligation to issue the warrants arose from the time the debt facility was signed; consequently, a liability for the warrants was recognized in November 2021. The warrants were legally issued on January 11, 2022 and may be exercised within 7 years of issuance. On the issuance date of the Oaktree facility and the warrants, the warrants were initially measured at fair value and the Oaktree borrowing liability measured as the difference between the $60.0 million received from the Oaktree facility and the fair value of the warrants. In December 2022, the Group amended the terms of the loan agreement with Oaktree and in connection with the loan amendment, Oaktree was granted warrants to purchase 455,000 ADSs at $3.70 per ADS, a 15% premium to the 30-day VWAP. The Group determined that an obligation to issue the warrants arose from the time the first amendment to the loan agreement was signed; consequently, a liability for the warrants was recognized in December 2022. The warrants were legally issued on March 8, 2023 and may be exercised within 7 years of issuance. Refer to Note 5(g)(vi) for more details on warrants issued. In the year ended June 30, 2023, t he Group recognized a loss of $1.6 million in the C onsolidated Income Statement as remeasurement of borrowing arrangements within finance costs. Within this $1.6 million loss, $1.0 million relates to the remeasurement due to additional warrants being issued to Oaktree as a result of the first amendment to the loan agreement and $0.6 million relates to the adjustment of the carrying amount of our financial liability to reflect the revised estimated future cash flows from our credit facility . In the year ended June 30, 2022, the Group recognized a minimal gain in the Consolidated Income Statement as remeasurement of borrowing arrangements within finance costs in relation to the adjustment of the carrying amount of our financial liability to reflect the revised estimated future cash flows from our credit facility. No remeasurement of borrowing arrangements was recognized in the year ended June 30, 2021. The Group has pledged substantially all of its assets as collateral under the loan facility with Oaktree. NovaQuest Capital Management, L.L.C. On June 29, 2018, the Group entered into an eight-year, $40.0 million loan and security agreement with NovaQuest before drawing the first tranche of $30.0 million of the principal in July 2018. The loan term includes an interest only period of approximately four years through until July 8, 2022, then a four-year amortization period through until maturity on July 8, 2026. All interest and principal payments will be deferred until after the first commercial sale of remestemcel-L for the treatment in pediatric patients with SR-aGVHD, in the United States and other geographies excluding Asia (“pediatric SR-aGVHD”). Principal is repayable in equal quarterly instalments over the amortization period of the loan and is subject to the payment cap described below. The loan has a fixed interest rate of 15% per annum. If there are no net sales of remestemcel-L for pediatric SR-aGVHD, the loan is only repayable at maturity. The Group can elect to prepay all outstanding amounts owing at any time prior to maturity, subject to a prepayment charge, and may decide to do so if net sales of remestemcel-L for pediatric SR-aGVHD are significantly higher than current forecasts. Following approval and first commercial sales, repayments commence based on a percentage of net sales and are limited by a payment cap which is equal to the principal due for the next 12 months, plus accumulated unpaid principal and accrued unpaid interest. During the four-year period commencing July 8, 2022, principal amortizes in equal quarterly instalments payable only after approval and first commercial sales. If in any quarterly period, 25% of net sales of remestemcel-L for pediatric SR-aGVHD exceed the annual payment cap, the Group will pay the payment cap and an additional portion of excess sales which will be used towards the prepayment amount in the event there is an early prepayment of the loan. If in any quarterly period 25% of net sales of remestemcel-L for pediatric SR-aGVHD is less than the annual payment cap, then the payment is limited to 25% of net sales of remestemcel-L for pediatric SR-aGVHD. Any unpaid interest will be added to the principal amounts owing and shall accrue further interest. At maturity date, any unpaid loan balances are repaid. Because of this relationship of net sales and repayments, changes in our estimated net sales may trigger an adjustment of the carrying amount of the financial liability to reflect the revised estimated cash flows. The carrying amount adjustment is recalculated by computing the present value of the revised estimated future cash flows at the financial instrument’s original effective interest rate. The adjustment is recognized in the Consolidated Income Statement as remeasurement of borrowing arrangements within finance costs in the period the revision is made. In the year ended June 30, 2023, the Group recognized a gain of $0.9 million in the Consolidated Income Statement as remeasurement of borrowing arrangements within finance costs in relation to the adjustment of the carrying amount of our financial liability to reflect the revised estimated future cash flows as a net result of changes to the key assumption in development timelines. In the years ended June 30, 2022 and 2021, respectively, the Group recognized gains of $0.5 million and $4.8 million in the Consolidated Income Statement as remeasurement of borrowing arrangements within finance costs in relation to the adjustment of the carrying amount of the Group's financial liability to reflect the revised estimated future cash flows from our credit facility. The Group recognizes a liability as current based on repayments linked to estimates of sales of remestemcel-L. However, if sales of remestemcel-L are higher than estimated, actual repayments will exceed this amount, subject to the annual payment cap described above. The carrying amount of the loan and security agreement with NovaQuest is subordinated to the Group’s fixed rate loan with the senior creditor, Oaktree. The Group have pledged a portion of our assets relating to the SR-aGVHD product candidate as collateral under the loan facility with NovaQuest. (ii) Compliance with loan covenants Our loan facilities with Oaktree and NovaQuest contain a number of covenants that impose operating restrictions on us, which may restrict our ability to respond to changes in our business or take specified actions. The Group has an operating objective to at all times maintain unrestricted cash reserves in excess of six months liquidity. The objective aligns with our loan and security agreement with Oaktree where the Group is currently obliged to maintain a minimum unrestricted cash balance in the United States of $35.0 million. The Group has complied with the financial and other restrictive covenants of its borrowing facilities during the year ended June 30, 2023 and during the year ended June 30, 2022. (iii) Net debt reconciliation As of June 30, (in U.S. dollars, in thousands) 2023 2022 Cash and cash equivalents 71,318 60,447 Borrowings (108,763) (96,634) Lease liabilities (7,732) (10,271) Warrant liability (5,426) (2,185) Net Debt (1) (50,603) (48,643) Cash and cash equivalents 71,318 60,447 Gross debt - fixed interest rates (116,495) (106,905) Gross debt - variable interest rates — — Warrant liability (5,426) (2,185) Net Debt (1) (50,603) (48,643) (1) Net debt amount includes leases and borrowing arrangements Liabilities from financing activities Other assets (in U.S. dollars, in thousands) Borrowings Leases Warrant liability Sub-total Cash and cash Total Net Debt as at June 30, 2022 (96,634) (10,271) (2,185) (109,090) 60,447 (48,643) Cash Flows (1) 5,926 3,170 — 9,096 11,039 20,135 Remeasurement adjustments 358 — (2,205) (1,847) — (1,847) Other Changes (2) (18,413) (738) — (19,151) — (19,151) Issuance of warrants — — (1,036) (1,036) — (1,036) Acquisition – leases — — — — — — Foreign exchange adjustments — 107 107 (168) (61) Net Debt as at June 30, 2023 (108,763) (7,732) (5,426) (121,921) 71,318 (50,603) (1) Cash flows include the payments of borrowings, lease liabilities, interest and debt transaction costs which are presented as financing cash flows in the statement of cash flows. (2) Other changes include modification of leases and accrued interest expenses for borrowings and leases. (i) Fair values of borrowing arrangements The carrying amount of the borrowings at amortized cost in accordance with our accounting policy is a reasonable approximation of fair value. g . Recognized fair value measurements (i) Fair value hierarchy The following table presents the Group's financial assets and financial liabilities measured and recognized at fair value as of June 30, 2023 and June 30, 2022 on a recurring basis, categorized by level according to the significance of the inputs used in making the measurements: As of June 30, 2023 (in U.S. dollars, in thousands) Notes Level 1 Level 2 Level 3 Total Financial Assets Financial assets at fair value through other comprehensive income: Equity securities - biotech sector 5(c) — — 1,757 1,757 Total Financial Assets — — 1,757 1,757 Financial Liabilities Financial liabilities at fair value through profit or loss: Contingent consideration 5(g)(iii) — — 17,199 17,199 Warrant liabilities 5(g)(vi) — — 5,426 5,426 Total Financial Liabilities — — 22,625 22,625 There were no transfers between any of the levels for recurring fair value measurements during the period. As of June 30, 2022 (in U.S. dollars, in thousands) Notes Level 1 Level 2 Level 3 Total Financial Assets Financial assets at fair value through other comprehensive income: Equity securities - biotech sector 5(c) — — 1,758 1,758 Total Financial Assets — — 1,758 1,758 Financial Liabilities Financial liabilities at fair value through profit or loss: Contingent consideration 5(g)(iii) — — 23,284 23,284 Warrant liabilities 5(g)(vi) — — 2,185 2,185 Total Financial Liabilities — — 25,469 25,469 The Group’s policy is to recognize transfers into and transfers out of fair value hierarchy levels as at the end of the reporting period. Level 1: The fair value of financial instruments traded in active markets (such as publicly traded derivatives, and trading and financial assets at fair value through other comprehensive income securities) is based on quoted market prices at the end of the reporting period. The quoted market price used for financial assets held by the Group is the current bid price. These instruments are included in level 1. Level 2: The fair value of financial instruments that are not traded in an active market (for example, foreign exchange contracts) is determined using valuation techniques which maximize the use of observable market data and rely as little as possible on entity-specific estimates. If all significant inputs required to fair value an instrument are observable, the instrument is included in level 2. Level 3: If one or more of the significant inputs is not based on observable market data, the instrument is included in level 3. This is the case for provisions (contingent consideration), equity securities (unlisted) and warrant liabilities. (ii) Valuation techniques used. The Group did not hold any level 1 or 2 financial instruments as at June 30, 2023 or June 30, 2022. The Group’s level 3 assets consists of an investment in unlisted equity securities in the biotechnology sector. Level 3 assets were 100% of total assets measured at fair value as at June 30, 2023 and June 30, 2022. The Group’s level 3 liabilities consist of a contingent consideration provision related to the acquisition of Osiris’ MSC business and warrant liabilities related to the warrants granted to Oaktree as part of the debt facility. Level 3 liabilities were 100% of total liabilities measured at fair value as at June 30, 2023 and June 30, 2022. The Group used discounted cash flow analysis to determine the fair value measurements of Osiris’ MSC business and used the Black-Scholes valuation method to determine the fair value of warrant liabilities. Refer to Note 5(g)(vi) for the fair value measurement and movements in warrant liability for the period ended June 30, 2023 and June 30, 2022. (iii) Fair value measurements using significant unobservable inputs (level 3) The following table presents the changes in the contingent consideration balances within the level 3 instruments for the years ended June 30, 2023 and June 30, 2022: (in U.S. dollars, in thousands) Contingent consideration provision Opening balance - July 1, 2021 25,409 Amount used during the period (1,212) Charged/(credited) to consolidated income statement: Remeasurement (1) (913) Closing balance - June 30, 2022 23,284 Opening balance - July 1, 2022 23,284 Reclassification during the period 2,686 Charged/(credited) to consolidated income statement: Remeasurement (2) (8,771) Closing balance - June 30, 2023 17,199 (1) In the year ended June 30, 2022, a gain of $0.9 million was recognized on the remeasurement of contingent consideration pertaining to the acquisition of assets from Osiris. This remeasurement was a net result of changing the key assumptions of the contingent consideration valuation such as developmental timelines, market growth and the increase in valuation as the time period shortens between the valuation date and the potential settlement dates of contingent consideration. (2) In the year ended June 30, 2023, a gain of $8.8 million was recognized on the remeasurement contingent consideration pertaining to the acquisition of assets from Osiris. This remeasurement was a net result of changing key assumptions of the contingent consideration valuation, such as probability of payment, development timelines and the increase in valuation as the time period shortens between the valuation date and the potential settlement dates of contingent consideration, including the impact from the complete response from the FDA on the Group's BLA for remestemcel-L for the treatment of pediatric SR-aGVHD in August 2023. The assumptions relating to development timelines have been updated to reflect current expectations as a result of the complete response, as discussed in Note 15. (iv) Valuation inputs and relationship to fair value The following table summarizes the quantitative information about the significant unobservable inputs used in level 3 fair value measurements: Range of inputs (weighted average) (in U.S. dollars, in thousands, except percent data) Description Fair value Fair value Valuation Unobservable inputs (1) Year Ended Year Ended Relationship of Contingent consideration provision 17,199 23,284 Discounted cash flows Risk adjusted 11%-13% (12.5%) 11%-13% (12.5%) Year ended June 30, 2023: A change in the discount rate by 0.5% would increase/decrease the fair value by 0.01%. Year ended June 30, 2022: A change in the discount rate by 0.5% would increase/decrease the fair value by 0.2%. Expected unit Various Various Year ended June 30, 2023: A change in the price assumptions by 10% would increase/decrease the fair value by 0.1%. Year ended June 30, 2022: A change in the price assumptions by 10% would increase/decrease the fair value by 2%. Expected sales Various Various Year ended June 30, 2023: A change in the volume assumptions by 10% would increase/decrease the fair value by 0.1%. Year ended June 30, 2022: A change in the volume assumptions by 10% would increase/decrease the fair value by 2%. Probability of success and payment Various Various Year ended June 30, 2023: A change in the probability of success and payment assumptions by 10% and 20% would increase/decrease the fair value by 8% and 16%, respectively. Year ended June 30, 2022: A change in the probability of success and payment assumptions by 10% and 20% would increase/decrease the fair value by 8.6% and 17.2%, respectively. (1) There were no significant inter-relationships between unobservable inputs that materially affect fair values. (v) Valuation processes In connection with the Osiris acquisition, on October 11, 2013 (the “acquisition date”), an independent valuation of the contingent consideration was carried out by an independent valuer. For the years ended June 30, 2023 and June 30, 2022, the Group has adopted a process to value contingent consideration internally. This valuation has been completed by the Group’s internal valuation team and reviewed by the interim Chief Financial Officer (the "CFO"). The valuation team is responsible for the valuation model. The valuation team also manages a process to continually refine the key assumptions within the model. This is done with input from the relevant business units. The key assumptions in the model have been clearly defined and the responsibility for refining those assumptions has been assigned to the most relevant business units. For each indication we determine the probability of success based on the current development status within each jurisdiction and payment provisions within the agreement. Cash flows relevant to each jurisdiction are discounted appropriately based on the discount rate assumed. The remeasurement charged to the consolidated income statement in the year ended June 30, 2023 was a net result of changing the key assumptions of the contingent consideration valuation such as probability of payment, development timelines and the increase in valuation as the time period shortens between the valuation date and the potential settlement dates of contingent consideration, including the impact from the complete response from the FDA on the BLA for remestemcel-L for the treatment of pediatric SR-aGVHD in August 2023. The assumptions relating to development timelines have been updated to reflect current expectations as a result of the complete response, as discussed in Note 15. Future discussions with the FDA could lead to a change in the assumptions associated with SR-aGVHD and a further remeasurement of contingent consideration, up or down, could occur. As of June 30, The fair value of contingent consideration (in U.S. dollars, in thousands) 2023 2022 Fair value of cash or stock payable, dependent on achievement of future late-stage clinical or regulatory targets 16,606 17,827 Fair value of royalty payments from commercialization of the intellectual property acquired 593 5,457 17,199 23,284 The main level 3 inputs used by the Group are evaluated as follows: Risk adjusted discount rate: The discount rate used in the valuation has been determined based on required rates of returns of listed companies in the biotechnology industry (having regards to their stage of development, their size and number of projects) and the indicative rates of return required by suppliers of venture capital for investments with similar technical and commercial risks. This assumption is reviewed as part of the valuation process outlined above. Expected unit sales prices: Expected market sale price giving consideration to comparable products available in the market place and a value based pricing assessment. This assumption is reviewed as part of the valuation process outlined above. Expected sales volumes: Expected sales volumes of the most comparable products currently available in the market place. This assumption is reviewed as part of the valuation process outlined above. Probability of success and payment: Expected cash flows used to measure contingent consideration are risk adjusted for the probability of successful development of products. This assumption is reviewed as part of the valuation process outlined above. (vi) Warrant liability (in U.S. dollars, in thousands) As of June 30, Warrant liability 2023 2022 Opening balance 2,185 — Warrants fair value at grant date - November 19, 2021 — 8,081 Warrants fair value at grant date - December 22, 2022 1,036 — Remeasurement of warrant liability 2,205 (5,896) Closing Balance 5,426 2,185 On November 19, 2021, in connection with the $60.0 million drawdown of the Oaktree debt, Oaktree was granted the right to warrants to purchase 1,769,669 ADSs at US$7.26 per ADS, a 15% premium to the 30-day VWAP. Given that Oaktree received an unconditional right to the warrants on November 19, 2021, this date has been determined as the measurement date. The warrant instruments were issued on January 11, 2022, following the required administrative process, and these warrants may be exercised within 7 years of issuance of the warrant instruments. The warrants do not confer any rights to dividends or a right to participate in a new issue without exercising the warrant. On December 21, 2022, the Group amended the terms of the loan agreement with Oaktree and in connection with the loan amendment, Oaktree was granted warrants to purchase 455,000 ADSs at $3.70 per ADS, a 15% premium to the 30-day VWAP. The Group determined that an obligation to issue the warrants arose from the time the first amendment to the loan agreement was signed; consequently, a liability for the warrants was recognized in December 2022. The warrants were legally issued on March 8, 2023 and may be exercised within 7 years of issuance. The warrants do not confer any rights to dividends or a right to participate in a new issue without exercising the warrant. The exercise price of the warrants will be received in US$, which is different to Mesoblast Limited’s functional currency of A$ which gives rise to variability in the cash flow. As a result, the warrants are classified as a financial liability in accordance with IAS32 Financial Instruments: Presentation . The financial liability is recorded in warrant liability at fair value at grant date and subsequently remeasured at each reporting period with changes being recorded in the Consolidated Income Statement as remeasurement of warrant liability. The warrant liabilities are considered level 3 liabilities as the determination of fair value includes various assumptions about the share prices and historical volatility as inputs. As of June 30, 2023 and 2022, the fair value of warrant liability was $5.4 million and $2.2 million, respectively. During the year ended June 30, 2023, a remeasurement loss of $2.2 million was recognized on the remeasurement of warrant liability. During the year ended June 30, 2022, a remeasurement gain of $5.9 million was recognized on the remeasurement of warrant liability. (vii) Fair value of warrants The warrants granted are not traded in an active market and therefore the fair value has been estimated by using the Black-Scholes valuation method based on the following assumptions. Key terms of the warrants are included below. The following assumptions were based on observable market conditions that existed as of June 30, 2023 and 2022. (in U.S. dollars, except percent data and as otherwise noted) As of June 30, As of June

Non-financial Assets and Liabil

Non-financial Assets and Liabilities	12 Months Ended
Non-financial Assets and Liabilities	Jun. 30, 2023
Disclosure Of Non Financial Assets And Liabilities [Abstract]
Non-financial Assets and Liabilities	6. Non-financial assets and liabilities a. Property, plant and equipment (in U.S. dollars, in thousands) Plant and Equipment Office Furniture and Equipment Computer Hardware and Software Total Year Ended June 30, 2022 Opening net book amount 1,953 811 257 3,021 Additions 143 3 42 188 Exchange differences 54 (70) (4) (20) Depreciation charge (942) (52) (150) (1,144) Closing net book value 1,208 692 145 2,045 As of June 30, 2022 Cost 6,846 1,925 3,379 12,150 Accumulated depreciation (5,638) (1,233) (3,234) (10,105) Net book value 1,208 692 145 2,045 Year Ended June 30, 2023 Opening net book amount 1,208 692 145 2,045 Additions 171 43 60 274 Exchange differences (104) 113 (18) (9) Depreciation charge (818) (45) (90) (953) Closing net book value 457 803 97 1,357 As of June 30, 2023 Cost 6,910 2,074 3,353 12,337 Accumulated depreciation (6,453) (1,271) (3,256) (10,980) Net book value 457 803 97 1,357 (i) Depreciation methods and useful lives Depreciation is calculated using the straight-line method to allocate their cost or revalued amounts, net of their residual values, over the estimated useful lives. The estimated useful lives are: • Plant and equipment 3 – 15 years • Office furniture and equipment 5 – 10 years • Computer hardware and software 3 – 5 years See Note 23(o) for other accounting policies relevant to property, plant and equipment. b. Leases (i) Amounts recognized on the consolidated balance sheet Right-of-use assets (in U.S. dollars, in thousands) Buildings Manufacturing Total Year Ended June 30, 2022 Opening net book amount 5,417 3,702 9,119 Additions 1,464 — 1,464 Reassessment 97 494 591 Exchange differences (165) — (165) Depreciation charge (1,717) (1,372) (3,089) Closing net book value 5,096 2,824 7,920 As of June 30, 2022 Cost 9,957 6,178 16,135 Accumulated depreciation (4,861) (3,354) (8,215) Net book value 5,096 2,824 7,920 Year Ended June 30, 2023 Opening net book amount 5,096 2,824 7,920 Additions/(derecognition) (649) — (649) Reassessment 526 (302) 224 Exchange differences (15) — (15) Depreciation charge (1,661) (685) (2,346) Closing net book value 3,297 1,837 5,134 As of June 30, 2023 Cost 9,957 6,178 16,135 Accumulated depreciation (6,660) (4,341) (11,001) Net book value 3,297 1,837 5,134 Lease liabilities As of June 30, 2023 2022 Current 4,060 3,186 Non-current 3,672 7,085 Lease liabilities included in the balance sheet 7,732 10,271 The lease liability is measured at the present value of the fixed and variable lease payments net of cash lease incentives that are not paid at the balance date. Lease payments are apportioned between the finance charges and reduction of the lease liability using the incremental borrowing rate to achieve a constant rate of interest on the remaining balance of the liability. Lease payments for buildings exclude service fees for cleaning and other costs. The interest expense (included in finance costs) for leases was $0.5 million for the year ended June 30, 2023, and $0.6 million for the years ended June 30, 2022 and 2021, respectively. In the years ended June 30, 2023 and 2022, total payments associated with lease liabilities were $3.2 million and $3.4 million, respectively. Payments associated with short-term leases with a lease term of 12 months or less, contracts that contain lease and non-lease components that are cancellable within 12 months and leases of low-value assets are recognized on a straight-line basis as an expense in profit or loss. The expense relating to short term leases was $1.1 million for the year ended June 30, 2023 and $3.2 million for the year ended June 30, 2022. (ii) Depreciation methods and useful lives of right-of use assets Depreciation is calculated using the straight-line method to allocate their cost or revalued amounts, net of their residual values, over the estimated useful lives. Depreciation for leases for the years ended June 30, 2023, 2022 and 2021 was $1.7 million, $1.7 million and $1.7 million, respectively. (iii) Extension and termination options Extension options and termination options may be included in the right-of-use asset leases across the Group. These are used to maximize operational flexibility in terms of managing the assets used in the Group’s operations. In determining the lease term, management considers all facts and circumstances that create an economic incentive to exercise an extension option, or not exercise a termination option. Extension options and periods after termination options are only included in the lease term if the lease is reasonably certain to be extended or not terminated. A right-of-use asset and lease liability has been recognized in relation to the manufacturing service agreement entered into with Lonza in October 2019 for the supply of commercial product for the potential approval and launch of remestemcel-L for the treatment of SR-aGVHD in the US market. Management has determined that this agreement has a non-cancellable lease term expiring within 2 years from June 30, 2023 , which is cancellable in limited circumstances. As of June 30, 2023, the anticipated future contractual cash flows relating to the lease component of the Lonza agreement are $3.0 million on an undiscounted basis, as included within lease liabilities in Note 10(c). The anticipated future contractual cash flows exclude cashflows beyond the non-cancellable lease term as it is not reasonably certain the Group will extend the agreement. At the Group's discretion, the minimum financial commitment relating to the lease component under this manufacturing services agreement can be reduced by $1.1 million under certain conditions. See Note 23(v) for other accounting policies relevant to lease accounting. c. Intangible assets (in U.S. dollars, in thousands) Goodwill Acquired licenses to patents In-process research and development acquired Current marketed products Total Year Ended June 30, 2022 Opening net book amount 134,453 2,072 427,779 16,242 580,546 Additions/reversals — (450) — — (450) Exchange differences — 74 — 1 75 Amortization charge — (64) — (1,455) (1,519) Closing net book amount 134,453 1,632 427,779 14,788 578,652 As of June 30, 2022 Cost 134,453 2,987 489,698 24,000 651,138 Accumulated amortization — (1,355) — (9,212) (10,567) Accumulated impairment — — (61,919) — (61,919) Net book amount 134,453 1,632 427,779 14,788 578,652 Year Ended June 30, 2023 Opening net book amount 134,453 1,632 427,779 14,788 578,652 Additions — 23 — — 23 Exchange differences — 1 — — 1 Amortization charge — (38) — (1,455) (1,493) Closing net book amount 134,453 1,618 427,779 13,333 577,183 As of June 30, 2023 Cost 134,453 2,993 489,698 23,999 651,143 Accumulated amortization — (1,375) — (10,666) (12,041) Accumulated impairment — — (61,919) — (61,919) Net book amount 134,453 1,618 427,779 13,333 577,183 (i) Carrying value of in-process research and development acquired by product As of June 30, (in U.S. dollars, in thousands) 2023 2022 Cardiovascular products (1) 254,351 254,351 Intravenous products for metabolic diseases and inflammatory/immunologic conditions (2) 70,730 70,730 MSC products (3) 102,698 102,698 427,779 427,779 (1) Includes MPC-150-IM for the treatment or prevention of chronic heart failure and MPC-25-IC for the treatment or prevention of acute myocardial infarction (2) Includes MPC-300-IV for the treatment of biologic-refractory rheumatoid arthritis and diabetic nephropathy (3) Includes remestemcel-L for the treatment of SR-aGVHD and remestemcel-L for the treatment of Crohn’s disease For all products included within the above balances, the underlying currency of each item recorded is US$. (ii) Amortization methods and useful lives The Group amortizes intangible assets with a finite useful life using the straight-line method over the following periods: • Acquired licenses to patents 7 – 16 years • Current marketed products 15 – 20 years See Note 23(p) for the other accounting policies relevant to intangible assets and Note 23(j) for the Group’s policy regarding impairments. (iii) Significant estimate: Impairment of goodwill and assets with an indefinite useful life The Group tests annually, or more frequently if events or changes in circumstances indicate that they might be impaired, whether goodwill and its assets with indefinite useful lives have suffered any impairment in accordance with its accounting policy stated in Note 23(j). The recoverable amounts of these assets and cash-generating units have been determined based on fair value less costs to dispose calculations, which require the use of market-participant assumptions that are based on development strategies using external data sources as well as past experience. The full annual impairment assessment was performed at March 31, 2023 and no impairment of the in-process research and development and goodwill was identified. In August 2023, as disclosed in Note 15, the FDA issued a complete response to the Group's BLA for remestemcel-L for the treatment of pediatric SR-aGVHD and the Group has considered this to be an impairment indicator that could cause the carrying amount of its intangible assets to exceed its recoverable amounts. As a result, the Group completed an impairment assessment on its MSC products intangible asset and goodwill. The assumptions used in the impairment assessment were updated from the March 31, 2023 impairment assessment and included changes to the market population and penetration, product pricing and launch timings. There were no other significant changes in key assumptions, including the probability of success. No impairment to the in-process research and development and goodwill was identified. (iv) Impairment tests for goodwill and intangible assets with an indefinite useful life The Group has recognized goodwill as a result of two separate acquisitions. Goodwill of $118.4 million was recognized on acquisition of Angioblast Systems Inc. in 2010, $13.9 million was recognized on the acquisition of the MSC assets from Osiris (“MSC business combination”) in 2013 and $2.1 million was recognized on finalization of the MSC business combination of Osiris in 2015. In all cases the goodwill recognized represented excess in the purchase price over the net identifiable assets and in-process research and development acquired in the transaction. On acquisition, goodwill was not able to be allocated to the cash generating unit (“CGU”) level or to a group of CGU given the synergies of the underlying research and development. For the purpose of impairment testing, goodwill is monitored by management at the operating segment level. The Group is managed as one operating segment, being the development of cell technology platform for commercialization. IFRS requires that acquired in-process research and development be measured at fair value upon acquisition and carried as an indefinite life intangible asset subject to annual impairment reviews. The Group have recognized in-process research and development as a result of two separate acquisitions. In-process research and development of $387.0 million was recognized on the acquisition of Angioblast Systems Inc. in 2010 and $126.7 million was recognized on the acquisition of assets from Osiris in 2013 and $24.0 million was reclassified to current marketed products upon the TEMCELL asset becoming available for use in Japan. In 2016, the Group fully impaired $61.9 million of in-process research and development relating to our product candidates, MPC-MICRO-IO for the treatment of age-related macular degeneration and MPC-CBE for the expansion of hematopoietic stem cells within cord blood, as the Group suspended further patient enrollment of the Phase IIa MPC-MICRO-IO clinical trial and the Phase III MPC-CBE clinical trial as the Group prioritized the funding of its lead product candidates. The Group still believe these product candidates remain viable upon further funding, or partnership, and accordingly these products should not be regarded as abandoned, where typically, abandoned programs would be closed down and the related research and development efforts are considered impaired and the asset is fully expensed. The remaining carrying amount of in-process research and development as at June 30, 2023 and June 30, 2022 was $427.8 million. In-process research and development acquired is considered to be an indefinite life intangible asset on the basis that it is incomplete and cannot be used in its current form (see Note 23(p)(iii)). The intangible asset’s life will remain indefinite until such time it is completed and commercialized or impaired. The carrying value of in-process research and development is a separate asset which has been subject to impairment testing at the cash generating unit level, which has been determined to be at the product level. The recoverable amount of both goodwill and in-process research and development was assessed as of March 31, 2023 based on the fair value less costs to dispose. Management assess for indicators of impairment as at June 30, 2023 including considering events up to the date of the approval of the financial statements. As a result of the receipt of the complete response from the FDA in August 2023, an impairment assessment was performed over the MSC products in-process research and development asset and goodwill. No impairment was identified as a result of this impairment assessment. (v) Key assumptions used for fair value less costs to dispose calculations In determining the fair value less costs to dispose the Group has given consideration to the following internal and external indicators: • discounted expected future cash flows of programs valued by the Group’s internal valuation team and reviewed by the interim CFO. The valuation team also manages a process to continually refine the key assumptions within the model. This is done with input from the relevant business units. The key assumptions in the model have been clearly defined and the responsibility for refining those assumptions has been assigned to the most relevant business units. When determining key assumptions, the business units refer to both external sources and past experience as appropriate. The valuation is considered to be level 3 in the fair value hierarchy due to unobservable inputs used in the valuation; • the scientific results and progress of the trials since acquisition; • the market capitalization of the Group on the ASX (ASX:MSB); and • the valuation of the Group’s assets from an independent valuation. An independent valuation was obtained for all assets at March 31, 2023 and for the MSC products for the impairment assessment performed as a result of the receipt of the complete response. Costs of disposal were assumed to be immaterial. Discounted cash-flows used a real post-tax discount rate range of 13.8% to 15.5%, and include estimated real cash inflows and outflows for each program through to expected patent expiry which ranges from 9 to 25 years. In relation to cash outflows consideration has been given to cost of goods sold, selling costs and clinical trial schedules including estimates of numbers of patients and per patient costs. Associated expenses such as regulatory fees and patent maintenance have been included as well as any further preclinical development if applicable. In relation to cash inflows consideration has been given to product pricing, market population and penetration, sales rebates and discounts, launch timings and probability of success in the relevant applicable markets. There are no standard growth rates applied, other than our estimates of market penetration which increase initially, plateau and then decline. The assessment of the recoverable amount of each product has been made in accordance with the discounted cash-flow assumptions outlined above. The assessments showed that the recoverable amount of each product exceeds the carrying amount and therefore there is no impairment. The assessment of goodwill showed the recoverable amount of the Group's operating segment, including goodwill and remaining in-process research and development, exceeds carrying amounts, and therefore there is no impairment. (vi) Impact of possible changes in key assumptions The Group has considered and assessed reasonably possible changes in the key assumptions and has not identified any instances that could cause the carrying amount of our intangible assets to exceed its recoverable amount. Whilst there is no impairment, the key sensitivities in the valuation are dependent on the continued successful development of our technology platforms. Future discussion with the FDA as discussed in Note 15, could change the assumptions used within the impairment assessments. If the Group is unable to successfully develop our technology platforms, an impairment of the carrying amount of our intangible assets may result. d. Provisions As of June 30, 2023 As of June 30, 2022 (in U.S. dollars, in thousands) Current Non-current Total Current Non-current Total Contingent consideration 636 16,563 17,199 10,823 12,461 23,284 Employee benefits 2,013 49 2,062 3,333 62 3,395 Provision for license agreements 3,750 — 3,750 3,750 — 3,750 6,399 16,612 23,011 17,906 12,523 30,429 (i) Information about individual provisions and significant estimates Contingent consideration The contingent consideration provision relates to the Group’s liability for certain milestones and royalty achievements pertaining to the acquired MSC assets from Osiris. Further disclosures can be found in Note 5(g)(iii). Employee benefits The provision for employee benefits relates to the Group’s liability for annual leave, short term incentives and long service leave. Employee benefits include accrued annual leave. As of June 30, 2023 and 2022, the entire amount of the annual leave accrual was $1.1 million and $1.0 million respectively, and is presented as current, since the Group does not have an unconditional right to defer settlement for any of these obligations. (ii) Movements The contingent consideration provision relates to the Group’s liability for certain milestones and royalty achievements. Refer to Note 5(g)(iii) for movements in contingent consideration for the years ended June 30, 2023 and 2022. e. Deferred tax balances (i) Deferred tax balances As of June 30, (in U.S. dollars, in thousands) 2023 2022 Deferred tax assets The balance comprises temporary differences attributable to: Tax losses 76,020 80,411 Other temporary differences 11,972 7,831 Total deferred tax assets 87,992 88,242 Deferred tax liabilities The balance comprises temporary differences attributable to: Intangible assets 87,992 88,242 Total deferred tax liabilities 87,992 88,242 Net deferred tax liabilities — — (ii) Movements (in U.S. dollars, in thousands) Tax losses (1) (DTA) Other temporary differences (1) (DTA) Intangible assets (DTL) Total (DTL) As of June 30, 2021 (71,916) (8,248) 80,164 — Charged/(credited) to: - profit or loss (8,742) 425 8,078 (239) - directly to equity 247 (8) — 239 As of June 30, 2022 (80,411) (7,831) 88,242 — Charged/(credited) to: - profit or loss 4,179 (4,141) (250) (212) - directly to equity 212 — — 212 As of June 30, 2023 (76,020) (11,972) 87,992 — (1) Deferred tax assets are netted against deferred tax liabilities. f. Deferred consideration As of June 30, (in U.S. dollars, in thousands) 2023 2022 Opening balance (1) 2,500 2,500 Amount recognized as revenue during the period — — Balance as of the end of the period 2,500 2,500 (1) The $2.5 million milestone payment received in December 2019 from Grünenthal was considered constrained and resulted in deferred consideration as of June 30, 2023.

Equity

Equity	12 Months Ended
Equity	Jun. 30, 2023
Disclosure of classes of share capital [abstract]
Equity	Equity a. Contributed equity (i) Share capital As of June 30, 2023 2022 2021 2023 2022 2021 Shares No. (U.S. dollars, in thousands) Contributed equity (i) Share capital Ordinary shares 814,204,825 650,454,551 648,696,070 1,249,123 1,165,309 1,163,153 Less: Treasury Shares (542,903) (542,903) (771,983) — — — Total Contributed Equity 813,661,922 649,911,648 647,924,087 1,249,123 1,165,309 1,163,153 (ii) Movements in ordinary share capital As of June 30, As of June 30, 2023 2022 2021 2023 2022 2021 Shares No. (U.S. dollars, in thousands) Opening balance 650,454,551 648,696,070 583,949,612 1,165,309 1,163,153 1,051,450 Issues of ordinary shares during the period Exercise of share options (1) — — — — 209 9,223 Transfer to employee share trust (1) — — 3,450,000 — — — Share based compensation for services rendered — 1,758,481 1,187,168 — 1,698 1,867 Placement of shares under a share placement agreement (2)(3) 163,750,274 — 60,109,290 89,141 — 97,031 Transaction costs arising on share issue — — — (5,327) 21 (1,312) Total contributions of equity during the period 163,750,274 1,758,481 64,746,458 83,814 1,928 106,809 Share options reserve transferred to equity on exercise of options — — — — 228 4,894 Ending balance 814,204,825 650,454,551 648,696,070 1,249,123 1,165,309 1,163,153 (1) Options are issued to employees, directors and consultants in accordance with the Mesoblast Employee Share Option Plan. Unpaid shares are issued to the share trust to enable future option exercises to be settled. On exercise of options, the proceeds of the exercise are recorded in ordinary share capital in Mesoblast Limited and the exercise is settled by transfer of the shares from the share trust to the employee. (2) In March 2021, 60,109,290 shares were issued in an equity purchase of Mesoblast Limited at A$2.30 per share to existing and new institutional investors, representing a 6.50% discount to the price calculated at the close of trading February 25, 2021. The investors also received warrants to acquire a further 15 million shares at a price of A$2.88 per share, a 25% premium to the placement price, which may raise up to a further A$43.2 million, on or before March 15, 2028. These warrants have been classified within warrant reserves, refer to Note 7(b). (3) In August 2022, 86,666,667 shares were issued in an equity purchase of Mesoblast Limited at A$0.75 per share to existing and new institutional investors, representing a 5.00% discount to the thirty trading-day volume weighted average price. In April 2023, 77,083,607 shares were issued in an equity purchase of Mesoblast Limited at A$0.85 per share primarily to existing major shareholders, representing a 15.00% discount to the five trading-day volume weighted average price. (iii) Movements of shares in share trust As of June 30 As of June 30 2023 2022 2021 2023 2022 2021 Shares No. (U.S. dollars, in thousands) Opening balance (1) 542,903 771,983 3,500,000 — — — Movement of shares in share trust Transfer to employee share trust (2) — — 3,450,000 — — — Exercise of share options (2) — (229,080) (6,178,017) — — — Ending balance 542,903 542,903 771,983 — — — (1) In July 2020, the Group formed the Mesoblast Employee Share Trust, being a new trust formed to administer the Group’s employee share scheme. Prior to forming the new trust, the Group had been using the Mesoblast Limited Employee Share Trust for administering some aspects of the Group’s employee share scheme. In July 2020, 3,500,000 shares were transferred from Mesoblast Limited Employee Share Trust to the new Mesoblast Employee Share Trust. These trusts have been consolidated, as the substance of the relationship is that the trusts are controlled by the Group. (2) Options are issued to employees, directors and consultants in accordance with the Mesoblast Employee Share Option Plan. Unpaid shares are issued to the share trust to enable future option exercises to be settled. On exercise of options, the proceeds of the exercise are recorded in ordinary share capital in Mesoblast Limited and the exercise is settled by transfer of the shares from the share trust to the employee. (iv) Ordinary shares Ordinary shares participate in dividends and the proceeds on winding up of the Group in equal proportion to the number of shares held. At shareholders meetings each ordinary share is entitled to one vote when a poll is called, otherwise each shareholder has one vote on a show of hands. Ordinary shares have no par value and the Company does not have a limited amount of authorized capital. (v) Employee share options Information relating to the Group’s employee share option plan, including details of shares issued under the scheme, is set out in Note 17. b. Reserves (i) Reserves As at June 30, (in U.S. dollars, in thousands) 2023 2022 Share-based payments reserve 101,367 97,924 Investment revaluation reserve (543) (542) Foreign currency translation reserve (40,273) (39,700) Warrants reserve 12,969 12,969 73,520 70,651 (ii) Reconciliation of reserves (in U.S. dollars, in thousands) As at June 30, Share-based payments reserve 2023 2022 Opening balance 97,924 92,855 Tax credited / (debited) to equity (212) (239) Transfer to ordinary shares on exercise of options — (228) Share-based payment expense for the year 3,655 5,536 Closing Balance 101,367 97,924 Investment revaluation reserve Opening balance (542) (220) Changes in the fair value of financial assets through other comprehensive income (1) (322) Closing Balance (543) (542) Foreign currency translation reserve Opening balance (39,700) (39,791) Currency gain/(loss) on translation of foreign operations net assets (573) 91 Closing Balance (40,273) (39,700) Warrant reserve Opening balance 12,969 12,969 Movements during the period — — Closing Balance 12,969 12,969 (iii) Nature and purpose of reserves Share-based payment reserve The share-based payments reserve is used to recognize: • the fair value (1) of options issued but not exercised; and • the fair value (1) of deferred shares granted but not yet vested. (1) The fair value recognized is determined at the acceptance date, which is the date at which the entity and the employee agree to a share-based payment arrangement, being when the entity and the employee have a shared understanding of the terms and conditions of the arrangement or when they are approved by shareholders when this is required. Foreign currency translation reserve Exchange differences arising on translation of a foreign controlled entity are recognized in other comprehensive income and accumulated in a separate reserve within equity. The cumulative amount is reclassified to profit or loss when the net investment is disposed of. Warrants reserve In March 2021, the Group completed a A$138.0 million (US$110.0 million) private placement of 60,109,290 new fully-paid ordinary shares at a price of A$2.30. As part of this placement, the Group also issued one warrant for every four ordinary shares issued in the placement, which resulted in a further 15,027,327 warrants issued. Each warrant has an exercise price of A$2.88 per share and a 7 year term. The Group has a right to compel exercise of the warrants at any time, subject to the price of the Group’s ordinary shares trading at least A$4.32 for 45 consecutive days on the ASX. The warrants do not confer any rights to dividends or a right to participate in a new issue without exercising the warrant. The terms of the warrants include certain anti-dilution clauses, which adjust the exercise price or conversion ratio in the event of a rights issue or bonus issue. Management analyzed these clauses and determined the fixed-for-fixed requirement was still satisfied because the relative rights of shareholders and warrant holders were maintained. Therefore the warrants were classified as equity. The warrants were initially measured in equity at fair value, which was determined using a Monte Carlo simulation (refer to Note 7(b)(iv)), with the residual consideration being attributed to the ordinary shares issued in the same transaction. The warrants are not remeasured for subsequent changes in fair value. (iv) Fair value of warrants The warrants granted are not traded in an active market and therefore the fair value has been estimated by using the Monte Carlo pricing model based on the following assumptions. Key terms of the warrants are included above. The following assumptions were based on observable market conditions that existed at the issue date. (in U.S. dollars, except percent data and as otherwise noted) At Issue date - March 18, 2021 Rationale Share Price A$2.41 Closing share price on valuation date from external market source Exercise Price A$2.88 As per subscription agreement Expected Term 7 years As per subscription agreement Dividend Yield 0% Based on Company’s nil dividend history Expected Volatility 66.88% Based on historical volatility data for the Company A$-US$ FX Spot Rate 0.7827 Closing FX rate on valuation date from the Reserve Bank of Australia historical foreign exchange rate tables Risk Free Interest Rate 1.24% Based on the mid-point of the Australian Government issued 5 year and 10 year bonds Fair value per warrant $0.863 (A$1.103) Determined using Monte Carlo pricing models with the inputs above Fair value $12,968,583 Fair value of 15,027,327 warrants as at issue date

Cash flow information

Cash flow information	12 Months Ended
Cash flow information	Jun. 30, 2023
Statement of cash flows [abstract]
Cash flow information	Cash flow information (in U.S. dollars, in thousands) As of June 30, (a) Reconciliation of cash and cash equivalents 2023 2022 2021 Cash at bank 70,920 60,034 136,430 Deposits at call 398 413 451 71,318 60,447 136,881 (in U.S. dollars, in thousands) As of June 30, (b) Reconciliation of net cash flows used in operations with loss after income tax 2023 2022 2021 Loss for the period (81,889) (91,347) (98,811) Add/(deduct) net loss for non-cash items as follows: Depreciation and amortization 4,107 4,380 4,264 Foreign exchange losses/(gains) 62 536 (1,499) Finance costs 20,122 17,288 10,711 Remeasurement of contingent consideration (8,771) (913) (18,687) Remeasurement of warrant liabilities 2,205 (5,896) — Equity settled share-based payment 3,655 5,536 12,510 Deferred tax benefit (212) (235) (819) Gain on derecognition of right-of-use assets (76) — — Change in operating assets and liabilities: Decrease/(increase) in trade and other receivables (118) 140 (1,739) Decrease/(increase) in prepayments 1,650 1,555 (213) Increase/(decrease) in trade creditors and accruals (398) 4,777 (5,061) Decrease/(increase) in tax incentive recoverable (2,388) — — Increase/(decrease) in provisions (1,218) (1,603) (1,405) Net cash outflows used in operations (63,269) (65,782) (100,749)

Significant estimates, judgment

Significant estimates, judgments and errors	12 Months Ended
Significant estimates, judgments and errors	Jun. 30, 2023
Disclosure Of Significant Estimates Judgments And Errors [Abstract]
Significant estimates, judgments and errors	Significant estimates, judgments and errors The preparation of financial statements requires the use of accounting estimates which, by definition, will seldom equal the actual results. Management also needs to exercise judgment in applying the Group’s accounting policies. This note provides an overview of the areas that involved a higher degree of judgment or complexity, and of items which are more likely to be materially adjusted due to estimates and assumptions turning out to be wrong. Detailed information about each of these estimates and judgments is included in Notes 1 to 8 together with information about the basis of calculation for each affected line item in the financial statements. In addition, this note also explains where there have been actual adjustments this year as a result of an error and of changes to previous estimates. Significant estimates and judgments The areas involving significant estimates or judgments are: • recognition of revenue (Note 3 and Note 23(e)); • fair value of contingent liabilities and contingent purchase consideration in a business combination (Note 5(g) and 13); • recoverable amount of goodwill and other intangible assets including in-process research and development (Note 6(c)); • useful life of intangible assets (Note 6(c)); • recognition of deferred tax assets and deferred tax liabilities (Note 4); • fair value of share-based payments (Note 17); • remeasurement of borrowings due to change in estimated cash flows (Note 5(f)); • recognition of pre-launch inventory costs (Note 23(f)); and • fair value of warrant liability (Note 5(g)).

Financial Risk Management

Financial Risk Management	12 Months Ended
Financial Risk Management	Jun. 30, 2023
Disclosure Of Financial Risk Management [Abstract]
Financial Risk Management	Financial risk management This note explains the Group’s exposure to financial risks and how these risks could affect the Group’s future financial performance. Current year profit and loss information has been included where relevant to add further context. Risk Exposure arising from Measurement Management Market risk – currency risk Future commercial transactions Recognized financial assets and liabilities not denominated in the functional currency of each entity within the Group Cash flow forecasting The future cash flows of each currency are forecast and the quantum of cash reserves held for each currency are managed in line with future forecasted requirements. Cross currency swaps are undertaken as required. Market risk – interest rate risk Term deposits at fixed rates Sensitivity analysis Vary length of term deposits, utilize interest bearing accounts and periodically review interest rates available to ensure we earn interest at market rates. Market risk – price risk Long-term borrowings Sensitivity analysis Forecasts of net sales of the product underlying the NovaQuest borrowing arrangement are updated on a quarterly basis to evaluate the impact on the carrying amount of the financial liability. Credit risk Cash and cash equivalents, trade and other receivables and other non-current assets Aging analysis Transact primarily with the best risk rated banks available in each region giving consideration to the products required, the quantum of cash reserves held and future forecasted requirements Liquidity risk Cash and cash equivalents, borrowings, trade payables, lease liabilities and contingent consideration Rolling cash flow forecasts Future cash flows requirements are forecasted and capital raising strategies are planned to ensure sufficient cash balances are maintained to meet the Group’s future commitments. a. Market risk (i) Currency risk The Group has foreign currency amounts owing relating to clinical, regulatory and overhead activities and foreign currency deposits held primarily in the Group’s Australian based entity, whose functional currency is the A$. The Group also has foreign currency amounts owing in the Group’s Swiss and Singapore based entities, whose functional currencies are the US$. The Group also has foreign currency amounts owing in various other non-US$ currencies in A$ and US$ functional currency entities in the Group relating to clinical, regulatory and overhead activities. These foreign currency balances give rise to a currency risk, which is the risk of the exchange rate moving, in either direction, and the impact it may have on the Group’s financial performance. Currency risk is minimized by ensuring the proportion of cash reserves held in each currency matches the expected rate of spend of each currency. As of June 30, 2023, the Group held 67% of its cash in US$, and 33% in A$. As of June 30, 2022 the Group held 97% of its cash in US$, and 3% in A$. The balances held at the end of the year that give rise to currency risk exposure are presented in US$ in the following table, together with a sensitivity analysis which assesses the impact that a change of +/-20% in the exchange rate as of June 30, 2023 and June 30, 2022 would have had on the Group’s reported net profits/(losses) and/or equity balance. The bank balances held at the end of the year that are presented in the following table give rise to currency risk exposure as they are not in the functional currency of the entity in which it is held. +20% -20% (in U.S. dollars, in thousands, unless otherwise noted) Foreign Profit/(Loss) Profit/(Loss) Bank accounts – USD US$60 $ 12 $ (12) Bank accounts – CHF CHF79 $ 18 $ (18) Bank accounts – SGD S$80 $ 12 $ (12) Bank accounts – EUR EUR4 $ 1 $ (1) Trade and other receivables - USD US$400 $ 80 $ (80) Trade and other receivables - SGD S$106 $ 16 $ (16) Trade and other receivables - CHF CHF3 $ 1 $ (1) Trade and other receivables - EUR EUR292 $ 63 $ (63) Trade payables and accruals - USD (US$1,361) $ (272) $ 272 Trade payables and accruals - AUD (A$1,064) $ (141) $ 141 Trade payables and accruals - SGD (S$422) $ (62) $ 62 Trade payables and accruals - GBP (GBP45) $ (11) $ 11 Trade payables and accruals - EUR (EUR26) $ (6) $ 6 Trade payables and accruals - CHF (CHF40) $ (9) $ 9 Provisions – USD (US$1,750) $ (350) $ 350 $ (648) $ 648 +20% -20% (in U.S. dollars, in thousands, unless otherwise noted) Foreign Profit/(Loss) Profit/(Loss) Bank accounts – USD US$93 $ 19 $ (19) Bank accounts – CHF CHF55 $ 12 $ (12) Bank accounts – SGD S$140 $ 20 $ (20) Bank accounts – EUR EUR289 $ 60 $ (60) Trade and other receivables - SGD S$205 $ 30 $ (30) Trade and other receivables - CHF CHF6 $ 1 $ (1) Trade and other receivables - EUR EUR153 $ 32 $ (32) Trade payables and accruals - USD (US$274) $ (55) $ 55 Trade payables and accruals - AUD (A$752) $ (104) $ 104 Trade payables and accruals - SGD (S$429) $ (62) $ 62 Trade payables and accruals - GBP (GBP50) $ (12) $ 12 Trade payables and accruals - EUR (EUR42) $ (9) $ 9 Trade payables and accruals - CHF (CHF36) $ (7) $ 7 Provisions – USD (US$1,750) $ (350) $ 350 Provisions – SGD (S$62) $ (9) $ 9 $ (434) $ 434 (1) We have corrected for immaterial errors in the year ended June 30, 2022 within the financial risk management disclosure above. We do not believe this correction is material to the consolidated financial statements in any period presented. (ii) Cash flow and interest rate risk The Group is exposed to interest rate movements which impacts interest income earned on its deposits and at call accounts. The interest rate risk is managed by spreading the maturity date of our deposits across various periods. The Group ensures that sufficient funds are available, in at call accounts, to meet the working capital requirements of the Group. The deposits held which derive interest revenue are described in the table below, together with the maximum and minimum interest rates being earned as of June 30, 2023 and June 30, 2022. The effect on profit is shown if interest rates change by 10%, in either direction, is as follows: As of As of (in U.S. dollars, in thousands, except percent data) Low High US$ Low (1) High (1) US$ Funds invested – US$ 1.79 % 1.79 % 40,569 0.00 % 0.00 % 49,383 Rate increase by 10% 1.97 % 1.97 % 73 0.03 % 0.03 % 15 Rate decrease by 10% 1.61 % 1.61 % (73) 0.03 % 0.03 % (15) (in Australian dollars, in thousands, except percent data) Low High A$ Low High A$ Funds invested – A$ 4.59 % 4.59 % 600 1.50 % 1.50 % 600 Rate increase by 10% 5.05 % 5.05 % 3 1.65 % 1.65 % 1 Rate decrease by 10% 4.13 % 4.13 % (3) 1.35 % 1.35 % (1) (1) The interest rate was 0% for the period ended June 30, 2022. The sensitivity assumes the interest rate to increase or decrease by 0.03%, which is consistent with prior periods. (iii) Price risk Price risk is the risk that future cash flows derived from financial instruments will be altered as a result of a market price movement, which is defined as movements other than foreign currency rates and interest rates. The Group is exposed to price risk which arises from long-term borrowings under its facility with NovaQuest, where the timing and amounts of principal and interest payments is dependent on net sales of remestemcel-L for the treatment of SR-aGVHD in pediatric patients in the United States and other territories excluding Asia. As net sales of remestemcel-L for the treatment of SR-aGVHD in pediatric patients in these territories increase/decrease, the timing and amount of principal and interest payments relating to the financing arrangement will also fluctuate, resulting in an adjustment to the carrying amount of financial liability. The adjustment is recognized in the Consolidated Income Statement as remeasurement of borrowing arrangements within finance costs in the period the revision is made. The exposure of the Group’s borrowing to price rate changes are as follows: As of As of (in U.S. dollars, in thousands, except percent data) Total % of total borrowings Total % of total borrowings Financial liabilities Current borrowings Borrowings – NovaQuest 336 0 % 372 0 % Non-current borrowings Borrowings – NovaQuest 55,739 51 % 47,898 50 % 56,075 51 % 48,270 50 % As at June 30, 2023, all other factors held constant, a +/-20% change in the forecast net sales of remestemcel-L for the treatment of SR-aGVHD in pediatric patients in the United States and other territories excluding Asia would have a minimal impact on non-current borrowings and profit. The Group is also exposed to price risk on contingent consideration provision balances, as expected unit revenues are a significant unobservable input used in the level 3 fair value measurements. As at June 30, 2023, all other factors held constant, the increase/decrease in price assumptions adopted in the fair value measurements of the contingent consideration provision are discussed in Note 5(g)( iv ). The Group does not consider it has any exposure to price risk other than those already described above. b. Credit risk Credit risk is the risk that one party to a financial instrument will fail to discharge its obligation and cause financial loss to the other party. The maximum exposure to credit risk at the end of the reporting period is the carrying amount of each class of financial assets. The Group’s receivables are tabled below. As of June 30, (in U.S. dollars, in thousands) 2023 2022 Cash and cash equivalents Deposits at call (Note 5(a)) - minimum A rated 398 413 Cash at bank (Note 5(a)) - minimum A rated 70,920 60,033 Trade and other receivables Receivable from other parties (non-rated) 2,276 2,382 Receivable from the Australian Government (Income Tax) 2,363 5 Receivable from the United States Government (U.S. tax credits) 1,473 1,475 Receivable from the Australian Government (Foreign Withholding Tax) 400 400 Receivable from the Australian Government (Goods and Services Tax) 121 102 Receivable from the Singapore Government (Goods and Services Tax) 78 — Receivable from the United States Government (Foreign Withholding Tax) 71 — Receivable from minimum A rated bank deposits (interest) 18 — Receivable from the Swiss Government (Value-Added Tax) 3 105 Receivable from the United States Government (Income Tax) — 20 Other non-current assets Minimum A rated bank deposits (held as security) 1,912 1,930 (1) We have corrected for immaterial errors in the year ended June 30, 2022 within the financial risk management disclosure above. We do not believe this correction is material to the consolidated financial statements in any period presented. c. Liquidity risk Liquidity risk is the risk that the Group will not be able to pay its debts as and when they fall due. Liquidity risk has been assessed in Note 1( i ). All financial liabilities, excluding contingent consideration, borrowings and lease liabilities held by the Group as of June 30, 2023 and June 30, 2022 mature within 6 months. Trade payables and contingent consideration held by the Group as of June 30, 2023 and June 30, 2022 are non-interest bearing. The total contractual cash flows associated with trade payables equate to the carrying amount disclosed within the financial statements. As of June 30, 2023, the maturity profile of the anticipated future contractual cash flows, on an undiscounted basis and removing probability adjustments as applicable for contingent consideration, and which, therefore differs from the carrying value, is as follows: (in U.S. dollars, in thousands) Within Between Between Over Total Carrying Borrowings (1)(2) (6,668) (15,639) (152,371) — (174,678) (108,763) Trade payables (20,145) — — — (20,145) (20,145) Lease liabilities (4,393) (2,592) (1,252) — (8,237) (7,732) Contingent consideration (3) (4,617) (935) (1,006) — (6,558) (593) (35,823) (19,166) (154,629) — (209,618) (137,233) (1) Contractual cash flows include payments of principal, interest and other charges. Interest is calculated based on debt held at June 30, 2023 without taking into account drawdowns of further tranches. (2) In relation to the contractual maturities of the NovaQuest borrowings, there is variability in the maturity profile of the anticipated future contractual cash flows given the timing and amount of payments are calculated based on our estimated net sales of remestemcel-L for the treatment of pediatric SR-aGVHD .

Capital Management

Capital Management	12 Months Ended
Capital Management	Jun. 30, 2023
Capital Management [Abstract]
Capital Management	Capital managementThe Group’s objective when managing capital is to safeguard its ability to continue as a going concern, so that it can provide returns for shareholders and benefits for other stakeholders. See Note 5(a) for the cash reserves of the Group as at the end of the financial reporting period.

Interests in other entities

Interests in other entities	12 Months Ended
Interests in other entities	Jun. 30, 2023
Disclosure of subsidiaries [abstract]
Interests in other entities	Interests in other entities The Group’s subsidiaries as of June 30, 2023 and 2022 are set out below. Unless otherwise stated, they have share capital consisting solely of ordinary shares that are held directly by the Group, and the proportion of ownership interests held equals the voting rights held by the Group. The country of incorporation or registration is also their principal place of business, aside from BeiCell Ltd, which was incorporated on November 15, 2018 in the Cayman Islands however operates in Hong Kong. Country of Class of Equity holding As of June 30, 2023 2022 % % Mesoblast, Inc. USA Ordinary 100 100 Mesoblast International Sàrl (includes Mesoblast International Sàrl Singapore Branch) Switzerland Ordinary 100 100 Mesoblast Australia Pty Ltd Australia Ordinary 100 100 Mesoblast UK Ltd United Kingdom Ordinary 100 100 BeiCell Ltd Cayman Islands Ordinary 100 100

Contingent assets and liabiliti

Contingent assets and liabilities	12 Months Ended
Contingent assets and liabilities	Jun. 30, 2023
Disclosure Of Contingent Assets And Liabilities [Abstract]
Contingent assets and liabilities	Contingent assets and liabilities a. Contingent assets The Group did not have any contingent assets outstanding as of June 30, 2023 and June 30, 2022. b. Contingent liabilities (i) Central Adelaide Local Health Network Incorporated (“CALHNI”) (formerly Medvet) The Group acquired certain intellectual property relating to our MPCs, or Medvet IP, pursuant to an Intellectual Property Assignment Deed, or IP Deed, with Medvet Science Pty Ltd, or Medvet. Medvet’s rights under the IP Deed were transferred to Central Adelaide Local Health Network Incorporated, or CALHNI, in November 2011. In connection with its use of the Medvet IP, on completion of certain milestones the Group will be obligated to pay CALHNI, as successor in interest to Medvet, (i) certain aggregated milestone payments of up to $2.2 million and single-digit royalties on net sales of products covered by the Medvet IP, for cardiac muscle and blood vessel applications and bone and cartilage regeneration and repair applications, subject to minimum annual royalties beginning in the first year of commercial sale of those products and (ii) single-digit royalties on net sales of the specified products for applications outside the specified fields. (ii) Other contingent liabilities The Group has entered into a number of other agreements with other third parties pertaining to intellectual property. Contingent liabilities may arise in the future if certain events or developments occur in relation to these agreements. As of June 30, 2023, the Group has assessed these contingent liabilities to be remote and specific disclosure is not required.

Commitments

Commitments	12 Months Ended
Commitments	Jun. 30, 2023
Commitments [Abstract]
Commitments	Commitments a. Capital commitments The Group did not have any commitments for future capital expenditure outstanding as of June 30, 2023 and June 30, 2022. b. Purchase commitments In December 2019, the Group commenced production under its manufacturing service agreement with Lonza for the supply of commercial product for the potential approval and launch of remestemcel-L for the treatment of pediatric SR-aGVHD in the US market. This agreement contains lease and non-lease components. As of June 30, 2023, the agreement contains a minimum remaining financial commitment of the non-lease component of $16.8 million, payable until December 2024, which is cancellable in limited circumstances. The Group has accounted for the lease component within the agreement as a lease liability separately from the non-lease components. As of June 30, 2023, the lease component is $3.0 million on an undiscounted basis, as disclosed within the total contractual cash flows as lease liabilities in Note 10(c). At the Group's discretion, the minimum financial commitment under this manufacturing services agreement can be reduced by $12.2 million under certain conditions, with $1.1 million of this reduction relating to the lease component and $11.1 million relating to the non-lease component of the agreement. The group have agreements with third parties related to contract manufacturing and other goods and services. As of June 30, 2023, the Group had $9.1 million of non-cancellable purchase commitments related to raw materials, manufacturing agreements and other goods and services. This amount represents our minimum contractual obligations, including termination fees. Certain agreements provide for termination rights subject to termination fees. Under such agreement, the Group are contractually obligated to make certain payments, mainly, to reimburse them for their unrecoverable outlays incurred prior to cancellation.

Events occurring after the repo

Events occurring after the reporting period	12 Months Ended
Events occurring after the reporting period	Jun. 30, 2023
Disclosure of non-adjusting events after reporting period [abstract]
Events occurring after the reporting period	Events occurring after the reporting period In August 2023, the FDA provided a complete response to the Group's BLA resubmission for remestemcel-L for the treatment of pediatric SR-aGVHD and requires more data to support marketing approval, including potency assay or clinical data. In line with the Group's overall commercial strategy to progress to adult populations, the Group intends to conduct a targeted, controlled study in the highest-risk adults with the greatest mortality. Assumptions associated with SR-aGVHD are included within the impairment assessment of Osiris MSC products within in-process research and development and goodwill, contingent consideration, pre-launch inventory and the NovaQuest borrowings on the consolidated balance sheet and forecast net operating cash usage. The Group has assessed and included the impact of the FDA's complete response to the Group's BLA resubmission for remestemcel-L for the treatment of pediatric SR-aGVHD in these areas. Future discussions with the FDA could lead to a change in the assumptions associated with SR-aGVHD within the impairment assessment of Osiris MSC products within in-process research and development and goodwill, contingent consideration, pre-launch inventory and the NovaQuest borrowings on the consolidated balance sheet and forecast net operating cash usage. There were no other events that have occurred after June 30, 2023 and prior to the signing of this financial report that would likely have a material impact on the financial results presented.

Related party transactions

Related party transactions	12 Months Ended
Related party transactions	Jun. 30, 2023
Disclosure Of Key Management Personnel Compensation [Abstract]
Related party transactions	Related party transactions a. Parent entity The parent entity within the Group is Mesoblast Limited. b. Subsidiaries Details of interests in subsidiaries are disclosed in Note 12 to the financial statements. c. Key management personnel compensation The aggregate compensation made to Directors and other members of key management personnel of the Group is set out below: Year Ended June 30, (in U.S. dollars) 2023 2022 Short-term employee benefits 2,153,181 2,294,897 Long-term employee benefits 11,326 12,206 Post-employment benefits 23,935 31,346 Share based payments 881,342 391,592 3,069,784 2,730,041 The aggregate other service payments made to Directors and other members of key management personnel of the Group is set out below: Philip Krause was appointed to a formal strategic advisory role on June 4, 2023. The consulting agreement is in addition to Philip Krause's existing role as non executive director, the terms of which remain unchanged. He will provide specialist regulatory advisory services and will be remunerated at an hourly rate. The agreement is ongoing with either party able to terminate on 15 written days notice. The total aggregate fees paid to Philip Krause as of June 30, 2023 was $110,383. There were no loans or other related transactions with KMP during the financial year. d. Transactions with other related parties Accounts receivable from revenues, accounts payable to expenses and loans from subsidiaries as at the end of the fiscal year have been eliminated on consolidation of the Group. e. Terms and conditions All other transactions were made on normal commercial terms and conditions and at market rates, except that there are no fixed terms for the repayment of loans between the parties. Outstanding balances are unsecured and are repayable in cash.

Share-based payments

Share-based payments	12 Months Ended
Share-based payments	Jun. 30, 2023
Disclosure Of Sharebased Payment Arrangements [Abstract]
Share-based payments	Share-based payments The Company has adopted an Employee Share Option Plan (“ESOP”) to foster an ownership culture within the Company and to motivate senior management and consultants to achieve performance targets. Selected directors, employees and consultants may be eligible to participate in ESOP at the absolute discretion of the board of directors, and in the case of directors, upon approval by shareholders. Grant policy In accordance with the Company’s policy, options are typically issued in three equal tranches. The length of time from grant date to expiry date is typically 7 years. Options issued to employees generally vest based on performance or time conditions, or both. In the year ended June 30, 2023, senior executives were issued options that vest based on performance and time conditions. These options are required to satisfy certain pre-specified performance conditions and time-based vesting conditions prior to vesting. Time-based conditions restrict vesting to a maximum of one third at 12 months, two thirds at 24 months and full grant at 36 months, but only if the pre-specified performance conditions have been met. For time-based vesting options, the first tranche typically vests 12 months after grant date, the second tranche 24 months after grant date, and the third tranche 36 months after grant date. The exercise price is determined by reference to the Company policy. Generally the exercise price is the higher of the volume weighted average share price of the five ASX trading days up to Board approval of the grant, and the last closing price of an ordinary share on the ASX at Board approval. In the case of options that have time-based vesting conditions only, the board of directors adds a 10% premium to the market price. Options with performance based vesting conditions are issued with no premium. The board of directors’ policy is not to issue options at a discount to the market price. The aggregate number of options which may be issued pursuant to the ESOP must not exceed 10,000,000 with respect to US incentive stock options, and with respect to Australian residents, the limit imposed under the Australian Securities and Investments Commission Class Order 14/1000. a. Reconciliation of outstanding share based payments Series Grant Date (1) Expiry Date Exercise Opening Granted No. Exercised Lapsed/Forfeited* Closing Vested and 34 27-Apr-16 06-Mar-23 A$2.80 1,678,979 — — (1,678,979) — — 34b 31-Oct-16 06-Mar-23 A$2.80 200,000 — — (200,000) — — 35a 08-Jul-20 08-Jul-23 A$2.86 1,500,000 — — — 1,500,000 1,500,000 36 06-Dec-16 05-Dec-23 A$1.31 533,000 — — — 533,000 533,000 36a 06-Dec-16 05-Dec-23 A$1.19 1,950,730 — — — 1,950,730 1,809,064 38 16-Sep-17 15-Sep-24 A$1.54 50,000 — — — 50,000 50,000 38a 16-Sep-17 15-Sep-24 A$1.40 150,000 — — (150,000) — — 39 13-Oct-17 12-Oct-24 A$1.94 975,000 — — — 975,000 975,000 39a 13-Oct-17 12-Oct-24 A$1.76 902,425 — — — 902,425 902,425 40 24-Nov-17 23-Nov-24 A$1.41 750,000 — — — 750,000 750,000 40a 24-Nov-17 23-Nov-24 A$1.28 750,000 — — — 750,000 — 41 18-Jun-18 17-Jun-25 A$1.52 200,000 — — — 200,000 200,000 42 11-Jul-18 10-Jul-25 A$1.56 200,000 — — — 200,000 200,000 43 18-Jul-18 17-Jul-25 A$1.87 3,793,332 — — (660,000) 3,133,332 3,133,332 43b 18-Jul-18 17-Jul-25 A$1.87 350,000 — — — 350,000 350,000 45 30-Nov-18 29-Nov-25 A$1.33 590,000 — — — 590,000 590,000 46 19-Jan-19 18-Jan-26 A$1.45 3,333 — — — 3,333 3,333 47 19-Jan-19 18-Jan-26 A$1.45 150,000 — — — 150,000 150,000 48 04-Apr-19 03-Apr-26 A$1.48 300,000 — — — 300,000 300,000 49 20-Jul-19 19-Jul-26 A$1.62 3,098,670 — — (66,667) 3,018,669 3,018,669 49 20-Jul-19 19-Jul-26 A$1.62 — — (13,334) * 49a 20-Jul-19 19-Jul-26 A$1.47 3,499,998 — — (466,666) 2,833,332 1,883,332 49a 20-Jul-19 19-Jul-26 A$1.47 — — (200,000) * 49b 20-Jul-19 19-Jul-26 A$1.47 1,346,667 — — — 1,346,667 673,334 49c 20-Jul-19 19-Jul-26 A$1.47 538,667 — — — 538,667 538,667 50 20-Jul-19 19-Jul-26 A$1.47 700,000 — — — 700,000 175,000 50a 20-Jul-19 19-Jul-26 A$1.47 400,000 — — (400,000) * — — 52 29-Aug-19 28-Aug-26 A$1.62 400,000 — — (400,000) — — 53 29-Aug-19 28-Aug-26 A$1.47 800,000 — — (800,000) — — 54 25-Nov-19 24-Nov-26 A$1.98 153,334 — — (133,334) 20,000 20,000 55 29-May-19 28-May-26 A$1.48 350,000 — — — 350,000 300,000 56 18-Nov-19 17-Nov-26 A$1.83 200,000 — — — 200,000 200,000 57 25-Nov-19 24-Nov-26 A$1.80 100,000 — — — 100,000 100,000 58 25-Nov-19 24-Nov-26 A$1.98 450,000 — — (200,000) 150,000 150,000 58 25-Nov-19 24-Nov-26 A$1.98 — — (100,000) * 59 24-Jan-20 23-Jan-27 A$3.38 10,000 — — — 10,000 10,000 63 18-May-20 17-May-27 A$4.02 1,200,000 — — — 1,200,000 1,200,000 63a 18-May-20 17-May-27 A$3.65 2,400,000 — — (800,000) 1,200,000 200,000 63a 18-May-20 17-May-27 A$3.65 — — (400,000) * 64 16-Jul-20 15-Jul-27 A$3.75 3,498,333 — — (176,668) 3,253,333 2,160,009 64 16-Jul-20 15-Jul-27 A$3.75 — — (68,332) * 64a 16-Jul-20 15-Jul-27 A$3.41 2,700,000 — — (965,000) * 1,735,000 478,334 64c 16-Jul-20 15-Jul-27 A$3.41 350,000 — — — 350,000 116,666 64d 16-Jul-20 15-Jul-27 A$3.41 300,000 — — — 300,000 100,000 64e 16-Jul-20 15-Jul-27 A$3.41 1,200,000 — — — 1,200,000 720,000 65 26-Aug-20 25-Aug-27 A$5.76 5,000 — — (3,334) — — 65 26-Aug-20 25-Aug-27 A$5.76 — — (1,666) * 66 11-Sep-20 10-Sep-27 A$4.78 200,000 — — — 200,000 100,000 68 20-Nov-20 19-Nov-27 A$3.60 200,000 — — — 200,000 133,333 69 20-Nov-20 19-Nov-27 A$3.60 100,000 — — — 100,000 100,000 71 17-Feb-21 16-Feb-28 A$2.67 250,000 — — — 250,000 166,667 72 15-Apr-21 14-Apr-28 A$2.28 200,000 — — — 200,000 133,334 74 08-Sep-21 07-Sep-28 A$1.77 3,423,000 — — (50,001) 3,186,333 1,051,007 74 08-Sep-21 07-Sep-28 A$1.77 — — (186,666) * 74a 08-Sep-21 07-Sep-28 A$1.77 4,150,000 — — (300,000) * 3,850,000 923,334 74b 08-Sep-21 07-Sep-28 A$1.77 1,550,000 — — — 1,550,000 — 74c 08-Sep-21 07-Sep-28 A$1.77 650,000 — — (650,000) * — — 75 23-Dec-21 22-Dec-28 A$1.42 200,000 — — — 200,000 100,000 76 17-Oct-22 16-Oct-29 A$1.03 — 1,250,000 — — 1,250,000 — 77 23-May-22 22-May-29 A$1.01 — 200,000 — — 200,000 66,667 78 24-Aug-22 23-Aug-29 A$0.85 — 200,000 — — 200,000 — 79 17-Oct-22 16-Oct-29 A$1.13 — 5,844,500 — (90,000) * 5,754,500 — 79a 17-Oct-22 16-Oct-29 A$1.03 — 4,350,000 — — 4,350,000 — 79b 17-Oct-22 16-Oct-29 A$1.13 — 225,000 — — 225,000 — 79c 17-Oct-22 16-Oct-29 A$1.03 — 3,225,000 — — 3,225,000 — 79d 17-Oct-22 16-Oct-29 A$1.03 — 1,200,000 — — 1,200,000 — 80 08-Aug-22 07-Aug-29 A$0.93 — 100,000 — — 100,000 100,000 81 11-Dec-20 10-Dec-27 A$4.60 — 100,000 — — 100,000 100,000 82 21-Nov-22 20-Nov-29 A$1.12 — 100,000 — — 100,000 — 83 30-Mar-23 29-Mar-30 A$1.03 — 180,000 — (30,000) * 150,000 — June 30, 2023 49,650,468 16,974,500 — (9,190,647) 57,434,321 26,464,507 Weighted average share purchase price A$2.21 A$1.08 A$— A$2.39 A$1.85 A$2.12 (1) The dates presented in the grant date column represent the date on which board approval was obtained. For valuation dates per IFRS 2, refer to Note 17(c). Series Grant Date (1) Expiry Date Exercise Opening Granted No. Exercised Lapsed/Forfeited* Closing Vested and 32 10-Jul-15 30-Jun-22 A$4.20 1,753,334 — — (1,753,334) — — 33 26-Aug-15 16-Aug-22 A$4.05 75,000 — — (75,000) — — 34 27-Apr-16 06-Mar-23 A$2.80 1,858,979 — — (180,000) 1,678,979 1,678,979 34b 31-Oct-16 06-Mar-23 A$2.80 200,000 — — — 200,000 200,000 35a 08-Jul-20 08-Jul-23 A$2.86 1,500,000 — — — 1,500,000 1,500,000 36 06-Dec-16 05-Dec-23 A$1.31 623,000 — (50,000) (40,000) 533,000 533,000 36a 06-Dec-16 05-Dec-23 A$1.19 1,950,730 — — — 1,950,730 1,809,064 38 16-Sep-17 15-Sep-24 A$1.54 50,000 — — — 50,000 50,000 38a 16-Sep-17 15-Sep-24 A$1.40 150,000 — — — 150,000 150,000 39 13-Oct-17 12-Oct-24 A$1.94 1,090,000 — — (115,000) 975,000 975,000 39a 13-Oct-17 12-Oct-24 A$1.76 902,425 — — — 902,425 902,425 40 24-Nov-17 23-Nov-24 A$1.41 750,000 — — — 750,000 750,000 40a 24-Nov-17 23-Nov-24 A$1.28 750,000 — — — 750,000 — 41 18-Jun-18 17-Jun-25 A$1.52 200,000 — — — 200,000 200,000 42 11-Jul-18 10-Jul-25 A$1.56 200,000 — — — 200,000 200,000 43 18-Jul-18 17-Jul-25 A$1.87 4,201,666 — (20,000) (388,334) 3,793,332 3,793,332 43b 18-Jul-18 17-Jul-25 A$1.87 350,000 — — — 350,000 350,000 44 15-Jul-18 14-Jul-25 A$1.72 150,000 — — (150,000) — — 45 30-Nov-18 29-Nov-25 A$1.33 590,000 — — — 590,000 590,000 46 19-Jan-19 18-Jan-26 A$1.45 3,333 — — — 3,333 3,333 47 19-Jan-19 18-Jan-26 A$1.45 150,000 — — — 150,000 150,000 48 04-Apr-19 03-Apr-26 A$1.48 300,000 — — — 300,000 300,000 49 20-Jul-19 19-Jul-26 A$1.62 3,638,671 — (113,334) (277,999) 3,098,670 1,940,654 49 20-Jul-19 19-Jul-26 A$1.62 — (148,668) * 49a 20-Jul-19 19-Jul-26 A$1.47 3,999,998 — — (333,334) 3,499,998 1,316,665 49a 20-Jul-19 19-Jul-26 A$1.47 — (166,666) * 49b 20-Jul-19 19-Jul-26 A$1.47 1,346,667 — — — 1,346,667 673,334 49c 20-Jul-19 19-Jul-26 A$1.47 538,667 — — — 538,667 359,112 50 20-Jul-19 19-Jul-26 A$1.47 700,000 — — — 700,000 — 50a 20-Jul-19 19-Jul-26 A$1.47 400,000 — — — 400,000 — 51 29-Aug-19 28-Aug-26 A$1.47 150,000 — — (150,000) * — — 52 29-Aug-19 28-Aug-26 A$1.62 400,000 — — — 400,000 266,666 53 29-Aug-19 28-Aug-26 A$1.47 800,000 — — — 800,000 533,334 54 25-Nov-19 24-Nov-26 A$1.98 295,000 — — (25,000) 153,334 146,668 54 25-Nov-19 24-Nov-26 A$1.98 — (116,666) * 55 29-May-19 28-May-26 A$1.48 350,000 — — — 350,000 300,000 56 18-Nov-19 17-Nov-26 A$1.83 200,000 — — — 200,000 133,332 57 25-Nov-19 24-Nov-26 A$1.80 100,000 — — — 100,000 100,000 58 25-Nov-19 24-Nov-26 A$1.98 450,000 — — — 450,000 300,000 59 24-Jan-20 23-Jan-27 A$3.38 10,000 — — — 10,000 10,000 61 17-Apr-20 16-Apr-27 A$2.51 50,000 — — (16,666) — — 61 17-Apr-20 16-Apr-27 A$2.51 — (33,334) * 63 18-May-20 17-May-27 A$4.02 1,200,000 — — — 1,200,000 800,000 63a 18-May-20 17-May-27 A$3.65 2,400,000 — — — 2,400,000 400,000 64 16-Jul-20 15-Jul-27 A$3.75 4,280,000 — — (225,003) 3,498,333 1,201,676 64 16-Jul-20 15-Jul-27 A$3.75 (556,664) * 64a 16-Jul-20 15-Jul-27 A$3.41 3,050,000 — — (350,000) * 2,700,000 133,334 64b 16-Jul-20 15-Jul-27 A$3.41 325,000 — — (325,000) * — — 64c 16-Jul-20 15-Jul-27 A$3.41 350,000 — — — 350,000 — 64d 16-Jul-20 15-Jul-27 A$3.41 300,000 — — — 300,000 — 64e 16-Jul-20 15-Jul-27 A$3.41 1,200,000 — — — 1,200,000 — 65 26-Aug-20 25-Aug-27 A$5.76 5,000 — — — 5,000 1,667 66 11-Sep-20 10-Sep-27 A$4.78 200,000 — — — 200,000 100,000 67 08-Oct-20 07-Oct-27 A$3.84 200,000 — — (66,667) — — 67 08-Oct-20 07-Oct-27 A$3.84 — (133,333) * 68 20-Nov-20 19-Nov-27 A$3.60 200,000 — — — 200,000 66,666 69 20-Nov-20 19-Nov-27 A$3.60 100,000 — — — 100,000 100,000 71 17-Feb-21 16-Feb-28 A$2.67 250,000 — — — 250,000 — 72 15-Apr-21 14-Apr-28 A$2.28 — 200,000 — — 200,000 66,667 73 30-Jun-21 30-Aug-21 A$— 45,746 — (45,746) — — — 74 08-Sep-21 07-Sep-28 A$1.77 — 3,973,000 — (550,000) * 3,423,000 — 74a 08-Sep-21 07-Sep-28 A$1.77 — 4,150,000 — — 4,150,000 — 74b 08-Sep-21 07-Sep-28 A$1.77 — 1,550,000 — — 1,550,000 — 74c 08-Sep-21 07-Sep-28 A$1.77 — 650,000 — — 650,000 — 75 23-Dec-21 22-Dec-28 A$1.42 — 200,000 — — 200,000 — June 30, 2022 45,333,216 10,723,000 (229,080) (6,176,668) 49,650,468 23,084,908 Weighted average share purchase price A$2.42 A$1.77 A$1.25 A$2.99 A$2.21 A$2.06 (1) The dates presented in the grant date column represent the date on which board approval was obtained. For valuation dates per IFRS 2, refer to Note 17(c). Series Grant Date (1) Expiry Date Exercise Opening Granted No. Exercised Lapsed/Forfeited* Closing Vested and 32 10-Jul-15 30-Jun-22 US$4.20 2,268,334 — (515,000) — 1,753,334 1,753,334 33 26-Aug-15 16-Aug-22 A$4.05 75,000 — — — 75,000 75,000 34 27-Apr-16 6-Mar-23 A$2.80 2,638,334 — (769,355) (10,000) 1,858,979 1,858,979 34a 27-Apr-16 17-Apr-23 A$2.74 200,000 — (116,666) (83,334) — — 34b 31-Oct-16 6-Mar-23 A$2.80 200,000 — — — 200,000 200,000 35 30-Jun-16 30-Jun-22 (2) A$2.20 900,000 — (900,000) — — — 35a 8-Jul-20 8-Jul-23 A$2.86 — 1,500,000 — — 1,500,000 1,500,000 36 6-Dec-16 5-Dec-23 A$1.31 923,000 — (300,000) — 623,000 623,000 36a 6-Dec-16 5-Dec-23 A$1.19 2,519,064 — (426,668) (141,666) * 1,950,730 1,809,064 36b 13-Jan-17 12-Jan-24 A$1.65 300,000 — (300,000) — — — 37 28-Jun-17 27-Jun-24 A$2.23 150,000 — (150,000) — — — 38 16-Sep-17 15-Sep-24 A$1.54 66,666 — (16,666) — 50,000 50,000 38a 16-Sep-17 15-Sep-24 A$1.40 150,000 — — — 150,000 150,000 39 13-Oct-17 12-Oct-24 A$1.94 1,655,000 — (565,000) — 1,090,000 1,090,000 39a 13-Oct-17 12-Oct-24 A$1.76 1,302,425 — (400,000) — 902,425 902,425 40 24-Nov-17 23-Nov-24 A$1.41 750,000 — — — 750,000 750,000 40a 24-Nov-17 23-Nov-24 A$1.28 750,000 — — — 750,000 — 41 18-Jun-18 17-Jun-25 A$1.52 200,000 — — — 200,000 200,000 42 11-Jul-18 10-Jul-25 A$1.56 200,000 — — — 200,000 133,334 43 18-Jul-18 17-Jul-25 A$1.87 5,398,334 — (944,998) (251,670) * 4,201,666 2,526,653 43b 18-Jul-18 17-Jul-25 A$1.87 350,000 — — — 350,000 233,334 44 15-Jul-18 14-Jul-25 A$1.72 300,000 — (150,000) — 150,000 50,000 45 30-Nov-18 29-Nov-25 A$1.33 590,000 — — — 590,000 393,332 46 19-Jan-19 18-Jan-26 A$1.45 5,000 — (1,667) — 3,333 1,667 47 19-Jan-19 18-Jan-26 A$1.45 150,000 — — — 150,000 150,000 48 4-Apr-19 3-Apr-26 A$1.48 300,000 — — — 300,000 200,000 49 20-Jul-19 19-Jul-26 A$1.62 4,690,000 — (523,661) (6,666) 3,638,671 1,030,310 49 20-Jul-19 19-Jul-26 A$1.62 — (521,002) * 49a 20-Jul-19 19-Jul-26 A$1.47 5,500,000 — (800,002) (700,000) * 3,999,998 400,001 49b 20-Jul-19 19-Jul-26 A$1.47 1,346,667 — — — 1,346,667 448,889 49c 20-Jul-19 19-Jul-26 A$1.47 538,667 — — — 538,667 179,556 50 20-Jul-19 19-Jul-26 A$1.47 700,000 — — — 700,000 — 50a 20-Jul-19 19-Jul-26 A$1.47 400,000 — — — 400,000 — 51 29-Aug-19 28-Aug-26 A$1.47 150,000 — — — 150,000 — 52 29-Aug-19 28-Aug-26 A$1.62 400,000 — — — 400,000 133,333 53 29-Aug-19 28-Aug-26 A$1.47 800,000 — — — 800,000 266,667 54 25-Nov-19 24-Nov-26 A$1.98 845,000 — (98,334) (11,667) 295,000 98,334 54 25-Nov-19 24-Nov-26 A$1.98 — (439,999) * 55 29-May-19 28-May-26 A$1.48 450,000 — (100,000) — 350,000 300,000 56 18-Nov-19 17-Nov-26 A$1.83 200,000 — — — 200,000 66,666 57 25-Nov-19 24-Nov-26 A$1.80 100,000 — — — 100,000 100,000 58 25-Nov-19 24-Nov-26 A$1.98 450,000 — — — 450,000 150,000 59 24-Jan-20 23-Jan-27 A$3.38 — 65,000 — (55,000) * 10,000 3,333 60 17-Apr-20 16-Apr-27 A$2.51 — 57,660 — (57,660) * — — 61 17-Apr-20 16-Apr-27 A$2.51 — 250,000 — (200,000) * 50,000 16,666 63 18-May-20 17-May-27 A$4.02 — 1,200,000 — — 1,200,000 400,000 63a 18-May-20 17-May-27 A$3.65 — 2,400,000 — — 2,400,000 — 64 16-Jul-20 15-Jul-27 A$3.75 — 5,970,000 — (1,690,000) * 4,280,000 — 64a 16-Jul-20 15-Jul-27 A$3.41 — 3,400,000 — (350,000) * 3,050,000 — 64b 16-Jul-20 15-Jul-27 A$3.41 — 325,000 — — 325,000 — 64c 16-Jul-20 15-Jul-27 A$3.41 — 350,000 — — 350,000 — 64 16-Jul-20 15-Jul-27 A$3.41 — 300,000 — — 300,000 — 64e 16-Jul-20 15-Jul-27 A$3.41 — 1,200,000 — — 1,200,000 — 65 26-Aug-20 25-Aug-27 A$5.76 — 140,000 — (135,000) * 5,000 — 66 11-Sep-20 10-Sep-27 A$4.78 — 200,000 — — 200,000 — 67 8-Oct-20 7-Oct-27 A$3.84 — 240,000 — (40,000) * 200,000 — 68 20-Nov-20 19-Nov-27 A$3.60 — 200,000 — — 200,000 — 69 20-Nov-20 19-Nov-27 A$3.60 — 100,000 — — 100,000 100,000 71 17-Feb-21 16-Feb-28 A$2.67 — 250,000 — — 250,000 — 73 30-Jun-21 30-Aug-21 A$— — 45,746 — — 45,746 45,746 June 30, 2021 38,911,491 18,193,406 (7,078,017) (4,693,664) 45,333,216 18,389,623 Weighted average share purchase price A$1.86 A$3.56 A$2.06 A$2.76 A$2.42 A$2.15 (1) The dates presented in the grant date column represent the date on which board approval was obtained. For valuation dates per IFRS 2, refer to Note 17(c). (2) Based on the amended terms, the incentive rights granted pursuant to the Equity Facility Agreement with Kentgrove Capital, dated June 30, 2016, will expire thirty six months after the effective date, July 1, 2019. The weighted average share price at the date of exercise of options exercised during the years ended June 30, 2023, 2022 and 2021 were Nil, A$1.82 and A$4.42 respectively. The weighted average remaining contractual life of share options outstanding as of June 30, 2023, 2022 and 2021 were 4.13 years, 4.16 years and 4.49 years, respectively. b. Existing share-based payment arrangements General terms and conditions attached to share based payments Share options pursuant to the employee share option plan are generally granted in three equal tranches. The length of time from grant date to expiry date is typically seven years. Vesting occurs based on achievement of performance conditions and/or progressively over the life of the option with the first tranche vesting one year from grant date, the second tranche two years from grant date, and the third tranche three years from grant date. On cessation of employment the Company’s board of directors determines if a leaver is a bad leaver or not. If a participant is deemed a bad leaver, all rights, entitlements and interests in any unexercised options held by the participant will be forfeited and will lapse immediately. If a leaver is not a bad leaver they may retain vested options, however, they must be exercised within 60 days of cessation of employment (or within a longer period if so determined by the Company’s board of directors), after which time they will lapse. Unvested options will normally be forfeited and lapse. This policy applies to all issues shown in the above table with the exception of the following: 35 Incentive rights granted pursuant to the Equity Facility Agreement with Kentgrove Capital, dated June 30, 2016, had fully vested on the agreement date and will expire thirty six months after the date of the issue of the incentive right. The terms of this agreement were amended on July 30, 2019. Under the amended terms, these incentive rights will expire thirty six months after the effective date of July 1, 2019. 35a Additional incentive rights granted pursuant to the Amendment Deed of the Equity Facility Agreement with Kentgrove Capital, dated July 30, 2019, had fully vested on the agreement date and will expire thirty six months after the date of the issue of the incentive right. 36a & 36b Options were granted in two or three equal tranches and will vest on the date that the option holder has direct involvement (to the reasonable satisfaction of the Company’s board of directors) in the Company achieving certain confidential commercial objectives. 49a, 49b, 50, 50a, 53, 64b, 64c, 64d, 64e, 71, 74a, 74b, 74c, 79c Options were granted two or three equal tranches and are required to satisfy certain pre-specified performance conditions and time-based vesting conditions prior to vesting. Time-based conditions restrict vesting to a maximum of one third at 12 months, two thirds at 24 months and full grant at 36 months, but only if the pre-specified performance conditions have been met. 38a, 40a, 57 & 66 Options were granted in one tranche and will vest on the date that the option holder has direct involvement (to the reasonable satisfaction of the Company’s board of directors) in the Company achieving certain confidential commercial objectives. 39a Options were granted in one or two equal tranches and will vest on the date that the option holder has direct involvement (to the reasonable satisfaction of the Company’s board of directors) in the Company achieving certain confidential commercial objectives. 51 & 75 Options were granted in two equal tranches and will vest on the date that the option holder has direct involvement (to the reasonable satisfaction of the Company’s board of directors) in the Company achieving certain confidential commercial objectives. 55 Options were granted in five tranches and will vest on the date that the option holder has direct involvement (to the reasonable satisfaction of the Company’s board of directors) in the Company achieving certain confidential commercial objectives. 63a Options were granted in three or eight tranches and will vest on the date that the option holder has direct involvement (to the reasonable satisfaction of the Company’s board of directors) in the Company achieving certain confidential commercial objectives. Time-based conditions restrict vesting to a maximum of one third at 12 months, two thirds at 24 months and full grant at 36 months, but only if the pre-specified performance conditions have been met. 64a Options were granted in one, two, three or five tranches and will vest on the date that the option holder has direct involvement (to the reasonable satisfaction of the Company’s board of directors) in the Company achieving certain confidential commercial objectives. Time-based conditions restrict vesting to a maximum of one third at 12 months, two thirds at 24 months and full grant at 36 months, but only if the pre-specified performance conditions have been met. 69, 73, 80 & 81 Options were granted in one tranche and vested on the date on which board approval was obtained 79a, 79d Options were granted in two, three, four or five tranches and will vest on the date that the option holder has direct involvement (to the reasonable satisfaction of the Company's board of directors) in the Company achieving certain confidential commercial objectives. Time-based conditions restrict vesting to a maximum of one third at 12 months, two thirds at 24 months and full grant at 36 months, but only if the pre-specified performance conditions have been met. Modifications to share-based payment arrangements There were no modifications made to share-based payment arrangements during the years ended June 30, 2023, June 30, 2022, and June 30, 2021. c. Fair values of share based payments The weighted average fair value of share options granted during the years ended June 30, 2023, 2022 and 2021 were A$0.66, A$0.56 and A$1.42, respectively. The fair value of all shared-based payments made has been calculated using the Black-Scholes model. This model requires the following inputs: Share price at acceptance date The share price used in valuation is the share price at the date at which the entity and the employee agree to a share-based payment arrangement, being when the entity and the employee have a shared understanding of the terms and conditions of the arrangement or at shareholder approval date where this approval is required. This price is generally the volume weighted average share price for the five trading days leading up to the date. Exercise price The exercise price is a known value that is contained in the agreements. Share price volatility The model requires the Company’s share price volatility to be measured. In estimating the expected volatility of the underlying shares our objective is to approximate the expectations that would be reflected in a current market or negotiated exchange price for the option. Historical volatility data is considered in determining expected future volatility. Life of the option The life is generally the time period from grant date through to expiry. Certain assumptions have been made regarding “early exercise” i.e. options exercised ahead of the expiry date. These assumptions have been based on historical trends for option exercises within the Company and take into consideration exercise trends that are also evident as a result of local taxation laws. Dividend yield The Company has yet to pay a dividend so it has been assumed the dividend yield on the shares underlying the options will be 0%. Risk free interest rate This has been sourced from the Reserve Bank of Australia historical interest rate tables for government bonds. Model inputs The model inputs for the valuations of options approved and granted during the year ended June 30, 2023 are as follows: Series Valuation date (1) Exercise Share price at Expected share Life (2) Dividend yield Risk-free 76 23-Nov-22 1.03 0.99 65.37% 6.3 yrs 0% 3.38% 77 23-Nov-22 1.01 0.99 65.37% 5.9 yrs 0% 3.38% 78 23-Nov-22 0.85 0.99 65.37% 6.1 yrs 0% 3.38% 79 09-Dec-22 1.13 1.04 65.43% 6.2 yrs 0% 3.11% 79a 21-Jun-23 1.03 1.18 65.04% 5.8 yrs 0% 3.88% 79b 16-Mar-23 1.13 0.97 65.29% 6.0 yrs 0% 2.99% 79c 23-Nov-22 1.03 0.99 65.37% 6.3 yrs 0% 3.38% 79d (3) 30-Jun-23 1.03 1.15 64.98% 5.7 yrs 0% 4.19% 80 18-Nov-22 0.93 0.95 65.35% 6.1 yrs 0% 3.35% 81 18-Nov-22 4.60 0.95 65.35% 4.6 yrs 0% 3.35% 82 30-Dec-22 1.12 0.89 65.31% 6.3 yrs 0% 3.70% 83 06-Apr-23 1.03 0.97 65.17% 6.4 yrs 0% 2.90% (1) Valuation date is the date at which the entity and the employee agree to a share-based payment arrangement, being when the entity and the employee have a shared understanding of the terms and conditions of the arrangement. (2) Expected life after factoring likely early exercise. (3) Fair value estimated at June 30, 2023 as the valuation date under AASB2 has not been met as of June 30, 2023. The closing share market price of an ordinary share of Mesoblast Limited on the ASX as of June 30, 2023 was A$1.14. The model inputs for the valuations of options approved and granted during the year ended June 30, 2022 are as follows: Series Valuation date (1) Exercise Share price at Expected share Life (2) Dividend yield Risk-free 72 05-May-21 2.28 1.94 66.62% 6.3 yrs 0% 0.69% 74 10-Nov-21 1.95 1.69 65.85% 6.2 yrs 0% 1.31% 74a 07-Nov-22 1.77 0.93 65.41% 5.3 yrs 0% 3.55% 74b 07-Nov-22 1.77 0.93 65.41% 5.3 yrs 0% 3.55% 74c 15-Feb-22 1.77 1.16 65.89% 5.9 yrs 0% 1.91% 75 17-Mar-22 1.42 1.21 65.98% 6.1 yrs 0% 2.18% (1) Valuation date is the date at which the entity and the employee agree to a share-based payment arrangement, being when the entity and the employee have a shared understanding of the terms and conditions of the arrangement. (2) Expected life after factoring likely early exercise. The closing share market price of an ordinary share of Mesoblast Limited on the ASX as of June 30, 2022 was A$0.61. The model inputs for the valuations of options approved and granted during the year ended June 30, 2021 are as follows: Series Valuation date (1) Exercise Share price at Expected share Life (2) Dividend yield Risk-free 61 28-Jul-20 2.51 3.60 60.95% 6.1 yrs 0% 0.44% 63 08-Apr-21 4.02 2.21 66.74% 5.5 yrs 0% 0.65% 63a 05-Jul-21 3.65 2.03 66.45% 5.3 yrs 0% 0.72% 64 28-Jul-20 3.75 3.60 60.95% 6.3 yrs 0% 0.44% 64a 05-Jul-21 3.41 2.03 66.45% 5.5 yrs 0% 0.72% 64b 30-Jun-21 3.41 2.09 66.48% 5.5 yrs 0% 0.77% 64c 25-Nov-20 3.41 4.12 65.36% 6.0 yrs 0% 0.30% 64d 30-Jun-22 3.41 0.65 65.55% 4.6 yrs 0% 3.36% 64e 05-Jul-21 3.41 2.03 66.45% 5.5 yrs 0% 0.72% 65 25-Sep-20 5.76 5.02 63.16% 6.3 yrs 0% 0.34% 66 16-Oct-20 4.78 3.24 65.17% 6.3 yrs 0% 0.27% 67 10-Nov-20 3.84 3.22 65.06% 6.3 yrs 0% 0.30% 68 24-Dec-20 3.60 2.38 67.22% 6.3 yrs 0% 0.35% 69 24-Dec-20 3.60 2.38 67.22% 6.3 yrs 0% 0.35% 71 29-Mar-21 2.67 2.35 66.81% 6.2 yrs 0% 0.66% 73 30-Jun-21 — 2.09 66.48% 0.2 yrs 0% 0.77% (1) Valuation date is the date at which the entity and the employee agree to a share-based payment arrangement, being when the entity and the employee have a shared understanding of the terms and conditions of the arrangement. (2) Expected life after factoring likely early exercise. The closing share market price of an ordinary share of Mesoblast Limited on the ASX as of June 30, 2021 was A$1.98.

Remuneration of auditors

Remuneration of auditors	12 Months Ended
Remuneration of auditors	Jun. 30, 2023
Auditor's remuneration [abstract]
Remuneration of auditors	Remuneration of auditors During the year the following fees were paid or payable for services provided by the auditor of the parent entity, its related practices and non-related audit firms: Year Ended June 30, (in U.S. dollars) 2023 2022 2021 a. PricewaterhouseCoopers Australia Audit and other assurance services Audit and review of financial reports 669,603 745,021 747,783 Other audit services (1) 180,339 67,238 91,750 Total remuneration of PricewaterhouseCoopers Australia 849,942 812,259 839,533 b. Network firms of PricewaterhouseCoopers Australia Audit and other assurance services Audit and review of financial reports 144,864 133,309 130,450 Total remuneration of Network firms of PricewaterhouseCoopers Australia 144,864 133,309 130,450 Total auditors' remuneration (2) 994,806 945,568 969,983 (1) Other audit services relates to services performed in connection with the filing of registration statements on the Form S-8 and F-3. (2) All services provided are considered audit fees for the purpose of SEC classification.

Losses per share

Losses per share	12 Months Ended
Losses per share	Jun. 30, 2023
Earnings per share [abstract]
Losses per share	Losses per share Years Ended June 30, 2023 2022 2021 (Losses) per share (in cents) (a) Basic (losses) per share From continuing operations attributable to the ordinary equity holders of the company (11.08) (14.08) (16.33) Total basic (losses) per share attributable to the ordinary equity holders of the company (11.08) (14.08) (16.33) (b) Diluted (losses) per share From continuing operations attributable to the ordinary equity holders of the company (11.08) (14.08) (16.33) Total basic (losses) per share attributable to the ordinary equity holders of the company (11.08) (14.08) (16.33) (c) Reconciliation of (losses) used in calculating (losses) per share (in U.S. dollars, in thousands) Basic (losses) per share (Losses) attributable to the ordinary equity holders of the company used in calculating basic (losses) per share: From continuing operations (81,889) (91,347) (98,811) Diluted (losses) per share (Losses) from continuing operations attributable to the ordinary equity holders of the company: Used in calculating basic (losses) per share (81,889) (91,347) (98,811) (Losses) attributable to the ordinary equity holders of the company used in calculating diluted losses per share (81,889) (91,347) (98,811) 2023 2022 2021 Weighted average number of ordinary shares used as the denominator in calculating basic losses per share 739,039,547 648,899,589 605,064,036 Weighted average number of ordinary shares and potential ordinary shares used in calculating diluted losses per share 739,039,547 648,899,589 605,064,036 Options granted to employees and warrants (see Note 17) are considered to be potential ordinary shares. These securities have been excluded from the determination of basic losses per shares in the years ended June 30, 2023, 2022 and 2021. Shares that may be paid as contingent consideration have also been excluded from basic losses per share. They have also been excluded from the calculation of diluted losses per share because they are anti-dilutive for the years ended June 30, 2023, 2022 and 2021.

Parent entity financial informa

Parent entity financial information	12 Months Ended
Parent entity financial information	Jun. 30, 2023
Disclosure Of Parent Entity Financial Information [Abstract]
Parent entity financial information	Parent entity financial information a. Summary financial information The parent entity financial information disclosure is an Australian Disclosure Requirement as required by Corporations Regulations 2001 . The individual financial statements for the parent entity show the following aggregate amounts: As of June 30, (in U.S. dollars, in thousands) 2023 2022 Balance Sheet Current Assets 28,850 4,948 Total Assets 890,120 853,380 Current Liabilities 11,941 9,210 Total Liabilities 15,282 13,227 Shareholders' Equity Issued Capital 1,249,123 1,165,309 Reserves Foreign Currency Translation Reserve (261,377) (227,441) Share Options Reserve 86,274 82,619 Warrant Reserve 12,969 12,969 (Accumulated losses)/retained earnings (212,165) (193,317) 874,824 840,139 Loss for the period (18,848) (19,305) Total comprehensive loss for the period (18,848) (19,305) (1) We have corrected for immaterial errors in the year ended June 30, 2022 within the parent entity note disclosure above. We do not believe this correction is material to the consolidated financial statements in any period presented. b. Contingent liabilities of the parent entity (i) Central Adelaide Local Health Network Incorporated (“CALHNI”) (formerly Medvet)

Segment information

Segment information	12 Months Ended
Segment information	Jun. 30, 2023
Disclosure of operating segments [abstract]
Segment information	Segment informationOperating segments are identified on the basis of whether the allocation of resources and/or the assessment of performance of a particular component of the Company’s activities are regularly reviewed by the Company’s chief operating decision maker as a separate operating segment. By these criteria, the activities of the Company are considered to be one segment being the development of cell technology platform for commercialization, and the segmental analysis is the same as the analysis for the Company as a whole. The chief operating decision maker (Chief Executive Officer) reviews the consolidated income statement, consolidated balance sheet, and statement of cash flows regularly to make decisions about the Company’s resources and to assess overall performance.

Legal Proceedings

Legal Proceedings	12 Months Ended
Legal Proceedings	Jun. 30, 2023
Legal proceedings provision [abstract]
Legal proceedings	Legal proceedingsA class action proceeding in the Federal Court of Australia was served on the Company in May 2022 by the law firm William Roberts Lawyers on behalf of persons who, between February 22, 2018, and December 17, 2020, acquired an interest in Mesoblast shares, American Depository Receipts, and/or related equity swap arrangements. In June 2022, the firm Phi Finney McDonald commenced a second shareholder class action against the Company in the Federal Court of Australia asserting similar claims arising during the same period. Like the class action lawsuit from October 2020 filed in the U.S. Federal District Court for the Southern District of New York (which had court approval for settlement in August 2022), the Australian class actions relate to the Complete Response Letter released by the FDA in September 2020 in relation to the Company's GvHD product candidate; they also relate to certain representations made by the Company in relation to our COVID-19 product candidate and the decline in the market price of the Company's ordinary shares in December 2020. The Australian class actions have been consolidated into one lawsuit. The Company will continue to vigorously defend against the proceedings. The Company cannot provide any assurance as to the possible outcome or cost to us from the lawsuit, particularly as it is at an early stage, nor how long it may take to resolve such lawsuit. Thus, the Company has not accrued any amounts in connection with such legal proceedings.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
Summary of Significant Accounting Policies	Jun. 30, 2023
Disclosure Of Summary Of Significant Accounting Policies [Abstract]
Summary of significant accounting policies	Summary of significant accounting policies This note provides the principal accounting policies adopted in the preparation of these consolidated financial statements as set out below. These policies have been consistently applied to all the years presented, unless otherwise stated. The financial statements are for the consolidated entity consisting of Mesoblast Limited and its subsidiaries. a. Change in accounting policies There were no new accounting policies adopted by the Group in the year ended June 30, 2023. b. Principles of consolidation i. Subsidiaries The consolidated financial statements incorporate the assets and liabilities of all subsidiaries of Mesoblast Limited (“Company” or “Parent Entity”) as of June 30, 2023 and the results of all subsidiaries for the year then ended. Mesoblast Limited and its subsidiaries together are referred to in this financial report as the Group or the consolidated entity. Subsidiaries are all entities (including structured entities) over which the Group has control. The Group controls an entity when the Group is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the Group. They are deconsolidated from the date that control ceases. The acquisition method of accounting is used to account for business combinations by the Group. Intercompany transactions, balances and unrealized gains on transactions between Group companies are eliminated. Unrealized losses are also eliminated unless the transaction provides evidence of the impairment of the asset transferred. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Group. ii. Employee share trust The Group has formed a trust to administer the Group’s employee share scheme. This trust is consolidated, as the substance of the relationship is that the trust is controlled by the Group. c. Segment reporting The Group operates in one segment as set out in Note 21. d. Foreign currency translation (i) Functional and presentation currency Items included in the financial statements of each of the Group’s entities are measured using the currency of the primary economic environment in which the entity operates (the “functional currency”). The functional currency of Mesoblast Limited is A$. The consolidated financial statements are presented in US$, which is the Group’s presentation currency. (ii) Translations and balances Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the transaction at period end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in net loss, except when they are deferred in equity as qualifying cash flow hedges and qualifying net investment hedges or attributable to part of the net investment in a foreign operation. Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. Translation differences on assets and liabilities carried at fair value are reported as part of the fair value gain or loss. For example, translation differences on non-monetary assets and liabilities such as equities held at fair value through profit or loss are recognized in net loss as part of the fair value gain or loss and translation differences on non-monetary assets such as equities classified as financial assets at fair value are recognized in other comprehensive income. (iii) Group companies The results and financial position of all the Group entities (none of which has the currency of a hyperinflationary economy) that have a functional currency different from the presentation currency are translated into the presentation currency as follows: • assets and liabilities for the consolidated balance sheets presented are translated at the closing rate at the date of that consolidated balance sheets; • income and expenses for the statements of comprehensive income are translated at average exchange rates (unless this is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the dates of the transactions); and • all resulting exchange differences are recognized in other comprehensive income. (iv) Other On consolidation, exchange differences arising from the translation of any net investment in foreign entities, and of borrowings and other financial instruments designated as hedges of such investments, are recognized in other comprehensive income. When a foreign operation is sold or any borrowings forming part of the net investment are repaid, the associated exchange differences are reclassified to net loss, as part of the gain or loss on sale. Goodwill and fair value adjustments arising on the acquisition of a foreign entity are treated as assets and liabilities of the foreign entities and translated at the closing rate. e. Revenue recognition Revenue from contracts with customers is measured and recognized in accordance with the five step model prescribed by IFRS 15 Revenue from Contracts with Customers . First, contracts with customers within the scope of IFRS 15 are identified. Distinct promises within the contract are identified as performance obligations. The transaction price of the contract is measured based on the amount of consideration the Group expect to be entitled from the customer in exchange for goods or services. Factors such as requirements around variable consideration, significant financing components, noncash consideration, or amounts payable to customers also determine the transaction price. The transaction is then allocated to separate performance obligations in the contract based on relative standalone selling prices. Revenue is recognized when, or as, performance obligations are satisfied, which is when control of the promised good or service is transferred to the customer. Revenues from contracts with customers comprise commercialization and milestone revenue. (i) Commercialization and milestone revenue Commercialization and milestone revenue generally includes non-refundable upfront license and collaboration fees; milestone payments, the receipt of which is dependent upon the achievement of certain clinical, regulatory or commercial milestones; as well as royalties on product sales of licensed products, if and when such product sales occur; and revenue from the supply of products. Payment is generally due on standard terms of 30 to 60 days. Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue or deferred consideration in our consolidated balance sheets, depending on the nature of arrangement. Amounts expected to be recognized as revenue within the 12 months following the consolidated balance sheet date are classified within current liabilities. Amounts not expected to be recognized as revenue within the 12 months following the consolidated balance sheet date are classified within non-current liabilities. Milestone revenue The Group applies the five-step method under the standard to measure and recognize milestone revenue. The receipt of milestone payments is often contingent on meeting certain clinical, regulatory or commercial targets, and is therefore considered variable consideration. The Group estimate the transaction price of the contingent milestone using the most likely amount method. The Group include in the transaction price some or all of the amount of the contingent milestone only to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the contingent milestone is subsequently resolved. Milestone payments that are not within the control of the Company, such as regulatory approvals, are not considered highly probable of being achieved until those approvals are received. Any changes in the transaction price are allocated to all performance obligations in the contract unless the variable consideration relates only to one or more, but not all, of the performance obligations. When consideration for milestones is a sale-based or usage-based royalty that arises from licenses of IP (such as cumulative net sales targets), revenue is recognized at the later of when (or as) the subsequent sale or usage occurs, or when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Licenses of intellectual property When licenses of IP are distinct from other goods or services promised in the contract, the Group recognize the transaction price allocated to the license as revenue upon transfer of control of the license to the customer. The Group evaluate all other promised goods or services in the license agreement to determine if they are distinct. If they are not distinct, they are combined with other promised goods or services to create a bundle of promised goods or services that is distinct. The transaction price allocated to the license performance obligation is recognized based on the nature of the license arrangement. The transaction price is recognized over time if the nature of the license is a “right to access” license. This is when the Group undertake activities that significantly affect the IP to which the customer has rights, the rights granted by the license directly expose the customer to any positive or negative effects of our activities, and those activities do not result in the transfer of a good or service to the customer as those activities occur. When licenses do not meet the criteria to be a right to access license, the license is a “right to use” license, and the transaction price is recognized at the point in time when the customer obtains control over the license. Sales-based or usage-based royalties Licenses of IP can include royalties that are based on the customer’s usage of the IP or sale of products that contain the IP. The Group apply the specific exception to the general requirements of variable consideration and the constraint on variable consideration for sales-based or usage-based royalties promised in a license of IP. The exception requires such revenue to be recognized at the later of when (or as) the subsequent sale or usage occurs and the performance obligation to which some or all of the sales-based or usage-based royalty has been allocated has been satisfied (or partially satisfied). Grünenthal arrangement In September 2019, the Group entered into a strategic partnership with Grünenthal for the development and commercialization in Europe and Latin America of the Group’s allogeneic mesenchymal precursor cell (“MPC”) product, MPC-06-ID, receiving exclusive rights to the Phase 3 allogeneic product candidate for the treatment of low back pain due to degenerative disc disease. The Group received a non-refundable upfront payment of $15.0 million in October 2019, on signing of the contract with Grünenthal. The Group received a milestone payment in December 2019 of $2.5 million in relation to meeting a milestone event as part of the strategic partnership with Grünenthal. In June 2022, the Group announced its intention to leverage the results from a planned US trial to support potential product approvals in both the US and EU by including 20% EU patients in order to provide regulatory harmonization, cost efficiencies and streamlined timelines, without initiating an EU trial. As a result, the strategic partnership with Grünenthal has been amended and milestone payments relating to R&D and CMC services and other development services which were linked to the Europe trial have been removed, instead the Group is eligible to receive payments up to US$112.5 million prior to product launch in the EU, inclusive of US$17.5 million already received, if certain clinical and regulatory milestones are satisfied and reimbursement targets are achieved. Cumulative milestone payments could reach US$1 billion depending on the final outcome of Phase 3 studies and patient adoption. The Group will also receive tiered double-digit royalties on product sales as per the original agreement. The $2.5 million milestone payment received in December 2019 from Grünenthal was considered deferred consideration as of June 30, 2023. The performance obligation for the $2.5 million was previously satisfied under the original agreement, however under the amended agreement with Grünenthal it is subject to repayment to Grünenthal. Revenue will be recognized when the clinical trial has recruited the required amount of European patients, as the $2.5 million will no longer be subject to repayment to Grünenthal. There was no milestone revenue recognized in relation to this strategic partnership with Grünenthal in the years ended June 30, 2023, 2022 and 2021. Tasly arrangement In July 2018, the Group entered into a strategic alliance with Tasly for the development, manufacture and commercialization in China of the Group’s allogeneic mesenchymal precursor cell MPC products, MPC-150-IM and MPC-25-IC. Tasly received all exclusive rights for MPC-150-IM and MPC-25-IC in China and Tasly will fund all development, manufacturing and commercialization activities in China. The Group received a $20.0 million upfront technology access fee from Tasly upon closing of this strategic alliance in October 2018. The Group recognized $10.0 million from this $20.0 million upfront technology fee in milestone revenue at closing in October 2018 and the remaining $10.0 million was recognized in milestone revenue in February 2020. The Group is also entitled to receive $25.0 million on product regulatory approvals in China, double-digit escalating royalties on net product sales and up to six escalating milestone payments when the product candidates reach certain sales thresholds in China. For the years ended June 30, 2023, 2022 and 2021, no revenue was recognized in relation to this strategic alliance with Tasly. TiGenix arrangement In December 2017, the Group entered into a patent license agreement with TiGenix, now a wholly owned subsidiary of Takeda, which granted Takeda exclusive access to certain of our patents to support global commercialization of the adipose-derived MSC product, Alofisel® a registered trademark of TiGenix, previously known as Cx601, for the local treatment of fistulae. The agreement includes the right for Takeda to grant sub-licenses to affiliates and third parties. The Group is entitled to further payments up to €10.0 million when Takeda reaches certain product regulatory milestones. Additionally, the Group will receive single digit royalties on net sales of Alofisel®. In the years ended June 30, 2023, 2022 and 2021, the Group earned $0.4 million, $0.3 million and $0.2 million, respectively, of royalty income on sales of Alofisel® in Europe by our licensee Takeda. No milestone revenue was recognized in the year ended June 30, 2023 in relation to the Group's patent license agreement with Takeda entered into in December 2017. In the year ended June 30, 2022, $1.2 million milestone revenue was recognized with regards to the €1.0 million regulatory milestone payment receivable from Takeda given Takeda received approval to manufacture and market Alofisel® (darvadstrocel) in Japan for the treatment of complex perianal fistulas in patients with non-active or mildly active luminal Crohn’s Disease. No milestone revenue was recognized in the year ended June 30, 2021. JCR arrangement In October 2013, the Group acquired all of the culture-expanded, MSC-based assets from Osiris. These assets included assumption of a collaboration agreement with JCR, a research and development oriented pharmaceutical company in Japan. Revenue recognized under this agreement is limited to the amount of cash received or for which the Group is entitled, as JCR has the right to terminate the agreement at any time. Under the JCR Agreement, JCR is responsible for all development and manufacturing costs including sales and marketing expenses. Under the JCR Agreement, JCR has the right to develop our MSCs in two fields for the Japanese market: exclusive in conjunction with the treatment of hematological malignancies by the use of hematopoietic stem cells derived from peripheral blood, cord blood or bone marrow, or the First JCR Field; and non-exclusive for developing assays that use liver cells for non-clinical drug screening and evaluation, or the Second JCR Field. With respect to the First JCR Field, the Group are entitled to payments when JCR reaches certain commercial milestones and to escalating double-digit royalties. These royalties are subject to possible renegotiation downward in the event of competition from non-infringing products in Japan. With respect to the Second JCR Field, the Group are entitled to a double-digit profit share. The Group expanded our partnership with JCR in Japan for two new indications: for wound healing in patients with Epidermolysis Bullosa (“EB”) in October 2018, and for hypoxic ischemic encephalopathy (“HIE”), a condition suffered by newborns who lack sufficient blood supply and oxygen to the brain, in June 2020. The Group will receive royalties on TEMCELL product sales for EB and HIE, if and when JCR begins selling TEMCELL for such indications in Japan. The Group applies the sales-based and usage-based royalty exception for licenses of intellectual property and therefore recognizes royalty revenue at the later of when the subsequent sale or usage occurs and the associated performance obligation has been satisfied. In the years ended June 30, 2023, 2022 and 2021, the Group recognized $7.1 million, $8.7 million, and $7.2 million in commercialization revenue, respectively, relating to royalty income earned on sales of TEMCELL in Japan by our licensee JCR. These amounts were recorded in revenue as there are no further performance obligations required in regards to these items. (ii) Interest income Interest income is accrued on a time basis by reference to the principal outstanding and at the effective interest rate applicable, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to that asset’s net carrying amount. (iii) Research and development tax incentive Tax incentives comprise payments from the Australian government’s Innovation Australia Research and Development Tax Incentive program for research and development activities conducted in relation to our qualifying research that meets the regulatory criteria. The research and development tax incentive credit is available for the Group's research and development activities in Australia. Eligible companies can receive a refundable tax offset for a percentage of their research and development spending. The research and development tax incentive credit is available for the Group’s research and development activities in Australia as well as research and development activities outside of Australia to the extent such non-Australian based activities relate to intellectual property owned by our Australian resident entities do not exceed half the expenses for the relevant activities and are approved by the Australian government. Eligible companies can receive a refundable tax offset for a percentage of their research and development spending. In October 2020, the Australian Government introduced new legislation for the refundable tax offset applicable to eligible companies for income tax years commencing from July 1, 2021. Per the new legislation, the refundable tax offset for companies with an aggregated turnover of A$20.0 million or more is the Company’s corporate tax rate plus a rate between 8.5% and 16.5% depending on the proportion of research and development expenditures in relation to total expenditures. For companies with an aggregated turnover below A$20.0 million, the refundable research and development tax offset is 18.5% above the Company's tax rate. The Group recorded $3.5 million in research and development tax incentive income for the year ended June 30, 2023. Within this $3.5 million, $1.2 million pertains to an estimate for the year ended June 30, 2023, $1.1 million pertains to the year ended June 30, 2022 and $1.2 million pertains to the year ended June 30, 2021. During the year ended June 30, 2023, management concluded its assessment of qualifying activities and the Group recognized the relevant income for the years ended June 30, 2023, 2022 and 2021. No income was recognized in the years ended June 30, 2022 and 2021 as management were yet to confirm if the Group's research and development activities were eligible under the incentive scheme. f. Inventories Inventories are included in the financial statements at the lower of cost (including raw materials, direct labour, other direct costs and related production overheads) and net realizable value. Pre-launch inventory is held as an asset when there is a high probability of regulatory approval for the product in accordance with IAS 2 Inventories . Before that point, a provision is made against the carrying value to its recoverable amount in accordance with IAS 37 Provisions, Contingent Liabilities and Contingent Assets ; the provision is then reversed at the point when a high probability of regulatory approval is determined. The Group considers a number of factors in determining the probability of the product candidate realizing future economic benefit, including the product candidate’s current status in the regulatory approval process, results from the related pivotal clinical trial, results from meetings with relevant regulatory agencies prior to the filing of regulatory applications, the market need, historical experience, as well as potential impediments to the approval process such as product safety or efficacy, commercialization and market trends. When a provision is made against the carrying value of pre-launch inventory the costs are recognized within Manufacturing Commercialization expenses. When the high probability threshold is met, the provision will be reversed through Manufacturing Commercialization expenses. All inventory costs are currently fully provided for and are recognized within Manufacturing Commercialization expenses. Where it is determined that the pre-launch inventory will be used within a clinical trial, that amount is removed from the cost of pre-launch inventory. There is no impact on the consolidated income statement as the carrying value has been previously fully provided for. As of June 30, 2023 and June 30, 2022, there was $22.4 million and $28.9 million of pre-launch inventory recognized on the consolidated balance sheet that was fully provided for, respectively. In the year ended June 30, 2023, the Group reclassified $10.0 million of costs within pre-launch inventory for use in clinical trials. The future commercial use of the remaining pre-launch inventory recognized on the consolidated balance sheet will be dependent on future discussions with the FDA and remains fully provided for. For the years ended June 30, 2023, 2022 and 2021, $3.5 million, $7.0 million and $13.1 million of pre-launch inventory costs have been recognized within Manufacturing Commercialization expenses in relation to the provision against the carrying value of pre-launch inventory, respectively. g. Research and development undertaken internally The Group currently does not have any capitalized development costs. Research expenditure is recognized as an expense as incurred. Costs incurred on development projects, which consist of preclinical and clinical trials, manufacturing development, and general research, are recognized as intangible assets when it is probable that the project will, after considering its commercial and technical feasibility, be completed and generate future economic benefits and its costs can be measured reliably. The expenditure capitalized comprises all directly attributable costs, including costs of materials, services, direct labor and an appropriate proportion of overheads. Other development costs that do not meet these criteria are expensed as incurred. Development costs previously recognized as expenses, are not recognized as an asset in a subsequent period and will remain expensed. Capitalized development costs are recorded as intangible assets and amortized from the point at which the asset is ready for use on a straight-line basis over its useful life. h. Income tax The income tax expense or benefit for the period is the tax payable on the current period’s taxable income based on the applicable income tax rate for each jurisdiction adjusted by changes in deferred tax assets and liabilities attributable to temporary differences and to unused tax losses. The current income tax charge is calculated on the basis of the tax laws enacted or substantively enacted at the end of the reporting period in the countries where the Group’s subsidiaries and associates operate and generate taxable income. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation. It establishes provisions where appropriate on the basis of amounts expected to be paid to the tax authorities. Deferred income tax is provided in full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. However, the deferred income tax is not accounted for if it arises from initial recognition of an asset or liability in a transaction other than a business combination that at the time of the transaction affects neither accounting, nor taxable profit or loss. Deferred income tax is determined using tax rates (and laws) that have been enacted or substantially enacted by the end of the reporting period and are expected to apply when the related deferred income tax asset is realized or the deferred income tax liability is settled. Deferred tax assets are recognized for deductible temporary differences and unused tax losses only if it is probable that future taxable amounts will be available to utilize those temporary differences and losses. Deferred tax assets are only recognized to the extent that there are sufficient deferred tax liabilities unwinding. Deferred tax liabilities and assets are not recognized for temporary differences between the carrying amount and tax bases of investments in controlled entities where the parent entity is able to control the timing of the reversal of the temporary differences and it is probable that the differences will not reverse in the foreseeable future. Deferred tax assets and liabilities are offset when there is a legally enforceable right to offset current tax assets and liabilities and when the deferred tax balances relate to the same taxation authority. Current tax assets and tax liabilities are offset where the entity has a legally enforceable right to offset and intends either to settle on a net basis, or to realize the asset and settle the liability simultaneously. Current and deferred tax is recognized in net loss, except to the extent that it relates to items recognized in other comprehensive income or directly in equity. In this case, the tax is also recognized in other comprehensive income or directly in equity, respectively. i. Business combinations The acquisition method of accounting is used to account for all business combinations, regardless of whether equity instruments or other assets are acquired. The consideration transferred for the acquisition of a subsidiary comprises the fair values of the assets transferred, the liabilities incurred and the equity interests issued by the Group. The consideration transferred also includes the fair value of any asset or liability resulting from a contingent consideration arrangement and the fair value of any pre-existing equity interest in the subsidiary. Acquisition-related costs are expensed as incurred. Identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are, with limited exceptions, measured initially at their fair values at the acquisition date. On an acquisition-by-acquisition basis, the Group recognizes any noncontrolling interest in the acquiree either at fair value or at the non-controlling interest’s proportionate share of the acquiree’s net identifiable assets. The excess of the consideration transferred and the amount of any non-controlling interest in the acquiree over the fair value of the net identifiable assets acquired is recorded as goodwill. If those amounts are less than the fair value of the net identifiable assets of the subsidiary acquired and the measurement of all amounts has been reviewed, the difference is recognized directly in net loss as a bargain purchase. Where settlement of any part of cash consideration is deferred, the amounts payable in the future are discounted to their present value as at the date of exchange. The discount rate used is the entity’s incremental borrowing rate, being the rate at which a similar borrowing could be obtained from an independent financier under comparable terms and conditions. Contingent consideration is classified either as equity or a financial liability. Amounts classified as a financial liability are subsequently remeasured to fair value with changes in fair value recognized in profit or loss. j. Impairment of assets Goodwill and intangible assets that have an indefinite useful life are not subject to amortization and are tested annually for impairment or more frequently if events or changes in circumstances indicate that they might be impaired. Other assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized for the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs to dispose and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows which are largely independent of the cash inflows from other assets or groups of assets (cash-generating units). Non-financial assets (other than goodwill) that have suffered impairment are reviewed for possible reversal of the impairment at the end of each reporting period. Management maintains internal valuations of each asset annually (or more frequently should indicators of impairment be identified) and valuations from independent experts are requested periodically, within every three year period. The internal valuations are continually reviewed by management and consideration is given as to whether there are indicators of impairment which would warrant impairment testing. An external valuation of our assets was carried out by an independent expert as at March 31, 2023 with the recoverable amount of each asset exceeding its carrying amount. In August 2023, as disclosed in Note 15, the FDA issued a complete response to the Group's BLA for remestemcel-L for the treatment of pediatric SR-aGVHD and the Group has considered this to be an impairment indicator that could cause the carrying amount of its intangible assets to exceed its recoverable amounts. As a result, the Group completed an impairment assessment on its MSC products intangible asset and goodwill, which has considered the impact of the FDA's complete response, and no impairment of the in-process research and development and goodwill was identified. An external valuation was obtained for the MSC products for the impairment assessment performed as a result of the receipt of the complete response. k. Cash and cash equivalents For the purpose of presentation in the statement of cash flows, cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short-term and highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value. l. Trade and other receivables Trade receivables and other receivables represent the principal amounts due at balance date less, where applicabl

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
Summary of Significant Accounting Policies (Policies)	Jun. 30, 2023
Disclosure Of Summary Of Significant Accounting Policies [Abstract]
Description of accounting policy for basis of preparation explanatory	Basis of preparation The general purpose financial statements of Mesoblast Limited and its subsidiaries have been prepared in accordance with International Financial Reporting Standards, as issued by the International Accounting Standards Board and Australian equivalent International Financial Reporting Standards, as issued by the Australian Accounting Standards Board. Mesoblast Limited is a for-profit entity for the purpose of preparing the financial statements. Certain comparative amounts have been reclassified to facilitate comparison to the current period. There was no material impact to the financial statements. The financial statements cover Mesoblast Limited and its subsidiaries. The financial statements were authorized for issue by the board of directors on August 31, 2023. The directors have the power to amend and reissue the financial statements. (i) Going concern The Group has continued its focus on maintaining tight control of net cash usage for operating activities, which was $63.3 million for the year ended June 30, 2023. As of June 30, 2023, the Group held total cash reserves of $71.3 million. The Group is implementing various cost containment and deferment strategies, including the reprioritization of projects and operational streamlining to manage net operating cash usage. In August 2023, the FDA provided a complete response to the Group's BLA resubmission for remestemcel-L for the treatment of pediatric SR-aGVHD and requires more data to support marketing approval, including potency assay or clinical data. In line with the Group's overall commercial strategy to progress to adult populations, the Group intends to conduct a targeted, controlled study in the highest-risk adults with the greatest mortality. In conjunction with implementing cost containment and deferment strategies, additional inflows from royalty monetization, capital markets, strategic partnerships or product specific financing will be required to meet the Group's projected expenditure consistent with the Group's business strategy over at least the next 12 months. As a result of these matters, there is material uncertainty related to events or conditions that may cast significant doubt (or raise substantial doubt as contemplated by Public Company Accounting Oversight Board (“PCAOB”) standards) on the Group’s ability to continue as a going concern and, therefore, that the Group may be unable to realize its assets and discharge its liabilities in the normal course of business. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. (ii) Historical cost convention These financial statements have been prepared under the historical cost convention, as modified by the revaluation of financial assets at fair value through other comprehensive income and financial assets and liabilities (including derivative instruments) at fair value through profit or loss, certain classes of property, plant and equipment and investment property. (iii) New and amended standards adopted by the Group There were no new or amended standards adopted by the Group in the year ended June 30, 2023. These financial statements follow the same accounting policies as compared to the June 30, 2022 consolidated financial statements and related notes as filed with the Australian Securities Exchange and the Securities and Exchange Commission. (iv) New accounting standards and interpretations not yet adopted by the Group There were no new accounting standards and interpretations not yet adopted by the Group for the June 30, 2023 reporting period that are expected to materially impact the Group. (v) Use of estimates The preparation of these consolidated financial statements requires the Group to make estimates and judgments that affect the reported amounts of assets, liabilities, income and expenses and related disclosures. On an ongoing basis, the Group evaluates its significant accounting policies and estimates. Estimates are based on historical experience and on various market-specific and other relevant assumptions that the Group believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities. (vi) Impact of after effects of COVID-19 and geopolitical instability Estimates are assessed each period and updated to reflect current information, such as the economic considerations related to the after effects of the COVID-19 pandemic could have on the Group’s significant accounting estimates. The Group is having to account for the after effects of the COVID-19 pandemic on healthcare network, which have been and may continue to be impacted by the pandemic with respect to patient care, operations/staffing, financials, and health and safety protocols. These impacts change the way that Mesoblast will have to engage with the relevant collaborators. Due to the effects of the COVID-19 pandemic, and recent geopolitical instability, countries in which the Group has operations have experienced some challenges in the ability of the Group’s suppliers and contractors to source, supply or acquire raw materials or components needed for its manufacturing process and supply chain. As a result, the manufacturing and commercialization of remestemcel-L and other product candidates could be adversely affected.
Change in accounting policies	a. Change in accounting policiesThere were no new accounting policies adopted by the Group in the year ended June 30, 2023.
Principles of consolidation	b. Principles of consolidation i. Subsidiaries The consolidated financial statements incorporate the assets and liabilities of all subsidiaries of Mesoblast Limited (“Company” or “Parent Entity”) as of June 30, 2023 and the results of all subsidiaries for the year then ended. Mesoblast Limited and its subsidiaries together are referred to in this financial report as the Group or the consolidated entity. Subsidiaries are all entities (including structured entities) over which the Group has control. The Group controls an entity when the Group is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the Group. They are deconsolidated from the date that control ceases. The acquisition method of accounting is used to account for business combinations by the Group. Intercompany transactions, balances and unrealized gains on transactions between Group companies are eliminated. Unrealized losses are also eliminated unless the transaction provides evidence of the impairment of the asset transferred. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Group. ii. Employee share trust The Group has formed a trust to administer the Group’s employee share scheme. This trust is consolidated, as the substance of the relationship is that the trust is controlled by the Group.
Segment reporting	c. Segment reporting The Group operates in one segment as set out in Note 21.
Foreign currency translation	d. Foreign currency translation (i) Functional and presentation currency Items included in the financial statements of each of the Group’s entities are measured using the currency of the primary economic environment in which the entity operates (the “functional currency”). The functional currency of Mesoblast Limited is A$. The consolidated financial statements are presented in US$, which is the Group’s presentation currency. (ii) Translations and balances Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the transaction at period end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in net loss, except when they are deferred in equity as qualifying cash flow hedges and qualifying net investment hedges or attributable to part of the net investment in a foreign operation. Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. Translation differences on assets and liabilities carried at fair value are reported as part of the fair value gain or loss. For example, translation differences on non-monetary assets and liabilities such as equities held at fair value through profit or loss are recognized in net loss as part of the fair value gain or loss and translation differences on non-monetary assets such as equities classified as financial assets at fair value are recognized in other comprehensive income. (iii) Group companies The results and financial position of all the Group entities (none of which has the currency of a hyperinflationary economy) that have a functional currency different from the presentation currency are translated into the presentation currency as follows: • assets and liabilities for the consolidated balance sheets presented are translated at the closing rate at the date of that consolidated balance sheets; • income and expenses for the statements of comprehensive income are translated at average exchange rates (unless this is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the dates of the transactions); and • all resulting exchange differences are recognized in other comprehensive income. (iv) Other On consolidation, exchange differences arising from the translation of any net investment in foreign entities, and of borrowings and other financial instruments designated as hedges of such investments, are recognized in other comprehensive income. When a foreign operation is sold or any borrowings forming part of the net investment are repaid, the associated exchange differences are reclassified to net loss, as part of the gain or loss on sale. Goodwill and fair value adjustments arising on the acquisition of a foreign entity are treated as assets and liabilities of the foreign entities and translated at the closing rate.
Revenue recognition	e. Revenue recognition Revenue from contracts with customers is measured and recognized in accordance with the five step model prescribed by IFRS 15 Revenue from Contracts with Customers . First, contracts with customers within the scope of IFRS 15 are identified. Distinct promises within the contract are identified as performance obligations. The transaction price of the contract is measured based on the amount of consideration the Group expect to be entitled from the customer in exchange for goods or services. Factors such as requirements around variable consideration, significant financing components, noncash consideration, or amounts payable to customers also determine the transaction price. The transaction is then allocated to separate performance obligations in the contract based on relative standalone selling prices. Revenue is recognized when, or as, performance obligations are satisfied, which is when control of the promised good or service is transferred to the customer. Revenues from contracts with customers comprise commercialization and milestone revenue. (i) Commercialization and milestone revenue Commercialization and milestone revenue generally includes non-refundable upfront license and collaboration fees; milestone payments, the receipt of which is dependent upon the achievement of certain clinical, regulatory or commercial milestones; as well as royalties on product sales of licensed products, if and when such product sales occur; and revenue from the supply of products. Payment is generally due on standard terms of 30 to 60 days. Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue or deferred consideration in our consolidated balance sheets, depending on the nature of arrangement. Amounts expected to be recognized as revenue within the 12 months following the consolidated balance sheet date are classified within current liabilities. Amounts not expected to be recognized as revenue within the 12 months following the consolidated balance sheet date are classified within non-current liabilities. Milestone revenue The Group applies the five-step method under the standard to measure and recognize milestone revenue. The receipt of milestone payments is often contingent on meeting certain clinical, regulatory or commercial targets, and is therefore considered variable consideration. The Group estimate the transaction price of the contingent milestone using the most likely amount method. The Group include in the transaction price some or all of the amount of the contingent milestone only to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the contingent milestone is subsequently resolved. Milestone payments that are not within the control of the Company, such as regulatory approvals, are not considered highly probable of being achieved until those approvals are received. Any changes in the transaction price are allocated to all performance obligations in the contract unless the variable consideration relates only to one or more, but not all, of the performance obligations. When consideration for milestones is a sale-based or usage-based royalty that arises from licenses of IP (such as cumulative net sales targets), revenue is recognized at the later of when (or as) the subsequent sale or usage occurs, or when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Licenses of intellectual property When licenses of IP are distinct from other goods or services promised in the contract, the Group recognize the transaction price allocated to the license as revenue upon transfer of control of the license to the customer. The Group evaluate all other promised goods or services in the license agreement to determine if they are distinct. If they are not distinct, they are combined with other promised goods or services to create a bundle of promised goods or services that is distinct. The transaction price allocated to the license performance obligation is recognized based on the nature of the license arrangement. The transaction price is recognized over time if the nature of the license is a “right to access” license. This is when the Group undertake activities that significantly affect the IP to which the customer has rights, the rights granted by the license directly expose the customer to any positive or negative effects of our activities, and those activities do not result in the transfer of a good or service to the customer as those activities occur. When licenses do not meet the criteria to be a right to access license, the license is a “right to use” license, and the transaction price is recognized at the point in time when the customer obtains control over the license. Sales-based or usage-based royalties Licenses of IP can include royalties that are based on the customer’s usage of the IP or sale of products that contain the IP. The Group apply the specific exception to the general requirements of variable consideration and the constraint on variable consideration for sales-based or usage-based royalties promised in a license of IP. The exception requires such revenue to be recognized at the later of when (or as) the subsequent sale or usage occurs and the performance obligation to which some or all of the sales-based or usage-based royalty has been allocated has been satisfied (or partially satisfied). Grünenthal arrangement In September 2019, the Group entered into a strategic partnership with Grünenthal for the development and commercialization in Europe and Latin America of the Group’s allogeneic mesenchymal precursor cell (“MPC”) product, MPC-06-ID, receiving exclusive rights to the Phase 3 allogeneic product candidate for the treatment of low back pain due to degenerative disc disease. The Group received a non-refundable upfront payment of $15.0 million in October 2019, on signing of the contract with Grünenthal. The Group received a milestone payment in December 2019 of $2.5 million in relation to meeting a milestone event as part of the strategic partnership with Grünenthal. In June 2022, the Group announced its intention to leverage the results from a planned US trial to support potential product approvals in both the US and EU by including 20% EU patients in order to provide regulatory harmonization, cost efficiencies and streamlined timelines, without initiating an EU trial. As a result, the strategic partnership with Grünenthal has been amended and milestone payments relating to R&D and CMC services and other development services which were linked to the Europe trial have been removed, instead the Group is eligible to receive payments up to US$112.5 million prior to product launch in the EU, inclusive of US$17.5 million already received, if certain clinical and regulatory milestones are satisfied and reimbursement targets are achieved. Cumulative milestone payments could reach US$1 billion depending on the final outcome of Phase 3 studies and patient adoption. The Group will also receive tiered double-digit royalties on product sales as per the original agreement. The $2.5 million milestone payment received in December 2019 from Grünenthal was considered deferred consideration as of June 30, 2023. The performance obligation for the $2.5 million was previously satisfied under the original agreement, however under the amended agreement with Grünenthal it is subject to repayment to Grünenthal. Revenue will be recognized when the clinical trial has recruited the required amount of European patients, as the $2.5 million will no longer be subject to repayment to Grünenthal. There was no milestone revenue recognized in relation to this strategic partnership with Grünenthal in the years ended June 30, 2023, 2022 and 2021. Tasly arrangement In July 2018, the Group entered into a strategic alliance with Tasly for the development, manufacture and commercialization in China of the Group’s allogeneic mesenchymal precursor cell MPC products, MPC-150-IM and MPC-25-IC. Tasly received all exclusive rights for MPC-150-IM and MPC-25-IC in China and Tasly will fund all development, manufacturing and commercialization activities in China. The Group received a $20.0 million upfront technology access fee from Tasly upon closing of this strategic alliance in October 2018. The Group recognized $10.0 million from this $20.0 million upfront technology fee in milestone revenue at closing in October 2018 and the remaining $10.0 million was recognized in milestone revenue in February 2020. The Group is also entitled to receive $25.0 million on product regulatory approvals in China, double-digit escalating royalties on net product sales and up to six escalating milestone payments when the product candidates reach certain sales thresholds in China. For the years ended June 30, 2023, 2022 and 2021, no revenue was recognized in relation to this strategic alliance with Tasly. TiGenix arrangement In December 2017, the Group entered into a patent license agreement with TiGenix, now a wholly owned subsidiary of Takeda, which granted Takeda exclusive access to certain of our patents to support global commercialization of the adipose-derived MSC product, Alofisel® a registered trademark of TiGenix, previously known as Cx601, for the local treatment of fistulae. The agreement includes the right for Takeda to grant sub-licenses to affiliates and third parties. The Group is entitled to further payments up to €10.0 million when Takeda reaches certain product regulatory milestones. Additionally, the Group will receive single digit royalties on net sales of Alofisel®. In the years ended June 30, 2023, 2022 and 2021, the Group earned $0.4 million, $0.3 million and $0.2 million, respectively, of royalty income on sales of Alofisel® in Europe by our licensee Takeda. No milestone revenue was recognized in the year ended June 30, 2023 in relation to the Group's patent license agreement with Takeda entered into in December 2017. In the year ended June 30, 2022, $1.2 million milestone revenue was recognized with regards to the €1.0 million regulatory milestone payment receivable from Takeda given Takeda received approval to manufacture and market Alofisel® (darvadstrocel) in Japan for the treatment of complex perianal fistulas in patients with non-active or mildly active luminal Crohn’s Disease. No milestone revenue was recognized in the year ended June 30, 2021. JCR arrangement In October 2013, the Group acquired all of the culture-expanded, MSC-based assets from Osiris. These assets included assumption of a collaboration agreement with JCR, a research and development oriented pharmaceutical company in Japan. Revenue recognized under this agreement is limited to the amount of cash received or for which the Group is entitled, as JCR has the right to terminate the agreement at any time. Under the JCR Agreement, JCR is responsible for all development and manufacturing costs including sales and marketing expenses. Under the JCR Agreement, JCR has the right to develop our MSCs in two fields for the Japanese market: exclusive in conjunction with the treatment of hematological malignancies by the use of hematopoietic stem cells derived from peripheral blood, cord blood or bone marrow, or the First JCR Field; and non-exclusive for developing assays that use liver cells for non-clinical drug screening and evaluation, or the Second JCR Field. With respect to the First JCR Field, the Group are entitled to payments when JCR reaches certain commercial milestones and to escalating double-digit royalties. These royalties are subject to possible renegotiation downward in the event of competition from non-infringing products in Japan. With respect to the Second JCR Field, the Group are entitled to a double-digit profit share. The Group expanded our partnership with JCR in Japan for two new indications: for wound healing in patients with Epidermolysis Bullosa (“EB”) in October 2018, and for hypoxic ischemic encephalopathy (“HIE”), a condition suffered by newborns who lack sufficient blood supply and oxygen to the brain, in June 2020. The Group will receive royalties on TEMCELL product sales for EB and HIE, if and when JCR begins selling TEMCELL for such indications in Japan. The Group applies the sales-based and usage-based royalty exception for licenses of intellectual property and therefore recognizes royalty revenue at the later of when the subsequent sale or usage occurs and the associated performance obligation has been satisfied. In the years ended June 30, 2023, 2022 and 2021, the Group recognized $7.1 million, $8.7 million, and $7.2 million in commercialization revenue, respectively, relating to royalty income earned on sales of TEMCELL in Japan by our licensee JCR. These amounts were recorded in revenue as there are no further performance obligations required in regards to these items. (ii) Interest income Interest income is accrued on a time basis by reference to the principal outstanding and at the effective interest rate applicable, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to that asset’s net carrying amount. (iii) Research and development tax incentive Tax incentives comprise payments from the Australian government’s Innovation Australia Research and Development Tax Incentive program for research and development activities conducted in relation to our qualifying research that meets the regulatory criteria. The research and development tax incentive credit is available for the Group's research and development activities in Australia. Eligible companies can receive a refundable tax offset for a percentage of their research and development spending. The research and development tax incentive credit is available for the Group’s research and development activities in Australia as well as research and development activities outside of Australia to the extent such non-Australian based activities relate to intellectual property owned by our Australian resident entities do not exceed half the expenses for the relevant activities and are approved by the Australian government. Eligible companies can receive a refundable tax offset for a percentage of their research and development spending. In October 2020, the Australian Government introduced new legislation for the refundable tax offset applicable to eligible companies for income tax years commencing from July 1, 2021. Per the new legislation, the refundable tax offset for companies with an aggregated turnover of A$20.0 million or more is the Company’s corporate tax rate plus a rate between 8.5% and 16.5% depending on the proportion of research and development expenditures in relation to total expenditures. For companies with an aggregated turnover below A$20.0 million, the refundable research and development tax offset is 18.5% above the Company's tax rate.
Inventories	f. Inventories Inventories are included in the financial statements at the lower of cost (including raw materials, direct labour, other direct costs and related production overheads) and net realizable value. Pre-launch inventory is held as an asset when there is a high probability of regulatory approval for the product in accordance with IAS 2 Inventories . Before that point, a provision is made against the carrying value to its recoverable amount in accordance with IAS 37 Provisions, Contingent Liabilities and Contingent Assets ; the provision is then reversed at the point when a high probability of regulatory approval is determined. The Group considers a number of factors in determining the probability of the product candidate realizing future economic benefit, including the product candidate’s current status in the regulatory approval process, results from the related pivotal clinical trial, results from meetings with relevant regulatory agencies prior to the filing of regulatory applications, the market need, historical experience, as well as potential impediments to the approval process such as product safety or efficacy, commercialization and market trends. When a provision is made against the carrying value of pre-launch inventory the costs are recognized within Manufacturing Commercialization expenses. When the high probability threshold is met, the provision will be reversed through Manufacturing Commercialization expenses. All inventory costs are currently fully provided for and are recognized within Manufacturing Commercialization expenses. Where it is determined that the pre-launch inventory will be used within a clinical trial, that amount is removed from the cost of pre-launch inventory. There is no impact on the consolidated income statement as the carrying value has been previously fully provided for. As of June 30, 2023 and June 30, 2022, there was $22.4 million and $28.9 million of pre-launch inventory recognized on the consolidated balance sheet that was fully provided for, respectively. In the year ended June 30, 2023, the Group reclassified $10.0 million of costs within pre-launch inventory for use in clinical trials. The future commercial use of the remaining pre-launch inventory recognized on the consolidated balance sheet will be dependent on future discussions with the FDA and remains fully provided for.
Research and development undertaken internally	g. Research and development undertaken internally The Group currently does not have any capitalized development costs. Research expenditure is recognized as an expense as incurred. Costs incurred on development projects, which consist of preclinical and clinical trials, manufacturing development, and general research, are recognized as intangible assets when it is probable that the project will, after considering its commercial and technical feasibility, be completed and generate future economic benefits and its costs can be measured reliably. The expenditure capitalized comprises all directly attributable costs, including costs of materials, services, direct labor and an appropriate proportion of overheads. Other development costs that do not meet these criteria are expensed as incurred. Development costs previously recognized as expenses, are not recognized as an asset in a subsequent period and will remain expensed. Capitalized development costs are recorded as intangible assets and amortized from the point at which the asset is ready for use on a straight-line basis over its useful life.
Income tax	h. Income tax The income tax expense or benefit for the period is the tax payable on the current period’s taxable income based on the applicable income tax rate for each jurisdiction adjusted by changes in deferred tax assets and liabilities attributable to temporary differences and to unused tax losses. The current income tax charge is calculated on the basis of the tax laws enacted or substantively enacted at the end of the reporting period in the countries where the Group’s subsidiaries and associates operate and generate taxable income. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation. It establishes provisions where appropriate on the basis of amounts expected to be paid to the tax authorities. Deferred income tax is provided in full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. However, the deferred income tax is not accounted for if it arises from initial recognition of an asset or liability in a transaction other than a business combination that at the time of the transaction affects neither accounting, nor taxable profit or loss. Deferred income tax is determined using tax rates (and laws) that have been enacted or substantially enacted by the end of the reporting period and are expected to apply when the related deferred income tax asset is realized or the deferred income tax liability is settled. Deferred tax assets are recognized for deductible temporary differences and unused tax losses only if it is probable that future taxable amounts will be available to utilize those temporary differences and losses. Deferred tax assets are only recognized to the extent that there are sufficient deferred tax liabilities unwinding. Deferred tax liabilities and assets are not recognized for temporary differences between the carrying amount and tax bases of investments in controlled entities where the parent entity is able to control the timing of the reversal of the temporary differences and it is probable that the differences will not reverse in the foreseeable future. Deferred tax assets and liabilities are offset when there is a legally enforceable right to offset current tax assets and liabilities and when the deferred tax balances relate to the same taxation authority. Current tax assets and tax liabilities are offset where the entity has a legally enforceable right to offset and intends either to settle on a net basis, or to realize the asset and settle the liability simultaneously. Current and deferred tax is recognized in net loss, except to the extent that it relates to items recognized in other comprehensive income or directly in equity. In this case, the tax is also recognized in other comprehensive income or directly in equity, respectively.
Business combinations	i. Business combinations The acquisition method of accounting is used to account for all business combinations, regardless of whether equity instruments or other assets are acquired. The consideration transferred for the acquisition of a subsidiary comprises the fair values of the assets transferred, the liabilities incurred and the equity interests issued by the Group. The consideration transferred also includes the fair value of any asset or liability resulting from a contingent consideration arrangement and the fair value of any pre-existing equity interest in the subsidiary. Acquisition-related costs are expensed as incurred. Identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are, with limited exceptions, measured initially at their fair values at the acquisition date. On an acquisition-by-acquisition basis, the Group recognizes any noncontrolling interest in the acquiree either at fair value or at the non-controlling interest’s proportionate share of the acquiree’s net identifiable assets. The excess of the consideration transferred and the amount of any non-controlling interest in the acquiree over the fair value of the net identifiable assets acquired is recorded as goodwill. If those amounts are less than the fair value of the net identifiable assets of the subsidiary acquired and the measurement of all amounts has been reviewed, the difference is recognized directly in net loss as a bargain purchase. Where settlement of any part of cash consideration is deferred, the amounts payable in the future are discounted to their present value as at the date of exchange. The discount rate used is the entity’s incremental borrowing rate, being the rate at which a similar borrowing could be obtained from an independent financier under comparable terms and conditions.
Impairment of assets	j. Impairment of assets Goodwill and intangible assets that have an indefinite useful life are not subject to amortization and are tested annually for impairment or more frequently if events or changes in circumstances indicate that they might be impaired. Other assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized for the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs to dispose and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows which are largely independent of the cash inflows from other assets or groups of assets (cash-generating units). Non-financial assets (other than goodwill) that have suffered impairment are reviewed for possible reversal of the impairment at the end of each reporting period. Management maintains internal valuations of each asset annually (or more frequently should indicators of impairment be identified) and valuations from independent experts are requested periodically, within every three year period. The internal valuations are continually reviewed by management and consideration is given as to whether there are indicators of impairment which would warrant impairment testing. An external valuation of our assets was carried out by an independent expert as at March 31, 2023 with the recoverable amount of each asset exceeding its carrying amount.
Cash and cash equivalents	k. Cash and cash equivalents For the purpose of presentation in the statement of cash flows, cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short-term and highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.
Trade and other receivables	l. Trade and other receivables Trade receivables and other receivables represent the principal amounts due at balance date less, where applicable, any provision for expected credit losses. The Group uses the simplified approach to measuring expected credit losses, which uses a lifetime expected credit loss allowance. Debts which are known to be uncollectible are written off in the consolidated income statement. All trade receivables and other receivables are recognized at the value of the amounts receivable, as they are due for settlement within 60 days and therefore do not require remeasurement.
Investments and other financial assets	m. Investments and other financial assets (i) Classification The Group classifies its financial assets in the following measurement categories: • those to be measured subsequently at fair value (either through OCI or through profit or loss); and • those to be measured at amortized cost The classification depends on the Group’s business model for managing the financial assets and the contractual terms of the cash flow. For assets measured at fair value, gains and losses will either be recorded in profit or loss or OCI. For investments in equity instruments that are not held for trading, this will depend on whether the group has made an irrevocable election at the time of initial recognition to account for the equity investment at fair value through other comprehensive income (FVOCI). See Note 5 for details about each type of financial asset. (ii) Recognition and derecognition Regular way purchases and sales of financial assets are recognized on trade-date, the date on which the Group commits to purchase or sell the asset. Financial assets are derecognized when the rights to receive cash flows from the financial assets have expired or have been transferred and the Group has transferred substantially all the risks and rewards of ownership. (iii) Measurement At initial recognition, the Group measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss (FVPL), transaction costs that are directly attributable to the acquisition of the financial asset. Transaction costs of financial assets carried at FVPL are expensed in profit or loss. Financial assets with embedded derivatives are considered in their entirety when determining whether their cash flows are solely payment of principal and interest. Details on how the fair value of financial instruments is determined are disclosed in Note 5(g). Equity instruments The group subsequently measures all equity investments at fair value. Where the Group has elected to present fair value gains and losses on equity investments in OCI, there is no subsequent reclassification of fair value gains and losses to profit or loss following the derecognition of the investment. Dividends from such investments continue to be recognized in profit or loss as other income when the group’s right to receive payments is established. Changes in the fair value of financial assets at FVPL are recognized in other gains/(losses) in the statement of profit or loss as applicable. Impairment losses (and reversal of impairment losses) on equity investments measured at FVOCI are not reported separately from other changes in fair value. (iv) Impairment For trade receivables, the group applies the simplified approach permitted by IFRS 9, which requires expected lifetime losses to be recognized from initial recognition of the receivables, see Note 5(b) for further details.
Derivatives	n. Derivatives Derivatives are initially recognized at fair value on the date a derivative contract is entered into and are subsequently remeasured to their fair value at the end of each reporting period. As at June 30, 2023 and 2022, the Group did not have any derivative instruments that qualified for hedge accounting. Derivatives that do not qualify for hedge accounting Certain derivative instruments do not qualify for hedge accounting. Changes in the fair value of any derivative instrument that does not qualify for hedge accounting are recognized immediately in profit or loss and are included in other income or other expenses.
Property, plant and equipment	o. Property, plant and equipment Plant and equipment are stated at historical cost less accumulated depreciation and impairment. Cost includes expenditure that is directly attributable to the acquisition of the item. Subsequent cost are included in the asset’s carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associates with the item will flow to the Group and the cost of the item can be measured reliably. All other repairs and maintenance are charged to profit and loss during the reporting period in which they are incurred. Property, plant and equipment, other than freehold land, are depreciated over their estimated useful lives using the straight line method (see Note 6(a)). The assets’ residual values and useful lives are reviewed, and adjusted if appropriate, at the end of each reporting period. An asset’s carrying amount is written down immediately to its recoverable amount if the asset’s carrying amount is greater than its estimated recoverable amount. Gains and losses on disposal of plant and equipment are taken into account in determining the profit for the year.
Intangible assets	p. Intangible assets (i) Goodwill Goodwill is measured as described in Note 23(i). Goodwill on acquisition of subsidiaries is included in intangible assets (Note 6(c)). Goodwill is not amortized but it is tested for impairment annually or more frequently if events or changes in circumstances indicate that it might be impaired, and is carried at cost less accumulated impairment losses. Gains and losses on the disposal of an entity include the carrying amount of goodwill relating to the entity sold. Goodwill is tested for impairment in accordance with IAS 36 Impairment of Assets which requires testing be performed at any time during an annual period, provided the test is performed at the same time every year. The Group tests for impairment annually in the third quarter of each year. Additionally, assets must be tested for impairment if there is an indication that an asset may be impaired. The recoverable amounts of our assets and cash-generating units have been determined based on fair value less costs to sell calculations, which require the use of certain assumptions. Goodwill is allocated to cash generating units for the purpose of impairment testing. The allocation is made to those cash generating units or groups of cash generating units that are expected to benefit from the business combination in which the goodwill arose, identified according to operating segments (Note 21). (ii) Acquired licenses to patents Acquired licenses have a finite useful life and are carried at cost less accumulated amortization and impairment losses. Each asset is amortized through to the estimated patent expiry date which is reviewed and adjusted as patent extensions are granted. Payments made to third parties to acquire licenses to patents, including initial upfront and subsequent milestone payments are capitalized. For subsequent payments under existing license agreements payments are capitalized if they meet the definition of an intangible asset. Management reviews the substance of the payment to determine its classification. Generally, payments made for a verifiable outcome, such as completion of a clinical trial, regulatory approvals and sales target milestones would be accumulated into the cost of the intangible. The Group periodically evaluates whether current facts or circumstances indicate that the carrying value of its acquired intangibles may not be recoverable. If such circumstances are determined to exist, an estimate of the undiscounted future cash flow of these assets, or appropriate assets grouping is compared to the carrying value to determine whether an impairment exists. If the asset is determined to be impaired, the loss is measured based on the differences between the carrying value of the intangible asset and its fair value, which is determined based on the net present value of estimated future cash flows. Royalty payments under license and sublicense agreements are expensed. (iii) In-process research and development acquired In-process research and development that has been acquired as part of a business acquisition is considered to be an indefinite life intangible asset on the basis that it is incomplete and cannot be used in its current form. Indefinite life intangible assets are not amortized but rather are tested for impairment annually in the third quarter of each year, or whenever events or circumstances present an indication of impairment. In-process research and development will continue to be tested for impairment until the related research and development efforts are either completed or abandoned. Upon completion of the related research and development efforts, management determines the remaining useful life of the intangible assets and amortizes them accordingly. In order for management to determine the remaining useful life of the asset, management would consider the expected flow of future economic benefits to the entity with reference to the product life cycle, competitive landscape, obsolescence, market demand, any remaining patent useful life and various other relevant factors. At the time of completion, when the asset becomes available for use, all costs recognized in in-process research and development that related to the completed asset are transferred to the intangible asset category, current marketed products, at the asset’s historical cost. In the case of abandonment, the related research and development efforts are considered impaired and the asset is fully expensed. (iv) Current marketed products Current marketed products contain products that are currently being marketed. The assets are recognized on our consolidated balance sheet as a result of business acquisitions or reclassifications from In-process research and development upon completion. Upon completion, when assets become available for use, assets are reclassified from in-process research and development to current marketed products at the historical value that they were recognized at within the in-process research and development category. Upon reclassification to the current market products category management determines the remaining useful life of the intangible assets and amortizes them from the date they become available for use. In order for management to determine the remaining useful life of the asset, management would consider the expected flow of future economic benefits to the entity with reference to the product life cycle, competitive landscape, obsolescence, market demand, any remaining patent useful life and any other relevant factors.
Trade and other payables	q. Trade and other payables Payables represent the principal amounts outstanding at balance date plus, where applicable, any accrued interest. Liabilities for payables and other amounts are carried at cost which approximates fair value of the consideration to be paid in the future for goods and services received, whether or not billed. The amounts are unsecured and are usually paid within 30 to 60 days of recognition.
Borrowings	r. Borrowings Borrowings are initially recognized at fair value, net of transaction costs incurred. Borrowings are subsequently measured at amortized cost. Any difference between the proceeds (net of transaction costs) and the redemption amount is recognized in profit or loss over the period of the borrowings using the effective interest method. Borrowings are removed from the consolidated balance sheet when the obligation specified in the contract is discharged, cancelled or expired. The difference between the carrying amount of a financial liability that has been extinguished or transferred to another party and the consideration paid, including any non-cash assets transferred of liabilities assumed, is recognized in profit or loss as other income or finance costs. Borrowings are classified as current liabilities unless the Group has an unconditional right to defer settlement of the liability for at least 12 months after the reporting period Funds associated with Oaktree Capital Management, L.P. (“Oaktree”) In November 2021, the Group entered into a $90.0 million five-year senior debt facility provided by funds associated with Oaktree. The Group drew the first tranche of $60.0 million on closing. The conditions required to draw down the additional $30.0 million tranche have not been met. The facility has a three-year interest only period, at a fixed rate of 9.75% per annum, after which time 40% of the principal amortizes over two years and a final payment is due no later than November 2026. The facility also allows the Group to make quarterly payments of interest at a rate of 8.0% per annum for the first two years, and the unpaid interest portion (1.75% per annum) will be added to the outstanding loan balance and shall accrue further interest at a fixed rate of 9.75% per annum. On November 19, 2021, Oaktree was granted warrants to purchase 1,769,669 American Depositary Shares (“ADSs”) at US$7.26 per ADS, a 15% premium to the 30-day VWAP. The Group determined that an obligation to issue the warrants has arisen from the time the debt facility was signed; consequently, a liability for the warrants was recognized in November 2021. The warrants were legally issued on January 11, 2022 and may be exercised within 7 years of issuance. On the issuance date of the Oaktree facility and the warrants, the warrants were initially measured at fair value and the Oaktree borrowing liability measured as the difference between the $60.0 million received from the Oaktree facility and the fair value of the warrants. In December 2022, the Group amended the terms of the loan agreement with Oaktree and in connection with the loan amendment, Oaktree was granted warrants to purchase 455,000 ADSs at $3.70 per ADS, a 15% premium to the 30-day VWAP. The Group determined that an obligation to issue the warrants arose from the time the first amendment to the loan agreement was signed; consequently, a liability for the warrants was recognized in December 2022. The warrants were legally issued on March 8, 2023 and may be exercised within 7 years of issuance. Refer to Note 5(g)(vi) for more details on warrants issued. In the year ended June 30, 2023, t he Group recognized a loss of $1.6 million in the C onsolidated Income Statement as remeasurement of borrowing arrangements within finance costs. Within this $1.6 million loss, $1.0 million relates to the remeasurement due to additional warrants being issued to Oaktree as a result of the first amendment to the loan agreement and $0.6 million relates to the adjustment of the carrying amount of our financial liability to reflect the revised estimated future cash flows from our credit facility . In the year ended June 30, 2022, the Group recognized a minimal gain in the C onsolidated Income Statement as remeasurement of borrowing arrangements within finance costs in relation to the adjustment of the carrying amount of our financial liability to reflect the revised estimated future cash flows from our credit facility. No remeasurement of borrowing arrangements was recognized in the year ended June 30, 2021. The Group has pledged substantially all of its assets as collateral under the loan facility with Oaktree. NovaQuest On June 29, 2018, the Group entered into an eight-year, $40.0 million loan and security agreement with NovaQuest before drawing the first tranche of $30.0 million of the principal in July 2018. The loan term includes an interest only period of approximately four years through until July 8, 2022, then a four-year amortization period through until maturity on July 8, 2026. All interest and principal payments will be deferred until after the first commercial sale of remestemcel-L for the treatment in pediatric patients with SR-aGVHD. Principal is repayable in equal quarterly instalments over the amortization period of the loan and is subject to the payment cap described below. The loan has a fixed interest rate of 15% per annum. If there are no net sales of remestemcel-L for pediatric SR-aGVHD, the loan is only repayable at maturity. The Group can elect to prepay all outstanding amounts owing at any time prior to maturity, subject to a prepayment charge, and may decide to do so if net sales of remestemcel-L for pediatric SR-aGVHD are significantly higher than current forecasts. Following approval and first commercial sales, repayments commence based on a percentage of net sales and are limited by a payment cap which is equal to the principal due for the next 12 months, plus accumulated unpaid principal and accrued unpaid interest. During the four-year period commencing July 8, 2022, principal amortizes in equal quarterly instalments payable only after approval and first commercial sales. If in any quarterly period, 25% of net sales of remestemcel-L for pediatric SR-aGVHD exceed the annual payment cap, the Group will pay the payment cap and an additional portion of excess sales which will be used towards the prepayment amount in the event there is an early prepayment of the loan. If in any quarterly period 25% of net sales of remestemcel-L for pediatric SR-aGVHD is less than the annual payment cap, then the payment is limited to 25% of net sales of remestemcel-L for pediatric SR-aGVHD. Any unpaid interest will be added to the principal amounts owing and shall accrue further interest. At maturity date, any unpaid loan balances are repaid. Because of this relationship of net sales and repayments, changes in our estimated net sales may trigger an adjustment of the carrying amount of the financial liability to reflect the revised estimated cash flows. The carrying amount is recalculated by computing the present value of the revised estimated future cash flows at the financial instrument’s original effective interest rate. The adjustment is recognized in the C onsolidated Income Statement as remeasurement of borrowing arrangements within finance costs in the period the revision is made. In the years ended June 30, 2023 and 2022, the Group recognized a gain of $0.9 million and $0.5 million, respectively, in the C onsolidated Income Statement as remeasurement of borrowing arrangements within finance costs in relation to the adjustment of the carrying amount of our financial liability to reflect the revised estimated future cash flows as a net result of changes to the key assumptions in development timelines. The Group recognizes a liability as current based on repayments linked to estimates of sales of remestemcel-L. However, if sales of remestemcel-L are higher than estimated, actual repayments will exceed this amount, subject to the annual payment cap described above.
Provisions	s. Provisions Provisions are recognized when the Group has a present legal obligation as a result of a past event, it is probable that the Group will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation. Provisions are measured at the present value of management’s best estimate of the expenditure required to settle the present obligation at the end of the reporting period. The discount rate used to determine the present value is a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. The increase in the provision due to the passage of time is recognized as interest expense. Provisions are recorded on acquisition of a subsidiary, to the extent they relate to a subsidiary’s contingent liabilities, if it relates to a past event, regardless of whether it is probable the amount will be paid.
Employee benefits	t. Employee benefits A liability is recognized for benefits accruing to employees in respect of wages and salaries, bonuses, annual leave and long service leave. Liabilities recognized in respect of employee benefits which are expected to be settled within 12 months after the end of the period in which the employees render the related services are measured at their nominal values using the remuneration rates expected to apply at the time of settlement. Liabilities recognized in respect of employee benefits which are not expected to be settled within 12 months after the end of the period in which the employees render the related services are measured as the present value of the estimated future cash outflows to be made by the Group in respect of services provided by employees up to reporting date. The obligations are presented as current liabilities in the consolidated balance sheet if the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period, regardless of when the actual settlement is expected to occur. Termination benefits are payable when employment is terminated by the Group before the normal retirement date, or when an employee accepts voluntary redundancy in exchange for these benefits. The Group recognizes termination benefits at the earlier of the following dates: when the Group can no longer withdraw the offer of those benefits and when the entity recognizes costs for a restructuring that is within the scope of IAS 37 and involves the payment of termination benefits.
Share-based payments	u. Share-based payments Share-based payments are provided to eligible employees, directors and consultants via the Employee Share Option Plan (“ESOP”) and the Australian Loan Funded Share Plan (“LFSP”). The terms and conditions of the LFSP are in substance the same as the employee share options and therefore they are accounted for on the same basis. Equity-settled share-based payments with employees and others providing similar services are measured at the fair value of the equity instrument at acceptance date. Fair value is measured using the Black-Scholes model. The expected life used in the model has been adjusted, based on management’s best estimate, for the effects of non-transferability, exercise restrictions, and behavioral considerations. It does not make any allowance for the impact of any service and non-market performance vesting conditions. Further details on how the fair value of equity-settled share-based transactions has been determined can be found in Note 17. The fair value determined at the acceptance date of the equity-settled share-based payments is expensed on a straight-line basis over the vesting period, based on management’s estimate of shares that will eventually vest, with a corresponding increase in equity. At the end of each period, the entity revises its estimates of the number of shared-based payments that are expected to vest based on the non-market vesting conditions. It recognizes the impact of the revision to original estimates, if any, in profit or loss, with a corresponding adjustment to equity.
Leases	v. Leases Leases are recognized as a right-of-use asset and a corresponding liability at the date at which the leased asset is available for use by the Group. Assets and liabilities arising from a lease are initially measured on a present value basis. Lease liabilities include the net present value of the following lease payments: • fixed payments (including in-substance fixed payments), less any lease incentives receivable; • variable lease payment that are based on an index or a rate; • amounts expected to be payable by the lessee under residual value guarantees; • the exercise price of a purchase option if the lessee is reasonably certain to exercise that option; and • payments of penalties for terminating the lease, if the lease term reflects the lessee exercising that option. Variable lease payments that are not based on an index or a rate are not included in the initial measurement of the lease liability and are expensed in the C onsolidated Income Statement when incurred. There were no variable lease payments that were expensed in the C onsolidated Income Statement for the years ended June 30, 2023, 2022 and 2021. The Group remeasures the lease liability and makes a corresponding adjustment to the related right-of-use asset whenever there is a change to the lease terms or expected payments under the lease, or a modification that is not accounted for as a separate lease. For certain contracts that contain lease and non-lease components, the Group accounts for each lease component within the contract as a lease separately from non-lease components of the contract. The Group identifies a separate lease component if there is an explicit or implicit identified asset in the contract and if the Group controls use of the identified asset. The lease payments are discounted using the interest rate implicit in the lease, if that rate can be determined, or the Group’s incremental borrowing rate. Right-of-use assets are measured at cost comprising the following: • the amount of the initial measurement of lease liability; • any lease payments made at or before the commencement date, less any lease incentives received; • any initial direct costs; and • restoration costs. Payments associated with short-term leases with a lease term of 12 months or less, contracts that contain lease and non-lease components that are cancellable within 12 months and leases of low-value assets are recognized on a straight-line basis as an expense in profit or loss. Low-value assets comprise IT-equipment and small items of office furniture.
Warrants	w. WarrantsWarrants reserve is measured as described in Note 7(b). For details on warrant liability, see Note 5(g)(vi).
Contributed equity	x. Contributed equity Ordinary shares are classified as equity. Transaction costs arising on the issue of equity instruments are recognized separately in equity. Transaction costs are the costs that are incurred directly in connection with the issue of those equity instruments and which would not have been incurred had those instruments not been issued.
Loss per share	y. Loss per share (i) Basic losses per share Basic losses per share is calculated by dividing: • the loss attributable to equity holders of the Group, excluding any costs of servicing equity other than ordinary shares; • by the weighted average number of ordinary shares outstanding during the fiscal year, adjusted for bonus elements in ordinary shares issued during the year. (ii) Diluted losses per share Diluted losses per share adjusts the figures used in the determination of basic earnings per share to take into account • the after income tax effect of interest and other financing costs associated with dilutive potential ordinary shares; and • the weighted average number of shares assumed to have been issued for no consideration in relation to dilutive potential ordinary shares.
Goods and services tax ("GST")	z. Goods and services tax (“GST”) Revenues, expenses and assets are recognized net of the amount of GST except where the GST incurred on a purchase of goods and services is not recoverable from the taxation authority, in which case the GST is recognized as part of the cost of acquisition of the asset or as part of the expense. Receivables and payables are stated with the amount of GST included. The net amount of GST recoverable from, or payable to, the taxation authority is included as part of receivables or payables in the Consolidated Balance Sheet. Cash flows are included in the statement of cash flow on a gross basis. The GST component of cash flows arising from investing and financing activities, which is recoverable from, or payable to, the taxation authority, are classified as operating cash flows.
Rounding of amounts	aa. Rounding of amountsOur company is of a kind referred to in ASIC Corporations (Rounding in Financial/Directors’ Reports) Instrument 2016/191, issued by the Australian Securities and Investments Commission, relating to the ‘rounding off’ of amounts in the financial report. Unless mentioned otherwise, amounts within this report have been rounded off in accordance with that Legislative Instrument to the nearest thousand dollars, or in certain cases, to the nearest dollar.

Loss before income tax (Tables)

Loss before income tax (Tables)	12 Months Ended
Loss before income tax (Tables)	Jun. 30, 2023
Disclosure Of Loss Before Income Tax [Abstract]
Summary of Loss Before Income Tax	Year Ended June 30, (in U.S. dollars, in thousands) Note 2023 2022 2021 Revenue Commercialization revenue 7,501 9,039 7,434 Milestone revenue — 1,172 — Total Revenue 7,501 10,211 7,434 Clinical trial and research & development (8,771) (10,483) (18,569) Manufacturing production & development (25,468) (28,884) (31,590) Employee benefits Salaries and employee benefits (17,197) (18,997) (26,804) Defined contribution superannuation expenses (384) (402) (379) Equity settled share-based payment transactions (1) (3,655) (5,536) (12,510) Total Employee benefits (21,236) (24,935) (39,693) Depreciation and amortization of non-current assets Plant and equipment depreciation (953) (1,144) (1,016) Right of use asset depreciation (1,661) (1,717) (1,691) Intellectual property amortization (1,493) (1,519) (1,557) Total Depreciation and amortization of non-current assets (4,107) (4,380) (4,264) Other Management & administration expenses Overheads & administration (10,104) (10,157) (7,757) Consultancy (3,922) (3,751) (5,386) Legal, patent and other professional fees (3,695) (5,571) (6,950) Intellectual property expenses (excluding the amount amortized above) (2,993) (2,621) (2,389) Total Other Management & administration expenses (20,714) (22,100) (22,482) Fair value remeasurement of contingent consideration Remeasurement of contingent consideration 5(g)(iii) 8,771 913 18,687 Total Fair value remeasurement of contingent consideration 8,771 913 18,687 Fair value remeasurement of warrant liability Remeasurement of warrant liability 5(g)(vi) (2,205) 5,896 — Total Fair value remeasurement of warrant liability (2,205) 5,896 — Other operating income and expenses Research and development tax incentive income (2) 3,506 — — Interest income 831 3 22 Foreign exchange (losses)/gains (163) (536) 1,471 Derecognition of right-of-use asset 76 — — Foreign withholding tax paid — (3) — Government grant revenue — — 68 Total Other operating income and expenses 4,250 (536) 1,561 Finance (costs)/gains Remeasurement of borrowing arrangements (678) (382) 5,225 Interest expense (19,444) (16,906) (15,939) Total Finance costs (20,122) (17,288) (10,714) Total loss before income tax (82,101) (91,586) (99,630) (1) Share-based payment transactions For the years ended June 30, 2023, 2022 and 2021, share-based payment transactions have been reflected in the Consolidated Statement of Comprehensive Income functional expense categories as follows: Year Ended June 30, (in U.S. dollars) 2023 2022 2021 Research and development 1,669,514 3,547,182 7,782,330 Manufacturing and commercialization (1,136) 378,096 547,998 Management and administration 1,986,968 1,610,567 4,179,416 Equity settled share-based payment transactions 3,655,346 5,535,845 12,509,744 (2) Research and development tax incentive The Group's research and development activities are eligible under the Australian government's Innovation Australia Research and Development Tax Incentive program for research and development activities conducted in relation to qualifying research that meets the regulatory criteria. Management has assessed these activities and expenditures to determine which costs are likely to be eligible under the incentive scheme. The Group assesses, on an annual basis, the quantum of previous research and development tax claims and on-going eligibility to claim this tax incentive in Australia.

Income tax benefit_(expense) (T

Income tax benefit/(expense) (Tables)	12 Months Ended
Income tax benefit/(expense) (Tables)	Jun. 30, 2023
Major components of tax expense (income) [abstract]
Summary of Reconciliation of Income Tax to Prima Facie Tax Payable	Year Ended June 30, (in U.S. dollars, in thousands) 2023 2022 2021 (a) Reconciliation of income tax to prima facie tax payable Loss from continuing operations before income tax (82,101) (91,586) (99,630) Tax benefit at the Australian tax rate of 30% (2022: 30%, 2021: 30%) (24,630) (27,476) (29,889) Tax effect of amounts which are not deductible/(exempt) in calculating taxable income: Share-based payments expense 1,089 1,588 2,836 Research and development tax concessions (730) (869) (894) Foreign exchange translation gains/(losses) 501 159 313 Contingent consideration (2,631) (274) (5,606) Other sundry items 695 (2,036) 121 Subtotal (25,706) (28,908) (33,119) Adjustments for current tax of prior periods 274 (923) (1) Differences in overseas tax rates 8,537 8,407 13,218 Tax benefit not recognized 16,683 21,185 19,083 Change in tax rate on Deferred tax assets (1) — (8,326) (482) Change in tax rate on Deferred tax liability (1) — 8,326 482 Income tax benefit attributable to loss before income tax (212) (239) (819) (1) On June 30, 2022, there was a change in the expected tax rate applicable on future taxable profits in Singapore. The Group was expecting to benefit from concessionary tax rates (tax holiday) in Singapore under the tax incentives granted to the Group by the Singapore Economic Development Board, however at June 30, 2022 the Group had not met the conditions under the agreement to access the concessionary tax rates and therefore have recognized a change in the expected tax rate in Singapore to reflect the statutory tax rate of 17%. The Group is in current discussions with the Singapore Economic Development Board to amend the conditions of the incentive agreement and access these concessionary tax rates in the future.
Summary of income tax expense/(benefit)	Year Ended June 30, (in U.S. dollars, in thousands) 2023 2022 2021 (b) Income tax (benefit)/expense Current tax Current tax — — — Total current tax (benefit)/expense — — — Deferred tax (Increase)/decrease in deferred tax assets 38 (8,317) (1,158) (Decrease)/increase in deferred tax liabilities (250) 8,078 339 Total deferred tax (benefit)/expense (212) (239) (819) Income tax (benefit)/expense (212) (239) (819)
Summary of Amounts That Would Be Recognized Directly in Equity if Brought to Account	Year Ended June 30, (in U.S. dollars, in thousands) 2023 2022 2021 (c) Amounts that would be recognized directly in equity if brought to account Aggregate current and deferred tax arising in the reporting period and not recognized in net loss or other comprehensive income but which would have been directly applied to equity had it been brought to account: Current tax recorded in equity (if brought to account) (1,716) (142) (525) Deferred tax recorded in equity (if brought to account) 839 715 905 (877) 573 380
Summary of Amounts That Would Be Recognized Directly in Equity	Year Ended June 30, (in U.S. dollars, in thousands) 2023 2022 2021 (d) Amounts recognized directly in equity Aggregate current and deferred tax arising in the reporting period and not recognized in net loss or other comprehensive income but debited/credited to equity Current tax recorded in equity — — — Deferred tax recorded in equity 212 239 91 212 239 91
Summary of Deferred Tax Assets Not Brought to Account	Year Ended June 30, (in U.S. dollars, in thousands) 2023 2022 2021 (e) Deferred tax assets not brought to account Unused tax losses Potential tax benefit at local tax rates 125,728 111,283 77,738 Other temporary differences Potential tax benefit at local tax rates 12,318 11,046 7,424 Other tax credits Potential tax benefit at local tax rates 3,220 3,220 3,220 141,266 125,549 88,382

Financial assets and liabilit_2

Financial assets and liabilities (Tables)	12 Months Ended
Financial assets and liabilities (Tables)	Jun. 30, 2023
Disclosure Of Financial Assets And Liabilities [Abstract]
Summary of Financial Instruments	The Group holds the following financial instruments: Financial assets Notes Assets at FVOCI (1) Assets at FVTPL (2) Assets at Total As of June 30, 2023 Cash & cash equivalents 5(a) — — 71,318 71,318 Trade & other receivables 5(b) — — 6,998 6,998 Financial assets at fair value through other comprehensive income 5(c) 1,757 — — 1,757 Other non-current assets 5(d) — — 2,326 2,326 1,757 — 80,642 82,399 As of June 30, 2022 Cash & cash equivalents 5(a) — — 60,447 60,447 Trade & other receivables 5(b) — — 4,403 4,403 Financial assets at fair value through other comprehensive income 5(c) 1,758 — — 1,758 Other non-current assets 5(d) — — 1,930 1,930 1,758 — 66,780 68,538 (1) Fair value through other comprehensive income (2) Fair value through profit or loss Financial liabilities Notes Liabilities at FVOCI (1) Liabilities at FVTPL (2) Liabilities at Total As of June 30, 2023 Trade and other payables 5(e) — — 20,145 20,145 Borrowings 5(f) — — 108,763 108,763 Contingent consideration 5(g)(iii) — 17,199 — 17,199 Warrant liability 5(g)(vi) — 5,426 — 5,426 — 22,625 128,908 151,533 As of June 30, 2022 Trade and other payables 5(e) — — 23,079 23,079 Borrowings 5(f) — — 96,634 96,634 Contingent consideration 5(g)(iii) — 23,284 — 23,284 Warrant liability 5(g)(vi) — 2,185 — 2,185 — 25,469 119,713 145,182 (1) Fair value through other comprehensive income (2) Fair value through profit or loss
Summary of Cash and Cash Equivalents	a. Cash and cash equivalents As of June 30, (in U.S. dollars, in thousands) 2023 2022 Cash at bank 70,920 60,034 Deposits at call (1) 398 413 71,318 60,447 (1) As of June 30, 2023 and June 30, 2022, interest-bearing deposits at call include amounts of $0.4 million and $0.4 million, respectively, held as security and restricted for use.
Summary of Trade and Other Receivables and Prepayments	b. Trade and other receivables and prepayments (i) Trade and other receivables As of June 30, (in U.S. dollars, in thousands) 2023 2022 Trade debtors 2,276 2,224 Tax incentives recoverable 2,363 — Foreign withholding tax recoverable 471 471 U.S. Tax credits 1,473 1,473 Net investment in sublease 195 — Interest receivables 18 — Other recoverable taxes (Goods and services tax and value-added tax) 202 235 Trade and other receivables 6,998 4,403 (ii) Prepayments As of June 30, (in U.S. dollars, in thousands) 2023 2022 Clinical trial research and development expenditure 950 1,313 Prepaid insurance and subscriptions 2,025 2,420 Other 367 1,254 Prepayments 3,342 4,987
Summary of Financial Assets at Fair Value through Other Comprehensive Income	Financial assets at fair value through other comprehensive income include the following classes of financial assets: As of June 30, (in U.S. dollars, in thousands) 2023 2022 Unlisted securities: Equity securities 1,757 1,758 1,757 1,758
Summary of Other Non-current Assets	Other non-current assets As of June 30, (in U.S. dollars, in thousands) 2023 2022 Bank guarantee 481 500 Net investment in sublease 414 — Letter of credit 1,179 1,178 Security deposit 252 252 2,326 1,930
Summary of Trade and Other Payables	Trade and other payables As of June 30, (in U.S. dollars, in thousands) 2023 2022 Trade payables and other payables 20,145 23,079 Trade and other payables 20,145 23,079
Summary of Borrowings	f. Borrowings As of June 30, (in U.S. dollars, in thousands) 2023 2022 Borrowings Secured liabilities: Borrowing arrangements 81,919 81,919 Less: transaction costs (8,740) (8,247) Amortization of carrying amount, net of payments made 35,584 22,962 108,763 96,634 As of June 30, (in U.S. dollars, in thousands) 2023 2022 Borrowings Current Borrowings - NovaQuest 336 372 Borrowings - Oaktree 5,616 4,645 5,952 5,017 Non-current Borrowings - NovaQuest 55,739 47,898 Borrowings - Oaktree 47,072 43,719 102,811 91,617 108,763 96,634
Summary of Net Debt	(iii) Net debt reconciliation As of June 30, (in U.S. dollars, in thousands) 2023 2022 Cash and cash equivalents 71,318 60,447 Borrowings (108,763) (96,634) Lease liabilities (7,732) (10,271) Warrant liability (5,426) (2,185) Net Debt (1) (50,603) (48,643) Cash and cash equivalents 71,318 60,447 Gross debt - fixed interest rates (116,495) (106,905) Gross debt - variable interest rates — — Warrant liability (5,426) (2,185) Net Debt (1) (50,603) (48,643) (1) Net debt amount includes leases and borrowing arrangements
Summary of Net Debt Reconciliation	Liabilities from financing activities Other assets (in U.S. dollars, in thousands) Borrowings Leases Warrant liability Sub-total Cash and cash Total Net Debt as at June 30, 2022 (96,634) (10,271) (2,185) (109,090) 60,447 (48,643) Cash Flows (1) 5,926 3,170 — 9,096 11,039 20,135 Remeasurement adjustments 358 — (2,205) (1,847) — (1,847) Other Changes (2) (18,413) (738) — (19,151) — (19,151) Issuance of warrants — — (1,036) (1,036) — (1,036) Acquisition – leases — — — — — — Foreign exchange adjustments — 107 107 (168) (61) Net Debt as at June 30, 2023 (108,763) (7,732) (5,426) (121,921) 71,318 (50,603) (1) Cash flows include the payments of borrowings, lease liabilities, interest and debt transaction costs which are presented as financing cash flows in the statement of cash flows. (2) Other changes include modification of leases and accrued interest expenses for borrowings and leases.
Summary of Financial Assets and Liabilities Measured and Recognized at Fair Value	The following table presents the Group's financial assets and financial liabilities measured and recognized at fair value as of June 30, 2023 and June 30, 2022 on a recurring basis, categorized by level according to the significance of the inputs used in making the measurements: As of June 30, 2023 (in U.S. dollars, in thousands) Notes Level 1 Level 2 Level 3 Total Financial Assets Financial assets at fair value through other comprehensive income: Equity securities - biotech sector 5(c) — — 1,757 1,757 Total Financial Assets — — 1,757 1,757 Financial Liabilities Financial liabilities at fair value through profit or loss: Contingent consideration 5(g)(iii) — — 17,199 17,199 Warrant liabilities 5(g)(vi) — — 5,426 5,426 Total Financial Liabilities — — 22,625 22,625 As of June 30, 2022 (in U.S. dollars, in thousands) Notes Level 1 Level 2 Level 3 Total Financial Assets Financial assets at fair value through other comprehensive income: Equity securities - biotech sector 5(c) — — 1,758 1,758 Total Financial Assets — — 1,758 1,758 Financial Liabilities Financial liabilities at fair value through profit or loss: Contingent consideration 5(g)(iii) — — 23,284 23,284 Warrant liabilities 5(g)(vi) — — 2,185 2,185 Total Financial Liabilities — — 25,469 25,469
Summary of Changes in the Contingent Consideration Fair Value of Level 3 Instruments	The following table presents the changes in the contingent consideration balances within the level 3 instruments for the years ended June 30, 2023 and June 30, 2022: (in U.S. dollars, in thousands) Contingent consideration provision Opening balance - July 1, 2021 25,409 Amount used during the period (1,212) Charged/(credited) to consolidated income statement: Remeasurement (1) (913) Closing balance - June 30, 2022 23,284 Opening balance - July 1, 2022 23,284 Reclassification during the period 2,686 Charged/(credited) to consolidated income statement: Remeasurement (2) (8,771) Closing balance - June 30, 2023 17,199 (1) In the year ended June 30, 2022, a gain of $0.9 million was recognized on the remeasurement of contingent consideration pertaining to the acquisition of assets from Osiris. This remeasurement was a net result of changing the key assumptions of the contingent consideration valuation such as developmental timelines, market growth and the increase in valuation as the time period shortens between the valuation date and the potential settlement dates of contingent consideration. (2) In the year ended June 30, 2023, a gain of $8.8 million was recognized on the remeasurement contingent consideration pertaining to the acquisition of assets from Osiris. This remeasurement was a net result of changing key assumptions of the contingent consideration valuation, such as probability of payment, development timelines and the increase in valuation as the time period shortens between the valuation date and the potential settlement dates of contingent consideration, including the impact from the complete response from the FDA on the Group's BLA for remestemcel-L for the treatment of pediatric SR-aGVHD in August 2023. The assumptions relating to development timelines have been updated to reflect current expectations as a result of the complete response, as discussed in Note 15.
Summary of Quantitative Information About the Significant Unobservable Inputs Used in Level 3 Fair Value Measurements	The following table summarizes the quantitative information about the significant unobservable inputs used in level 3 fair value measurements: Range of inputs (weighted average) (in U.S. dollars, in thousands, except percent data) Description Fair value Fair value Valuation Unobservable inputs (1) Year Ended Year Ended Relationship of Contingent consideration provision 17,199 23,284 Discounted cash flows Risk adjusted 11%-13% (12.5%) 11%-13% (12.5%) Year ended June 30, 2023: A change in the discount rate by 0.5% would increase/decrease the fair value by 0.01%. Year ended June 30, 2022: A change in the discount rate by 0.5% would increase/decrease the fair value by 0.2%. Expected unit Various Various Year ended June 30, 2023: A change in the price assumptions by 10% would increase/decrease the fair value by 0.1%. Year ended June 30, 2022: A change in the price assumptions by 10% would increase/decrease the fair value by 2%. Expected sales Various Various Year ended June 30, 2023: A change in the volume assumptions by 10% would increase/decrease the fair value by 0.1%. Year ended June 30, 2022: A change in the volume assumptions by 10% would increase/decrease the fair value by 2%. Probability of success and payment Various Various Year ended June 30, 2023: A change in the probability of success and payment assumptions by 10% and 20% would increase/decrease the fair value by 8% and 16%, respectively. Year ended June 30, 2022: A change in the probability of success and payment assumptions by 10% and 20% would increase/decrease the fair value by 8.6% and 17.2%, respectively. (1) There were no significant inter-relationships between unobservable inputs that materially affect fair values.
Disclosure of Detailed Information About Valuation Processes of Contingent Consideration at Fair Value Explanatory	As of June 30, The fair value of contingent consideration (in U.S. dollars, in thousands) 2023 2022 Fair value of cash or stock payable, dependent on achievement of future late-stage clinical or regulatory targets 16,606 17,827 Fair value of royalty payments from commercialization of the intellectual property acquired 593 5,457 17,199 23,284
Summary of Warrant Liability	(vi) Warrant liability (in U.S. dollars, in thousands) As of June 30, Warrant liability 2023 2022 Opening balance 2,185 — Warrants fair value at grant date - November 19, 2021 — 8,081 Warrants fair value at grant date - December 22, 2022 1,036 — Remeasurement of warrant liability 2,205 (5,896) Closing Balance 5,426 2,185
Summary of Fair Value of Warrants	The following assumptions were based on observable market conditions that existed as of June 30, 2023 and 2022. (in U.S. dollars, except percent data and as otherwise noted) As of June 30, As of June 30, 2022 Rationale Share Price $3.91 $2.22 Closing share price on valuation date from external market source Exercise Price $3.70 to $7.26 $7.26 As per subscription agreement Expected Term 6 to 7 years 7 years As per subscription agreement Dividend Yield 0% 0% Based on Company’s nil dividend history Expected Volatility 81.26% 83.22% Based on historical volatility data for the Company Risk Free Interest Rate 4.01% 3.08% Based on the closing U.S. treasury issued 7 year bonds on valuation date Fair value per warrant $2.3103 to $2.9401 $1.2350 Determined using Black-Scholes valuation model with the inputs above Fair value $5,426,212 $2,185,476 Fair value of 2,224,669 warrants of $5,426,212 as of June 30, 2023 and fair value of 1,769,669 warrants of $2,185,476 as of June 30, 2022

Non-financial Assets and Liab_2

Non-financial Assets and Liabilities (Tables)	12 Months Ended
Non-financial Assets and Liabilities (Tables)	Jun. 30, 2023
Disclosure Of Non Financial Assets And Liabilities [Abstract]
Summary of Property, Plant and Equipment	a. Property, plant and equipment (in U.S. dollars, in thousands) Plant and Equipment Office Furniture and Equipment Computer Hardware and Software Total Year Ended June 30, 2022 Opening net book amount 1,953 811 257 3,021 Additions 143 3 42 188 Exchange differences 54 (70) (4) (20) Depreciation charge (942) (52) (150) (1,144) Closing net book value 1,208 692 145 2,045 As of June 30, 2022 Cost 6,846 1,925 3,379 12,150 Accumulated depreciation (5,638) (1,233) (3,234) (10,105) Net book value 1,208 692 145 2,045 Year Ended June 30, 2023 Opening net book amount 1,208 692 145 2,045 Additions 171 43 60 274 Exchange differences (104) 113 (18) (9) Depreciation charge (818) (45) (90) (953) Closing net book value 457 803 97 1,357 As of June 30, 2023 Cost 6,910 2,074 3,353 12,337 Accumulated depreciation (6,453) (1,271) (3,256) (10,980) Net book value 457 803 97 1,357
Schedule of Right-of-Use Assets	Right-of-use assets (in U.S. dollars, in thousands) Buildings Manufacturing Total Year Ended June 30, 2022 Opening net book amount 5,417 3,702 9,119 Additions 1,464 — 1,464 Reassessment 97 494 591 Exchange differences (165) — (165) Depreciation charge (1,717) (1,372) (3,089) Closing net book value 5,096 2,824 7,920 As of June 30, 2022 Cost 9,957 6,178 16,135 Accumulated depreciation (4,861) (3,354) (8,215) Net book value 5,096 2,824 7,920 Year Ended June 30, 2023 Opening net book amount 5,096 2,824 7,920 Additions/(derecognition) (649) — (649) Reassessment 526 (302) 224 Exchange differences (15) — (15) Depreciation charge (1,661) (685) (2,346) Closing net book value 3,297 1,837 5,134 As of June 30, 2023 Cost 9,957 6,178 16,135 Accumulated depreciation (6,660) (4,341) (11,001) Net book value 3,297 1,837 5,134
Summary of Lease Liabilities	Lease liabilities As of June 30, 2023 2022 Current 4,060 3,186 Non-current 3,672 7,085 Lease liabilities included in the balance sheet 7,732 10,271
Summary of Intangible Assets	c. Intangible assets (in U.S. dollars, in thousands) Goodwill Acquired licenses to patents In-process research and development acquired Current marketed products Total Year Ended June 30, 2022 Opening net book amount 134,453 2,072 427,779 16,242 580,546 Additions/reversals — (450) — — (450) Exchange differences — 74 — 1 75 Amortization charge — (64) — (1,455) (1,519) Closing net book amount 134,453 1,632 427,779 14,788 578,652 As of June 30, 2022 Cost 134,453 2,987 489,698 24,000 651,138 Accumulated amortization — (1,355) — (9,212) (10,567) Accumulated impairment — — (61,919) — (61,919) Net book amount 134,453 1,632 427,779 14,788 578,652 Year Ended June 30, 2023 Opening net book amount 134,453 1,632 427,779 14,788 578,652 Additions — 23 — — 23 Exchange differences — 1 — — 1 Amortization charge — (38) — (1,455) (1,493) Closing net book amount 134,453 1,618 427,779 13,333 577,183 As of June 30, 2023 Cost 134,453 2,993 489,698 23,999 651,143 Accumulated amortization — (1,375) — (10,666) (12,041) Accumulated impairment — — (61,919) — (61,919) Net book amount 134,453 1,618 427,779 13,333 577,183
Summary of Carrying Value of In Process Research and Development Acquired by Product	Carrying value of in-process research and development acquired by product As of June 30, (in U.S. dollars, in thousands) 2023 2022 Cardiovascular products (1) 254,351 254,351 Intravenous products for metabolic diseases and inflammatory/immunologic conditions (2) 70,730 70,730 MSC products (3) 102,698 102,698 427,779 427,779 (1) Includes MPC-150-IM for the treatment or prevention of chronic heart failure and MPC-25-IC for the treatment or prevention of acute myocardial infarction (2) Includes MPC-300-IV for the treatment of biologic-refractory rheumatoid arthritis and diabetic nephropathy
Summary of Provisions	As of June 30, 2023 As of June 30, 2022 (in U.S. dollars, in thousands) Current Non-current Total Current Non-current Total Contingent consideration 636 16,563 17,199 10,823 12,461 23,284 Employee benefits 2,013 49 2,062 3,333 62 3,395 Provision for license agreements 3,750 — 3,750 3,750 — 3,750 6,399 16,612 23,011 17,906 12,523 30,429
Summary of Deferred Tax Balances	(i) Deferred tax balances As of June 30, (in U.S. dollars, in thousands) 2023 2022 Deferred tax assets The balance comprises temporary differences attributable to: Tax losses 76,020 80,411 Other temporary differences 11,972 7,831 Total deferred tax assets 87,992 88,242 Deferred tax liabilities The balance comprises temporary differences attributable to: Intangible assets 87,992 88,242 Total deferred tax liabilities 87,992 88,242 Net deferred tax liabilities — —
Schedule of Movements Related to Deferred Tax Assets and Liabilities	(ii) Movements (in U.S. dollars, in thousands) Tax losses (1) (DTA) Other temporary differences (1) (DTA) Intangible assets (DTL) Total (DTL) As of June 30, 2021 (71,916) (8,248) 80,164 — Charged/(credited) to: - profit or loss (8,742) 425 8,078 (239) - directly to equity 247 (8) — 239 As of June 30, 2022 (80,411) (7,831) 88,242 — Charged/(credited) to: - profit or loss 4,179 (4,141) (250) (212) - directly to equity 212 — — 212 As of June 30, 2023 (76,020) (11,972) 87,992 — (1) Deferred tax assets are netted against deferred tax liabilities.
Schedule of Deferred Consideration	As of June 30, (in U.S. dollars, in thousands) 2023 2022 Opening balance (1) 2,500 2,500 Amount recognized as revenue during the period — — Balance as of the end of the period 2,500 2,500 (1) The $2.5 million milestone payment received in December 2019 from Grünenthal was considered constrained and resulted in deferred consideration as of June 30, 2023.

Equity (Tables)

Equity (Tables)	12 Months Ended
Equity (Tables)	Jun. 30, 2023
Disclosure of classes of share capital [abstract]
Schedule of Share Capital	(i) Share capital As of June 30, 2023 2022 2021 2023 2022 2021 Shares No. (U.S. dollars, in thousands) Contributed equity (i) Share capital Ordinary shares 814,204,825 650,454,551 648,696,070 1,249,123 1,165,309 1,163,153 Less: Treasury Shares (542,903) (542,903) (771,983) — — — Total Contributed Equity 813,661,922 649,911,648 647,924,087 1,249,123 1,165,309 1,163,153
Summary of Movements in Ordinary Share Capital	(ii) Movements in ordinary share capital As of June 30, As of June 30, 2023 2022 2021 2023 2022 2021 Shares No. (U.S. dollars, in thousands) Opening balance 650,454,551 648,696,070 583,949,612 1,165,309 1,163,153 1,051,450 Issues of ordinary shares during the period Exercise of share options (1) — — — — 209 9,223 Transfer to employee share trust (1) — — 3,450,000 — — — Share based compensation for services rendered — 1,758,481 1,187,168 — 1,698 1,867 Placement of shares under a share placement agreement (2)(3) 163,750,274 — 60,109,290 89,141 — 97,031 Transaction costs arising on share issue — — — (5,327) 21 (1,312) Total contributions of equity during the period 163,750,274 1,758,481 64,746,458 83,814 1,928 106,809 Share options reserve transferred to equity on exercise of options — — — — 228 4,894 Ending balance 814,204,825 650,454,551 648,696,070 1,249,123 1,165,309 1,163,153 (1) Options are issued to employees, directors and consultants in accordance with the Mesoblast Employee Share Option Plan. Unpaid shares are issued to the share trust to enable future option exercises to be settled. On exercise of options, the proceeds of the exercise are recorded in ordinary share capital in Mesoblast Limited and the exercise is settled by transfer of the shares from the share trust to the employee. (2) In March 2021, 60,109,290 shares were issued in an equity purchase of Mesoblast Limited at A$2.30 per share to existing and new institutional investors, representing a 6.50% discount to the price calculated at the close of trading February 25, 2021. The investors also received warrants to acquire a further 15 million shares at a price of A$2.88 per share, a 25% premium to the placement price, which may raise up to a further A$43.2 million, on or before March 15, 2028. These warrants have been classified within warrant reserves, refer to Note 7(b). (3) In August 2022, 86,666,667 shares were issued in an equity purchase of Mesoblast Limited at A$0.75 per share to existing and new institutional investors, representing a 5.00% discount to the thirty trading-day volume weighted average price. In April 2023, 77,083,607 shares were issued in an equity purchase of Mesoblast Limited at A$0.85 per share primarily to existing major shareholders, representing a 15.00% discount to the five trading-day volume weighted average price.
Summary of Movements of Shares in Share Trust	(iii) Movements of shares in share trust As of June 30 As of June 30 2023 2022 2021 2023 2022 2021 Shares No. (U.S. dollars, in thousands) Opening balance (1) 542,903 771,983 3,500,000 — — — Movement of shares in share trust Transfer to employee share trust (2) — — 3,450,000 — — — Exercise of share options (2) — (229,080) (6,178,017) — — — Ending balance 542,903 542,903 771,983 — — — (1) In July 2020, the Group formed the Mesoblast Employee Share Trust, being a new trust formed to administer the Group’s employee share scheme. Prior to forming the new trust, the Group had been using the Mesoblast Limited Employee Share Trust for administering some aspects of the Group’s employee share scheme. In July 2020, 3,500,000 shares were transferred from Mesoblast Limited Employee Share Trust to the new Mesoblast Employee Share Trust. These trusts have been consolidated, as the substance of the relationship is that the trusts are controlled by the Group. (2) Options are issued to employees, directors and consultants in accordance with the Mesoblast Employee Share Option Plan. Unpaid shares are issued to the share trust to enable future option exercises to be settled. On exercise of options, the proceeds of the exercise are recorded in ordinary share capital in Mesoblast Limited and the exercise is settled by transfer of the shares from the share trust to the employee.
Summary of Reserves	(i) Reserves As at June 30, (in U.S. dollars, in thousands) 2023 2022 Share-based payments reserve 101,367 97,924 Investment revaluation reserve (543) (542) Foreign currency translation reserve (40,273) (39,700) Warrants reserve 12,969 12,969 73,520 70,651
Summary of Reconciliation of Reserves	(ii) Reconciliation of reserves (in U.S. dollars, in thousands) As at June 30, Share-based payments reserve 2023 2022 Opening balance 97,924 92,855 Tax credited / (debited) to equity (212) (239) Transfer to ordinary shares on exercise of options — (228) Share-based payment expense for the year 3,655 5,536 Closing Balance 101,367 97,924 Investment revaluation reserve Opening balance (542) (220) Changes in the fair value of financial assets through other comprehensive income (1) (322) Closing Balance (543) (542) Foreign currency translation reserve Opening balance (39,700) (39,791) Currency gain/(loss) on translation of foreign operations net assets (573) 91 Closing Balance (40,273) (39,700) Warrant reserve Opening balance 12,969 12,969 Movements during the period — — Closing Balance 12,969 12,969
Summary of Warrant Assumptions Based on Observable Market Conditions Existed at Issue Date	The warrants granted are not traded in an active market and therefore the fair value has been estimated by using the Monte Carlo pricing model based on the following assumptions. Key terms of the warrants are included above. The following assumptions were based on observable market conditions that existed at the issue date. (in U.S. dollars, except percent data and as otherwise noted) At Issue date - March 18, 2021 Rationale Share Price A$2.41 Closing share price on valuation date from external market source Exercise Price A$2.88 As per subscription agreement Expected Term 7 years As per subscription agreement Dividend Yield 0% Based on Company’s nil dividend history Expected Volatility 66.88% Based on historical volatility data for the Company A$-US$ FX Spot Rate 0.7827 Closing FX rate on valuation date from the Reserve Bank of Australia historical foreign exchange rate tables Risk Free Interest Rate 1.24% Based on the mid-point of the Australian Government issued 5 year and 10 year bonds Fair value per warrant $0.863 (A$1.103) Determined using Monte Carlo pricing models with the inputs above Fair value $12,968,583 Fair value of 15,027,327 warrants as at issue date

Cash flow information (Tables)

Cash flow information (Tables)	12 Months Ended
Cash flow information (Tables)	Jun. 30, 2023
Statement of cash flows [abstract]
Summary of Cash Flow Information	(in U.S. dollars, in thousands) As of June 30, (a) Reconciliation of cash and cash equivalents 2023 2022 2021 Cash at bank 70,920 60,034 136,430 Deposits at call 398 413 451 71,318 60,447 136,881 (in U.S. dollars, in thousands) As of June 30, (b) Reconciliation of net cash flows used in operations with loss after income tax 2023 2022 2021 Loss for the period (81,889) (91,347) (98,811) Add/(deduct) net loss for non-cash items as follows: Depreciation and amortization 4,107 4,380 4,264 Foreign exchange losses/(gains) 62 536 (1,499) Finance costs 20,122 17,288 10,711 Remeasurement of contingent consideration (8,771) (913) (18,687) Remeasurement of warrant liabilities 2,205 (5,896) — Equity settled share-based payment 3,655 5,536 12,510 Deferred tax benefit (212) (235) (819) Gain on derecognition of right-of-use assets (76) — — Change in operating assets and liabilities: Decrease/(increase) in trade and other receivables (118) 140 (1,739) Decrease/(increase) in prepayments 1,650 1,555 (213) Increase/(decrease) in trade creditors and accruals (398) 4,777 (5,061) Decrease/(increase) in tax incentive recoverable (2,388) — — Increase/(decrease) in provisions (1,218) (1,603) (1,405) Net cash outflows used in operations (63,269) (65,782) (100,749)

Financial Risk Management (Tabl

Financial Risk Management (Tables)	12 Months Ended
Financial Risk Management (Tables)	Jun. 30, 2023
Disclosure Of Financial Risk Management [Abstract]
Disclosure of Exposure to Financial Risks	This note explains the Group’s exposure to financial risks and how these risks could affect the Group’s future financial performance. Current year profit and loss information has been included where relevant to add further context. Risk Exposure arising from Measurement Management Market risk – currency risk Future commercial transactions Recognized financial assets and liabilities not denominated in the functional currency of each entity within the Group Cash flow forecasting The future cash flows of each currency are forecast and the quantum of cash reserves held for each currency are managed in line with future forecasted requirements. Cross currency swaps are undertaken as required. Market risk – interest rate risk Term deposits at fixed rates Sensitivity analysis Vary length of term deposits, utilize interest bearing accounts and periodically review interest rates available to ensure we earn interest at market rates. Market risk – price risk Long-term borrowings Sensitivity analysis Forecasts of net sales of the product underlying the NovaQuest borrowing arrangement are updated on a quarterly basis to evaluate the impact on the carrying amount of the financial liability. Credit risk Cash and cash equivalents, trade and other receivables and other non-current assets Aging analysis Transact primarily with the best risk rated banks available in each region giving consideration to the products required, the quantum of cash reserves held and future forecasted requirements Liquidity risk Cash and cash equivalents, borrowings, trade payables, lease liabilities and contingent consideration Rolling cash flow forecasts Future cash flows requirements are forecasted and capital raising strategies are planned to ensure sufficient cash balances are maintained to meet the Group’s future commitments.
Schedule of Balances Held at the End of Year with an Analysis which Assesses Impact on Profit and Loss Due to Change in Exchange Rate	The balances held at the end of the year that give rise to currency risk exposure are presented in US$ in the following table, together with a sensitivity analysis which assesses the impact that a change of +/-20% in the exchange rate as of June 30, 2023 and June 30, 2022 would have had on the Group’s reported net profits/(losses) and/or equity balance. The bank balances held at the end of the year that are presented in the following table give rise to currency risk exposure as they are not in the functional currency of the entity in which it is held. +20% -20% (in U.S. dollars, in thousands, unless otherwise noted) Foreign Profit/(Loss) Profit/(Loss) Bank accounts – USD US$60 $ 12 $ (12) Bank accounts – CHF CHF79 $ 18 $ (18) Bank accounts – SGD S$80 $ 12 $ (12) Bank accounts – EUR EUR4 $ 1 $ (1) Trade and other receivables - USD US$400 $ 80 $ (80) Trade and other receivables - SGD S$106 $ 16 $ (16) Trade and other receivables - CHF CHF3 $ 1 $ (1) Trade and other receivables - EUR EUR292 $ 63 $ (63) Trade payables and accruals - USD (US$1,361) $ (272) $ 272 Trade payables and accruals - AUD (A$1,064) $ (141) $ 141 Trade payables and accruals - SGD (S$422) $ (62) $ 62 Trade payables and accruals - GBP (GBP45) $ (11) $ 11 Trade payables and accruals - EUR (EUR26) $ (6) $ 6 Trade payables and accruals - CHF (CHF40) $ (9) $ 9 Provisions – USD (US$1,750) $ (350) $ 350 $ (648) $ 648 +20% -20% (in U.S. dollars, in thousands, unless otherwise noted) Foreign Profit/(Loss) Profit/(Loss) Bank accounts – USD US$93 $ 19 $ (19) Bank accounts – CHF CHF55 $ 12 $ (12) Bank accounts – SGD S$140 $ 20 $ (20) Bank accounts – EUR EUR289 $ 60 $ (60) Trade and other receivables - SGD S$205 $ 30 $ (30) Trade and other receivables - CHF CHF6 $ 1 $ (1) Trade and other receivables - EUR EUR153 $ 32 $ (32) Trade payables and accruals - USD (US$274) $ (55) $ 55 Trade payables and accruals - AUD (A$752) $ (104) $ 104 Trade payables and accruals - SGD (S$429) $ (62) $ 62 Trade payables and accruals - GBP (GBP50) $ (12) $ 12 Trade payables and accruals - EUR (EUR42) $ (9) $ 9 Trade payables and accruals - CHF (CHF36) $ (7) $ 7 Provisions – USD (US$1,750) $ (350) $ 350 Provisions – SGD (S$62) $ (9) $ 9 $ (434) $ 434
Schedule of Deposits Held which Derive Interest Revenue with Maximum and Minimum Interest Rates Being Earned	The deposits held which derive interest revenue are described in the table below, together with the maximum and minimum interest rates being earned as of June 30, 2023 and June 30, 2022. The effect on profit is shown if interest rates change by 10%, in either direction, is as follows: As of As of (in U.S. dollars, in thousands, except percent data) Low High US$ Low (1) High (1) US$ Funds invested – US$ 1.79 % 1.79 % 40,569 0.00 % 0.00 % 49,383 Rate increase by 10% 1.97 % 1.97 % 73 0.03 % 0.03 % 15 Rate decrease by 10% 1.61 % 1.61 % (73) 0.03 % 0.03 % (15) (in Australian dollars, in thousands, except percent data) Low High A$ Low High A$ Funds invested – A$ 4.59 % 4.59 % 600 1.50 % 1.50 % 600 Rate increase by 10% 5.05 % 5.05 % 3 1.65 % 1.65 % 1 Rate decrease by 10% 4.13 % 4.13 % (3) 1.35 % 1.35 % (1) (1) The interest rate was 0% for the period ended June 30, 2022. The sensitivity assumes the interest rate to increase or decrease by 0.03%, which is consistent with prior periods.
Summary of Borrowing to Price Rate Changes	The exposure of the Group’s borrowing to price rate changes are as follows: As of As of (in U.S. dollars, in thousands, except percent data) Total % of total borrowings Total % of total borrowings Financial liabilities Current borrowings Borrowings – NovaQuest 336 0 % 372 0 % Non-current borrowings Borrowings – NovaQuest 55,739 51 % 47,898 50 % 56,075 51 % 48,270 50 %
Schedule of Group's Receivables	Credit risk is the risk that one party to a financial instrument will fail to discharge its obligation and cause financial loss to the other party. The maximum exposure to credit risk at the end of the reporting period is the carrying amount of each class of financial assets. The Group’s receivables are tabled below. As of June 30, (in U.S. dollars, in thousands) 2023 2022 Cash and cash equivalents Deposits at call (Note 5(a)) - minimum A rated 398 413 Cash at bank (Note 5(a)) - minimum A rated 70,920 60,033 Trade and other receivables Receivable from other parties (non-rated) 2,276 2,382 Receivable from the Australian Government (Income Tax) 2,363 5 Receivable from the United States Government (U.S. tax credits) 1,473 1,475 Receivable from the Australian Government (Foreign Withholding Tax) 400 400 Receivable from the Australian Government (Goods and Services Tax) 121 102 Receivable from the Singapore Government (Goods and Services Tax) 78 — Receivable from the United States Government (Foreign Withholding Tax) 71 — Receivable from minimum A rated bank deposits (interest) 18 — Receivable from the Swiss Government (Value-Added Tax) 3 105 Receivable from the United States Government (Income Tax) — 20 Other non-current assets Minimum A rated bank deposits (held as security) 1,912 1,930
Schedule of Maturity Profile of Anticipated Future Contractual Cash Flows Borrowings and Carrying Value	As of June 30, 2023, the maturity profile of the anticipated future contractual cash flows, on an undiscounted basis and removing probability adjustments as applicable for contingent consideration, and which, therefore differs from the carrying value, is as follows: (in U.S. dollars, in thousands) Within Between Between Over Total Carrying Borrowings (1)(2) (6,668) (15,639) (152,371) — (174,678) (108,763) Trade payables (20,145) — — — (20,145) (20,145) Lease liabilities (4,393) (2,592) (1,252) — (8,237) (7,732) Contingent consideration (3) (4,617) (935) (1,006) — (6,558) (593) (35,823) (19,166) (154,629) — (209,618) (137,233)

Interests in other entities (Ta

Interests in other entities (Tables)	12 Months Ended
Interests in other entities (Tables)	Jun. 30, 2023
Disclosure of subsidiaries [abstract]
Summary of Group's Principal Subsidiaries	The Group’s subsidiaries as of June 30, 2023 and 2022 are set out below. Unless otherwise stated, they have share capital consisting solely of ordinary shares that are held directly by the Group, and the proportion of ownership interests held equals the voting rights held by the Group. The country of incorporation or registration is also their principal place of business, aside from BeiCell Ltd, which was incorporated on November 15, 2018 in the Cayman Islands however operates in Hong Kong. Country of Class of Equity holding As of June 30, 2023 2022 % % Mesoblast, Inc. USA Ordinary 100 100 Mesoblast International Sàrl (includes Mesoblast International Sàrl Singapore Branch) Switzerland Ordinary 100 100 Mesoblast Australia Pty Ltd Australia Ordinary 100 100 Mesoblast UK Ltd United Kingdom Ordinary 100 100 BeiCell Ltd Cayman Islands Ordinary 100 100

Related party transactions (Tab

Related party transactions (Tables)	12 Months Ended
Related party transactions (Tables)	Jun. 30, 2023
Disclosure Of Key Management Personnel Compensation [Abstract]
Summary of Aggregate Compensation made to Directors and other Members of key Management Personnel	The aggregate compensation made to Directors and other members of key management personnel of the Group is set out below: Year Ended June 30, (in U.S. dollars) 2023 2022 Short-term employee benefits 2,153,181 2,294,897 Long-term employee benefits 11,326 12,206 Post-employment benefits 23,935 31,346 Share based payments 881,342 391,592 3,069,784 2,730,041

Share-based payments (Tables)

Share-based payments (Tables)	12 Months Ended
Share-based payments (Tables)	Jun. 30, 2023
Disclosure Of Sharebased Payment Arrangements [Abstract]
Reconciliation of Outstanding Share Based Payments	a. Reconciliation of outstanding share based payments Series Grant Date (1) Expiry Date Exercise Opening Granted No. Exercised Lapsed/Forfeited* Closing Vested and 34 27-Apr-16 06-Mar-23 A$2.80 1,678,979 — — (1,678,979) — — 34b 31-Oct-16 06-Mar-23 A$2.80 200,000 — — (200,000) — — 35a 08-Jul-20 08-Jul-23 A$2.86 1,500,000 — — — 1,500,000 1,500,000 36 06-Dec-16 05-Dec-23 A$1.31 533,000 — — — 533,000 533,000 36a 06-Dec-16 05-Dec-23 A$1.19 1,950,730 — — — 1,950,730 1,809,064 38 16-Sep-17 15-Sep-24 A$1.54 50,000 — — — 50,000 50,000 38a 16-Sep-17 15-Sep-24 A$1.40 150,000 — — (150,000) — — 39 13-Oct-17 12-Oct-24 A$1.94 975,000 — — — 975,000 975,000 39a 13-Oct-17 12-Oct-24 A$1.76 902,425 — — — 902,425 902,425 40 24-Nov-17 23-Nov-24 A$1.41 750,000 — — — 750,000 750,000 40a 24-Nov-17 23-Nov-24 A$1.28 750,000 — — — 750,000 — 41 18-Jun-18 17-Jun-25 A$1.52 200,000 — — — 200,000 200,000 42 11-Jul-18 10-Jul-25 A$1.56 200,000 — — — 200,000 200,000 43 18-Jul-18 17-Jul-25 A$1.87 3,793,332 — — (660,000) 3,133,332 3,133,332 43b 18-Jul-18 17-Jul-25 A$1.87 350,000 — — — 350,000 350,000 45 30-Nov-18 29-Nov-25 A$1.33 590,000 — — — 590,000 590,000 46 19-Jan-19 18-Jan-26 A$1.45 3,333 — — — 3,333 3,333 47 19-Jan-19 18-Jan-26 A$1.45 150,000 — — — 150,000 150,000 48 04-Apr-19 03-Apr-26 A$1.48 300,000 — — — 300,000 300,000 49 20-Jul-19 19-Jul-26 A$1.62 3,098,670 — — (66,667) 3,018,669 3,018,669 49 20-Jul-19 19-Jul-26 A$1.62 — — (13,334) * 49a 20-Jul-19 19-Jul-26 A$1.47 3,499,998 — — (466,666) 2,833,332 1,883,332 49a 20-Jul-19 19-Jul-26 A$1.47 — — (200,000) * 49b 20-Jul-19 19-Jul-26 A$1.47 1,346,667 — — — 1,346,667 673,334 49c 20-Jul-19 19-Jul-26 A$1.47 538,667 — — — 538,667 538,667 50 20-Jul-19 19-Jul-26 A$1.47 700,000 — — — 700,000 175,000 50a 20-Jul-19 19-Jul-26 A$1.47 400,000 — — (400,000) * — — 52 29-Aug-19 28-Aug-26 A$1.62 400,000 — — (400,000) — — 53 29-Aug-19 28-Aug-26 A$1.47 800,000 — — (800,000) — — 54 25-Nov-19 24-Nov-26 A$1.98 153,334 — — (133,334) 20,000 20,000 55 29-May-19 28-May-26 A$1.48 350,000 — — — 350,000 300,000 56 18-Nov-19 17-Nov-26 A$1.83 200,000 — — — 200,000 200,000 57 25-Nov-19 24-Nov-26 A$1.80 100,000 — — — 100,000 100,000 58 25-Nov-19 24-Nov-26 A$1.98 450,000 — — (200,000) 150,000 150,000 58 25-Nov-19 24-Nov-26 A$1.98 — — (100,000) * 59 24-Jan-20 23-Jan-27 A$3.38 10,000 — — — 10,000 10,000 63 18-May-20 17-May-27 A$4.02 1,200,000 — — — 1,200,000 1,200,000 63a 18-May-20 17-May-27 A$3.65 2,400,000 — — (800,000) 1,200,000 200,000 63a 18-May-20 17-May-27 A$3.65 — — (400,000) * 64 16-Jul-20 15-Jul-27 A$3.75 3,498,333 — — (176,668) 3,253,333 2,160,009 64 16-Jul-20 15-Jul-27 A$3.75 — — (68,332) * 64a 16-Jul-20 15-Jul-27 A$3.41 2,700,000 — — (965,000) * 1,735,000 478,334 64c 16-Jul-20 15-Jul-27 A$3.41 350,000 — — — 350,000 116,666 64d 16-Jul-20 15-Jul-27 A$3.41 300,000 — — — 300,000 100,000 64e 16-Jul-20 15-Jul-27 A$3.41 1,200,000 — — — 1,200,000 720,000 65 26-Aug-20 25-Aug-27 A$5.76 5,000 — — (3,334) — — 65 26-Aug-20 25-Aug-27 A$5.76 — — (1,666) * 66 11-Sep-20 10-Sep-27 A$4.78 200,000 — — — 200,000 100,000 68 20-Nov-20 19-Nov-27 A$3.60 200,000 — — — 200,000 133,333 69 20-Nov-20 19-Nov-27 A$3.60 100,000 — — — 100,000 100,000 71 17-Feb-21 16-Feb-28 A$2.67 250,000 — — — 250,000 166,667 72 15-Apr-21 14-Apr-28 A$2.28 200,000 — — — 200,000 133,334 74 08-Sep-21 07-Sep-28 A$1.77 3,423,000 — — (50,001) 3,186,333 1,051,007 74 08-Sep-21 07-Sep-28 A$1.77 — — (186,666) * 74a 08-Sep-21 07-Sep-28 A$1.77 4,150,000 — — (300,000) * 3,850,000 923,334 74b 08-Sep-21 07-Sep-28 A$1.77 1,550,000 — — — 1,550,000 — 74c 08-Sep-21 07-Sep-28 A$1.77 650,000 — — (650,000) * — — 75 23-Dec-21 22-Dec-28 A$1.42 200,000 — — — 200,000 100,000 76 17-Oct-22 16-Oct-29 A$1.03 — 1,250,000 — — 1,250,000 — 77 23-May-22 22-May-29 A$1.01 — 200,000 — — 200,000 66,667 78 24-Aug-22 23-Aug-29 A$0.85 — 200,000 — — 200,000 — 79 17-Oct-22 16-Oct-29 A$1.13 — 5,844,500 — (90,000) * 5,754,500 — 79a 17-Oct-22 16-Oct-29 A$1.03 — 4,350,000 — — 4,350,000 — 79b 17-Oct-22 16-Oct-29 A$1.13 — 225,000 — — 225,000 — 79c 17-Oct-22 16-Oct-29 A$1.03 — 3,225,000 — — 3,225,000 — 79d 17-Oct-22 16-Oct-29 A$1.03 — 1,200,000 — — 1,200,000 — 80 08-Aug-22 07-Aug-29 A$0.93 — 100,000 — — 100,000 100,000 81 11-Dec-20 10-Dec-27 A$4.60 — 100,000 — — 100,000 100,000 82 21-Nov-22 20-Nov-29 A$1.12 — 100,000 — — 100,000 — 83 30-Mar-23 29-Mar-30 A$1.03 — 180,000 — (30,000) * 150,000 — June 30, 2023 49,650,468 16,974,500 — (9,190,647) 57,434,321 26,464,507 Weighted average share purchase price A$2.21 A$1.08 A$— A$2.39 A$1.85 A$2.12 (1) The dates presented in the grant date column represent the date on which board approval was obtained. For valuation dates per IFRS 2, refer to Note 17(c). Series Grant Date (1) Expiry Date Exercise Opening Granted No. Exercised Lapsed/Forfeited* Closing Vested and 32 10-Jul-15 30-Jun-22 A$4.20 1,753,334 — — (1,753,334) — — 33 26-Aug-15 16-Aug-22 A$4.05 75,000 — — (75,000) — — 34 27-Apr-16 06-Mar-23 A$2.80 1,858,979 — — (180,000) 1,678,979 1,678,979 34b 31-Oct-16 06-Mar-23 A$2.80 200,000 — — — 200,000 200,000 35a 08-Jul-20 08-Jul-23 A$2.86 1,500,000 — — — 1,500,000 1,500,000 36 06-Dec-16 05-Dec-23 A$1.31 623,000 — (50,000) (40,000) 533,000 533,000 36a 06-Dec-16 05-Dec-23 A$1.19 1,950,730 — — — 1,950,730 1,809,064 38 16-Sep-17 15-Sep-24 A$1.54 50,000 — — — 50,000 50,000 38a 16-Sep-17 15-Sep-24 A$1.40 150,000 — — — 150,000 150,000 39 13-Oct-17 12-Oct-24 A$1.94 1,090,000 — — (115,000) 975,000 975,000 39a 13-Oct-17 12-Oct-24 A$1.76 902,425 — — — 902,425 902,425 40 24-Nov-17 23-Nov-24 A$1.41 750,000 — — — 750,000 750,000 40a 24-Nov-17 23-Nov-24 A$1.28 750,000 — — — 750,000 — 41 18-Jun-18 17-Jun-25 A$1.52 200,000 — — — 200,000 200,000 42 11-Jul-18 10-Jul-25 A$1.56 200,000 — — — 200,000 200,000 43 18-Jul-18 17-Jul-25 A$1.87 4,201,666 — (20,000) (388,334) 3,793,332 3,793,332 43b 18-Jul-18 17-Jul-25 A$1.87 350,000 — — — 350,000 350,000 44 15-Jul-18 14-Jul-25 A$1.72 150,000 — — (150,000) — — 45 30-Nov-18 29-Nov-25 A$1.33 590,000 — — — 590,000 590,000 46 19-Jan-19 18-Jan-26 A$1.45 3,333 — — — 3,333 3,333 47 19-Jan-19 18-Jan-26 A$1.45 150,000 — — — 150,000 150,000 48 04-Apr-19 03-Apr-26 A$1.48 300,000 — — — 300,000 300,000 49 20-Jul-19 19-Jul-26 A$1.62 3,638,671 — (113,334) (277,999) 3,098,670 1,940,654 49 20-Jul-19 19-Jul-26 A$1.62 — (148,668) * 49a 20-Jul-19 19-Jul-26 A$1.47 3,999,998 — — (333,334) 3,499,998 1,316,665 49a 20-Jul-19 19-Jul-26 A$1.47 — (166,666) * 49b 20-Jul-19 19-Jul-26 A$1.47 1,346,667 — — — 1,346,667 673,334 49c 20-Jul-19 19-Jul-26 A$1.47 538,667 — — — 538,667 359,112 50 20-Jul-19 19-Jul-26 A$1.47 700,000 — — — 700,000 — 50a 20-Jul-19 19-Jul-26 A$1.47 400,000 — — — 400,000 — 51 29-Aug-19 28-Aug-26 A$1.47 150,000 — — (150,000) * — — 52 29-Aug-19 28-Aug-26 A$1.62 400,000 — — — 400,000 266,666 53 29-Aug-19 28-Aug-26 A$1.47 800,000 — — — 800,000 533,334 54 25-Nov-19 24-Nov-26 A$1.98 295,000 — — (25,000) 153,334 146,668 54 25-Nov-19 24-Nov-26 A$1.98 — (116,666) * 55 29-May-19 28-May-26 A$1.48 350,000 — — — 350,000 300,000 56 18-Nov-19 17-Nov-26 A$1.83 200,000 — — — 200,000 133,332 57 25-Nov-19 24-Nov-26 A$1.80 100,000 — — — 100,000 100,000 58 25-Nov-19 24-Nov-26 A$1.98 450,000 — — — 450,000 300,000 59 24-Jan-20 23-Jan-27 A$3.38 10,000 — — — 10,000 10,000 61 17-Apr-20 16-Apr-27 A$2.51 50,000 — — (16,666) — — 61 17-Apr-20 16-Apr-27 A$2.51 — (33,334) * 63 18-May-20 17-May-27 A$4.02 1,200,000 — — — 1,200,000 800,000 63a 18-May-20 17-May-27 A$3.65 2,400,000 — — — 2,400,000 400,000 64 16-Jul-20 15-Jul-27 A$3.75 4,280,000 — — (225,003) 3,498,333 1,201,676 64 16-Jul-20 15-Jul-27 A$3.75 (556,664) * 64a 16-Jul-20 15-Jul-27 A$3.41 3,050,000 — — (350,000) * 2,700,000 133,334 64b 16-Jul-20 15-Jul-27 A$3.41 325,000 — — (325,000) * — — 64c 16-Jul-20 15-Jul-27 A$3.41 350,000 — — — 350,000 — 64d 16-Jul-20 15-Jul-27 A$3.41 300,000 — — — 300,000 — 64e 16-Jul-20 15-Jul-27 A$3.41 1,200,000 — — — 1,200,000 — 65 26-Aug-20 25-Aug-27 A$5.76 5,000 — — — 5,000 1,667 66 11-Sep-20 10-Sep-27 A$4.78 200,000 — — — 200,000 100,000 67 08-Oct-20 07-Oct-27 A$3.84 200,000 — — (66,667) — — 67 08-Oct-20 07-Oct-27 A$3.84 — (133,333) * 68 20-Nov-20 19-Nov-27 A$3.60 200,000 — — — 200,000 66,666 69 20-Nov-20 19-Nov-27 A$3.60 100,000 — — — 100,000 100,000 71 17-Feb-21 16-Feb-28 A$2.67 250,000 — — — 250,000 — 72 15-Apr-21 14-Apr-28 A$2.28 — 200,000 — — 200,000 66,667 73 30-Jun-21 30-Aug-21 A$— 45,746 — (45,746) — — — 74 08-Sep-21 07-Sep-28 A$1.77 — 3,973,000 — (550,000) * 3,423,000 — 74a 08-Sep-21 07-Sep-28 A$1.77 — 4,150,000 — — 4,150,000 — 74b 08-Sep-21 07-Sep-28 A$1.77 — 1,550,000 — — 1,550,000 — 74c 08-Sep-21 07-Sep-28 A$1.77 — 650,000 — — 650,000 — 75 23-Dec-21 22-Dec-28 A$1.42 — 200,000 — — 200,000 — June 30, 2022 45,333,216 10,723,000 (229,080) (6,176,668) 49,650,468 23,084,908 Weighted average share purchase price A$2.42 A$1.77 A$1.25 A$2.99 A$2.21 A$2.06 (1) The dates presented in the grant date column represent the date on which board approval was obtained. For valuation dates per IFRS 2, refer to Note 17(c). Series Grant Date (1) Expiry Date Exercise Opening Granted No. Exercised Lapsed/Forfeited* Closing Vested and 32 10-Jul-15 30-Jun-22 US$4.20 2,268,334 — (515,000) — 1,753,334 1,753,334 33 26-Aug-15 16-Aug-22 A$4.05 75,000 — — — 75,000 75,000 34 27-Apr-16 6-Mar-23 A$2.80 2,638,334 — (769,355) (10,000) 1,858,979 1,858,979 34a 27-Apr-16 17-Apr-23 A$2.74 200,000 — (116,666) (83,334) — — 34b 31-Oct-16 6-Mar-23 A$2.80 200,000 — — — 200,000 200,000 35 30-Jun-16 30-Jun-22 (2) A$2.20 900,000 — (900,000) — — — 35a 8-Jul-20 8-Jul-23 A$2.86 — 1,500,000 — — 1,500,000 1,500,000 36 6-Dec-16 5-Dec-23 A$1.31 923,000 — (300,000) — 623,000 623,000 36a 6-Dec-16 5-Dec-23 A$1.19 2,519,064 — (426,668) (141,666) * 1,950,730 1,809,064 36b 13-Jan-17 12-Jan-24 A$1.65 300,000 — (300,000) — — — 37 28-Jun-17 27-Jun-24 A$2.23 150,000 — (150,000) — — — 38 16-Sep-17 15-Sep-24 A$1.54 66,666 — (16,666) — 50,000 50,000 38a 16-Sep-17 15-Sep-24 A$1.40 150,000 — — — 150,000 150,000 39 13-Oct-17 12-Oct-24 A$1.94 1,655,000 — (565,000) — 1,090,000 1,090,000 39a 13-Oct-17 12-Oct-24 A$1.76 1,302,425 — (400,000) — 902,425 902,425 40 24-Nov-17 23-Nov-24 A$1.41 750,000 — — — 750,000 750,000 40a 24-Nov-17 23-Nov-24 A$1.28 750,000 — — — 750,000 — 41 18-Jun-18 17-Jun-25 A$1.52 200,000 — — — 200,000 200,000 42 11-Jul-18 10-Jul-25 A$1.56 200,000 — — — 200,000 133,334 43 18-Jul-18 17-Jul-25 A$1.87 5,398,334 — (944,998) (251,670) * 4,201,666 2,526,653 43b 18-Jul-18 17-Jul-25 A$1.87 350,000 — — — 350,000 233,334 44 15-Jul-18 14-Jul-25 A$1.72 300,000 — (150,000) — 150,000 50,000 45 30-Nov-18 29-Nov-25 A$1.33 590,000 — — — 590,000 393,332 46 19-Jan-19 18-Jan-26 A$1.45 5,000 — (1,667) — 3,333 1,667 47 19-Jan-19 18-Jan-26 A$1.45 150,000 — — — 150,000 150,000 48 4-Apr-19 3-Apr-26 A$1.48 300,000 — — — 300,000 200,000 49 20-Jul-19 19-Jul-26 A$1.62 4,690,000 — (523,661) (6,666) 3,638,671 1,030,310 49 20-Jul-19 19-Jul-26 A$1.62 — (521,002) * 49a 20-Jul-19 19-Jul-26 A$1.47 5,500,000 — (800,002) (700,000) * 3,999,998 400,001 49b 20-Jul-19 19-Jul-26 A$1.47 1,346,667 — — — 1,346,667 448,889 49c 20-Jul-19 19-Jul-26 A$1.47 538,667 — — — 538,667 179,556 50 20-Jul-19 19-Jul-26 A$1.47 700,000 — — — 700,000 — 50a 20-Jul-19 19-Jul-26 A$1.47 400,000 — — — 400,000 — 51 29-Aug-19 28-Aug-26 A$1.47 150,000 — — — 150,000 — 52 29-Aug-19 28-Aug-26 A$1.62 400,000 — — — 400,000 133,333 53 29-Aug-19 28-Aug-26 A$1.47 800,000 — — — 800,000 266,667 54 25-Nov-19 24-Nov-26 A$1.98 845,000 — (98,334) (11,667) 295,000 98,334 54 25-Nov-19 24-Nov-26 A$1.98 — (439,999) * 55 29-May-19 28-May-26 A$1.48 450,000 — (100,000) — 350,000 300,000 56 18-Nov-19 17-Nov-26 A$1.83 200,000 — — — 200,000 66,666 57 25-Nov-19 24-Nov-26 A$1.80 100,000 — — — 100,000 100,000 58 25-Nov-19 24-Nov-26 A$1.98 450,000 — — — 450,000 150,000 59 24-Jan-20 23-Jan-27 A$3.38 — 65,000 — (55,000) * 10,000 3,333 60 17-Apr-20 16-Apr-27 A$2.51 — 57,660 — (57,660) * — — 61 17-Apr-20 16-Apr-27 A$2.51 — 250,000 — (200,000) * 50,000 16,666 63 18-May-20 17-May-27 A$4.02 — 1,200,000 — — 1,200,000 400,000 63a 18-May-20 17-May-27 A$3.65 — 2,400,000 — — 2,400,000 — 64 16-Jul-20 15-Jul-27 A$3.75 — 5,970,000 — (1,690,000) * 4,280,000 — 64a 16-Jul-20 15-Jul-27 A$3.41 — 3,400,000 — (350,000) * 3,050,000 — 64b 16-Jul-20 15-Jul-27 A$3.41 — 325,000 — — 325,000 — 64c 16-Jul-20 15-Jul-27 A$3.41 — 350,000 — — 350,000 — 64 16-Jul-20 15-Jul-27 A$3.41 — 300,000 — — 300,000 — 64e 16-Jul-20 15-Jul-27 A$3.41 — 1,200,000 — — 1,200,000 — 65 26-Aug-20 25-Aug-27 A$5.76 — 140,000 — (135,000) * 5,000 — 66 11-Sep-20 10-Sep-27 A$4.78 — 200,000 — — 200,000 — 67 8-Oct-20 7-Oct-27 A$3.84 — 240,000 — (40,000) * 200,000 — 68 20-Nov-20 19-Nov-27 A$3.60 — 200,000 — — 200,000 — 69 20-Nov-20 19-Nov-27 A$3.60 — 100,000 — — 100,000 100,000 71 17-Feb-21 16-Feb-28 A$2.67 — 250,000 — — 250,000 — 73 30-Jun-21 30-Aug-21 A$— — 45,746 — — 45,746 45,746 June 30, 2021 38,911,491 18,193,406 (7,078,017) (4,693,664) 45,333,216 18,389,623 Weighted average share purchase price A$1.86 A$3.56 A$2.06 A$2.76 A$2.42 A$2.15 (1) The dates presented in the grant date column represent the date on which board approval was obtained. For valuation dates per IFRS 2, refer to Note 17(c).
Summary of Valuations of Options Approved and Granted	The model inputs for the valuations of options approved and granted during the year ended June 30, 2023 are as follows: Series Valuation date (1) Exercise Share price at Expected share Life (2) Dividend yield Risk-free 76 23-Nov-22 1.03 0.99 65.37% 6.3 yrs 0% 3.38% 77 23-Nov-22 1.01 0.99 65.37% 5.9 yrs 0% 3.38% 78 23-Nov-22 0.85 0.99 65.37% 6.1 yrs 0% 3.38% 79 09-Dec-22 1.13 1.04 65.43% 6.2 yrs 0% 3.11% 79a 21-Jun-23 1.03 1.18 65.04% 5.8 yrs 0% 3.88% 79b 16-Mar-23 1.13 0.97 65.29% 6.0 yrs 0% 2.99% 79c 23-Nov-22 1.03 0.99 65.37% 6.3 yrs 0% 3.38% 79d (3) 30-Jun-23 1.03 1.15 64.98% 5.7 yrs 0% 4.19% 80 18-Nov-22 0.93 0.95 65.35% 6.1 yrs 0% 3.35% 81 18-Nov-22 4.60 0.95 65.35% 4.6 yrs 0% 3.35% 82 30-Dec-22 1.12 0.89 65.31% 6.3 yrs 0% 3.70% 83 06-Apr-23 1.03 0.97 65.17% 6.4 yrs 0% 2.90% (1) Valuation date is the date at which the entity and the employee agree to a share-based payment arrangement, being when the entity and the employee have a shared understanding of the terms and conditions of the arrangement. (2) Expected life after factoring likely early exercise. (3) Fair value estimated at June 30, 2023 as the valuation date under AASB2 has not been met as of June 30, 2023. The model inputs for the valuations of options approved and granted during the year ended June 30, 2022 are as follows: Series Valuation date (1) Exercise Share price at Expected share Life (2) Dividend yield Risk-free 72 05-May-21 2.28 1.94 66.62% 6.3 yrs 0% 0.69% 74 10-Nov-21 1.95 1.69 65.85% 6.2 yrs 0% 1.31% 74a 07-Nov-22 1.77 0.93 65.41% 5.3 yrs 0% 3.55% 74b 07-Nov-22 1.77 0.93 65.41% 5.3 yrs 0% 3.55% 74c 15-Feb-22 1.77 1.16 65.89% 5.9 yrs 0% 1.91% 75 17-Mar-22 1.42 1.21 65.98% 6.1 yrs 0% 2.18% (1) Valuation date is the date at which the entity and the employee agree to a share-based payment arrangement, being when the entity and the employee have a shared understanding of the terms and conditions of the arrangement. (2) Expected life after factoring likely early exercise. The model inputs for the valuations of options approved and granted during the year ended June 30, 2021 are as follows: Series Valuation date (1) Exercise Share price at Expected share Life (2) Dividend yield Risk-free 61 28-Jul-20 2.51 3.60 60.95% 6.1 yrs 0% 0.44% 63 08-Apr-21 4.02 2.21 66.74% 5.5 yrs 0% 0.65% 63a 05-Jul-21 3.65 2.03 66.45% 5.3 yrs 0% 0.72% 64 28-Jul-20 3.75 3.60 60.95% 6.3 yrs 0% 0.44% 64a 05-Jul-21 3.41 2.03 66.45% 5.5 yrs 0% 0.72% 64b 30-Jun-21 3.41 2.09 66.48% 5.5 yrs 0% 0.77% 64c 25-Nov-20 3.41 4.12 65.36% 6.0 yrs 0% 0.30% 64d 30-Jun-22 3.41 0.65 65.55% 4.6 yrs 0% 3.36% 64e 05-Jul-21 3.41 2.03 66.45% 5.5 yrs 0% 0.72% 65 25-Sep-20 5.76 5.02 63.16% 6.3 yrs 0% 0.34% 66 16-Oct-20 4.78 3.24 65.17% 6.3 yrs 0% 0.27% 67 10-Nov-20 3.84 3.22 65.06% 6.3 yrs 0% 0.30% 68 24-Dec-20 3.60 2.38 67.22% 6.3 yrs 0% 0.35% 69 24-Dec-20 3.60 2.38 67.22% 6.3 yrs 0% 0.35% 71 29-Mar-21 2.67 2.35 66.81% 6.2 yrs 0% 0.66% 73 30-Jun-21 — 2.09 66.48% 0.2 yrs 0% 0.77% (1) Valuation date is the date at which the entity and the employee agree to a share-based payment arrangement, being when the entity and the employee have a shared understanding of the terms and conditions of the arrangement. (2) Expected life after factoring likely early exercise.
Summary of Policies Related To Valuations of Options Approved and Granted	This policy applies to all issues shown in the above table with the exception of the following: 35 Incentive rights granted pursuant to the Equity Facility Agreement with Kentgrove Capital, dated June 30, 2016, had fully vested on the agreement date and will expire thirty six months after the date of the issue of the incentive right. The terms of this agreement were amended on July 30, 2019. Under the amended terms, these incentive rights will expire thirty six months after the effective date of July 1, 2019. 35a Additional incentive rights granted pursuant to the Amendment Deed of the Equity Facility Agreement with Kentgrove Capital, dated July 30, 2019, had fully vested on the agreement date and will expire thirty six months after the date of the issue of the incentive right. 36a & 36b Options were granted in two or three equal tranches and will vest on the date that the option holder has direct involvement (to the reasonable satisfaction of the Company’s board of directors) in the Company achieving certain confidential commercial objectives. 49a, 49b, 50, 50a, 53, 64b, 64c, 64d, 64e, 71, 74a, 74b, 74c, 79c Options were granted two or three equal tranches and are required to satisfy certain pre-specified performance conditions and time-based vesting conditions prior to vesting. Time-based conditions restrict vesting to a maximum of one third at 12 months, two thirds at 24 months and full grant at 36 months, but only if the pre-specified performance conditions have been met. 38a, 40a, 57 & 66 Options were granted in one tranche and will vest on the date that the option holder has direct involvement (to the reasonable satisfaction of the Company’s board of directors) in the Company achieving certain confidential commercial objectives. 39a Options were granted in one or two equal tranches and will vest on the date that the option holder has direct involvement (to the reasonable satisfaction of the Company’s board of directors) in the Company achieving certain confidential commercial objectives. 51 & 75 Options were granted in two equal tranches and will vest on the date that the option holder has direct involvement (to the reasonable satisfaction of the Company’s board of directors) in the Company achieving certain confidential commercial objectives. 55 Options were granted in five tranches and will vest on the date that the option holder has direct involvement (to the reasonable satisfaction of the Company’s board of directors) in the Company achieving certain confidential commercial objectives. 63a Options were granted in three or eight tranches and will vest on the date that the option holder has direct involvement (to the reasonable satisfaction of the Company’s board of directors) in the Company achieving certain confidential commercial objectives. Time-based conditions restrict vesting to a maximum of one third at 12 months, two thirds at 24 months and full grant at 36 months, but only if the pre-specified performance conditions have been met. 64a Options were granted in one, two, three or five tranches and will vest on the date that the option holder has direct involvement (to the reasonable satisfaction of the Company’s board of directors) in the Company achieving certain confidential commercial objectives. Time-based conditions restrict vesting to a maximum of one third at 12 months, two thirds at 24 months and full grant at 36 months, but only if the pre-specified performance conditions have been met. 69, 73, 80 & 81 Options were granted in one tranche and vested on the date on which board approval was obtained 79a, 79d Options were granted in two, three, four or five tranches and will vest on the date that the option holder has direct involvement (to the reasonable satisfaction of the Company's board of directors) in the Company achieving certain confidential commercial objectives. Time-based conditions restrict vesting to a maximum of one third at 12 months, two thirds at 24 months and full grant at 36 months, but only if the pre-specified performance conditions have been met.

Remuneration of auditors (Table

Remuneration of auditors (Tables)	12 Months Ended
Remuneration of auditors (Tables)	Jun. 30, 2023
Auditor's remuneration [abstract]
Summary of Fees were Paid or Payable for Services Provided by the Auditor of the Parent Entity	During the year the following fees were paid or payable for services provided by the auditor of the parent entity, its related practices and non-related audit firms: Year Ended June 30, (in U.S. dollars) 2023 2022 2021 a. PricewaterhouseCoopers Australia Audit and other assurance services Audit and review of financial reports 669,603 745,021 747,783 Other audit services (1) 180,339 67,238 91,750 Total remuneration of PricewaterhouseCoopers Australia 849,942 812,259 839,533 b. Network firms of PricewaterhouseCoopers Australia Audit and other assurance services Audit and review of financial reports 144,864 133,309 130,450 Total remuneration of Network firms of PricewaterhouseCoopers Australia 144,864 133,309 130,450 Total auditors' remuneration (2) 994,806 945,568 969,983 (1) Other audit services relates to services performed in connection with the filing of registration statements on the Form S-8 and F-3. (2) All services provided are considered audit fees for the purpose of SEC classification.

Losses per share (Tables)

Losses per share (Tables)	12 Months Ended
Losses per share (Tables)	Jun. 30, 2023
Earnings per share [abstract]
Summary of Loss Per Share	Years Ended June 30, 2023 2022 2021 (Losses) per share (in cents) (a) Basic (losses) per share From continuing operations attributable to the ordinary equity holders of the company (11.08) (14.08) (16.33) Total basic (losses) per share attributable to the ordinary equity holders of the company (11.08) (14.08) (16.33) (b) Diluted (losses) per share From continuing operations attributable to the ordinary equity holders of the company (11.08) (14.08) (16.33) Total basic (losses) per share attributable to the ordinary equity holders of the company (11.08) (14.08) (16.33) (c) Reconciliation of (losses) used in calculating (losses) per share (in U.S. dollars, in thousands) Basic (losses) per share (Losses) attributable to the ordinary equity holders of the company used in calculating basic (losses) per share: From continuing operations (81,889) (91,347) (98,811) Diluted (losses) per share (Losses) from continuing operations attributable to the ordinary equity holders of the company: Used in calculating basic (losses) per share (81,889) (91,347) (98,811) (Losses) attributable to the ordinary equity holders of the company used in calculating diluted losses per share (81,889) (91,347) (98,811) 2023 2022 2021 Weighted average number of ordinary shares used as the denominator in calculating basic losses per share 739,039,547 648,899,589 605,064,036 Weighted average number of ordinary shares and potential ordinary shares used in calculating diluted losses per share 739,039,547 648,899,589 605,064,036

Parent entity financial infor_2

Parent entity financial information (Tables)	12 Months Ended
Parent entity financial information (Tables)	Jun. 30, 2023
Disclosure Of Parent Entity Financial Information [Abstract]
Summary Of Parent Entity Financial Information Explanatory	The individual financial statements for the parent entity show the following aggregate amounts: As of June 30, (in U.S. dollars, in thousands) 2023 2022 Balance Sheet Current Assets 28,850 4,948 Total Assets 890,120 853,380 Current Liabilities 11,941 9,210 Total Liabilities 15,282 13,227 Shareholders' Equity Issued Capital 1,249,123 1,165,309 Reserves Foreign Currency Translation Reserve (261,377) (227,441) Share Options Reserve 86,274 82,619 Warrant Reserve 12,969 12,969 (Accumulated losses)/retained earnings (212,165) (193,317) 874,824 840,139 Loss for the period (18,848) (19,305) Total comprehensive loss for the period (18,848) (19,305)

Basis of preparation - Addition

Basis of preparation - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Basis Of Preparation [Abstract]
Maximum amount paid in cash outflows from operating activities	$ 63,300
Cash & cash equivalents	$ 71,318	$ 60,447	$ 136,881	$ 129,328

Significant changes in the cu_2

Significant changes in the current reporting period - Additional Information (Details) $ / shares in Units, $ in Millions, $ in Millions				1 Months Ended
	Apr. 25, 2023 USD ($)	Mar. 08, 2023	Aug. 11, 2022 USD ($)	Dec. 31, 2022 $ / shares shares	Aug. 31, 2022 USD ($)	Aug. 31, 2022 AUD ($)	Jun. 30, 2023 shares	Dec. 21, 2022 $ / shares shares	Jun. 30, 2022 shares	Nov. 19, 2021 $ / shares shares
Disclosure Of Significant Changes In Current Reporting Period [Line Items]
Proceeds from issue of shares \| $	$ 40
Proceeds from private placement \| $			$ 42.6
Warrants
Disclosure Of Significant Changes In Current Reporting Period [Line Items]
Number of shares warrants granted to purchase (in shares)							2,224,669		1,769,669
Oaktree Capital Management, L.P. \| American Depositary Shares
Disclosure Of Significant Changes In Current Reporting Period [Line Items]
Exercise price (in dollars per share) \| $ / shares								$ 3.70		$ 7.26
Oaktree Capital Management, L.P. \| Warrants
Disclosure Of Significant Changes In Current Reporting Period [Line Items]
Number of shares warrants granted to purchase (in shares)								455,000		1,769,669
Refinancing and Expansion of Senior Debt Facility \| Oaktree Capital Management, L.P.
Disclosure Of Significant Changes In Current Reporting Period [Line Items]
Percentage of share premium price				15%
VWAP, Period				30 days
Warrant exercise term		7 years
Refinancing and Expansion of Senior Debt Facility \| Oaktree Capital Management, L.P. \| American Depositary Shares
Disclosure Of Significant Changes In Current Reporting Period [Line Items]
Exercise price (in dollars per share) \| $ / shares				$ 3.70
Refinancing and Expansion of Senior Debt Facility \| Oaktree Capital Management, L.P. \| Warrants
Disclosure Of Significant Changes In Current Reporting Period [Line Items]
Number of shares warrants granted to purchase (in shares)				455,000
Private Placements
Disclosure Of Significant Changes In Current Reporting Period [Line Items]
Payment for financing global private placement					$ 45	$ 65

Loss before income tax - Summar

Loss before income tax - Summary of Loss Before Income Tax (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Dec. 31, 2019	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Revenue
Commercialization revenue		$ 7,501	$ 9,039	$ 7,434
Milestone revenue	$ 2,500	0	1,172	0
Total Revenue		7,501	10,211	7,434
Clinical trial and research & development		(8,771)	(10,483)	(18,569)
Manufacturing production & development		(25,468)	(28,884)	(31,590)
Employee benefits
Salaries and employee benefits		(17,197)	(18,997)	(26,804)
Defined contribution superannuation expenses		(384)	(402)	(379)
Equity settled share-based payment transactions		(3,655)	(5,536)	(12,510)
Total Employee benefits		(21,236)	(24,935)	(39,693)
Depreciation and amortization of non-current assets
Plant and equipment depreciation		(953)	(1,144)	(1,016)
Right of use asset depreciation		(1,661)	(1,717)	(1,691)
Intellectual property amortization		(1,493)	(1,519)	(1,557)
Total Depreciation and amortization of non-current assets		(4,107)	(4,380)	(4,264)
Other Management & administration expenses
Overheads & administration		(10,104)	(10,157)	(7,757)
Consultancy		(3,922)	(3,751)	(5,386)
Legal, patent and other professional fees		(3,695)	(5,571)	(6,950)
Intellectual property expenses (excluding the amount amortized above)		(2,993)	(2,621)	(2,389)
Total Other Management & administration expenses		(20,714)	(22,100)	(22,482)
Fair value remeasurement of contingent consideration
Remeasurement of contingent consideration		(8,771)	(913)	(18,687)
Total Fair value remeasurement of contingent consideration		8,771	913	18,687
Fair value remeasurement of warrant liability
Remeasurement of warrant liability		2,205	(5,896)	0
Total Fair value remeasurement of warrant liability		(2,205)	5,896	0
Other operating income and expenses
Research and development tax incentive income		3,506	0	0
Interest income		831	3	22
Foreign exchange (losses)/gains		(163)	(536)	1,471
Derecognition of right-of-use asset		76	0	0
Foreign withholding tax paid		0	(3)	0
Government grant revenue		0	0	68
Total Other operating income and expenses		4,250	(536)	1,561
Finance (costs)/gains
Remeasurement of borrowing arrangements		(678)	(382)	5,225
Interest expense		(19,444)	(16,906)	(15,939)
Total Finance costs		(20,122)	(17,288)	(10,714)
Total loss before income tax		$ 82,101	$ 91,586	$ 99,630

Loss Before Income Tax - Summ_2

Loss Before Income Tax - Summary of Loss Before Income Tax (Parenthetical) (Details) - Income Statement Functional Expense Categories - USD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Disclosure Of Loss Before Income Tax Line Item
Equity settled share-based payment transactions	$ 3,655,346	$ 5,535,845	$ 12,509,744
Research and development
Disclosure Of Loss Before Income Tax Line Item
Equity settled share-based payment transactions	1,669,514	3,547,182	7,782,330
Manufacturing and commercialization
Disclosure Of Loss Before Income Tax Line Item
Equity settled share-based payment transactions	(1,136)	378,096	547,998
Management and administration
Disclosure Of Loss Before Income Tax Line Item
Equity settled share-based payment transactions	$ 1,986,968	$ 1,610,567	$ 4,179,416

Loss Before Income Tax - Additi

Loss Before Income Tax - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Disclosure Of Loss Before Income Tax [Abstract]
Research and development tax incentive income	$ 3,506	$ 0	$ 0
Tax incentive income, current	$ 1,200	1,100	1,200
Tax incentive income		$ 0	$ 0

Income tax benefit_(expense) -

Income tax benefit/(expense) - Summary of Reconciliation of Income Tax to Prima Facie Tax Payable (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Disclosure Of Reconciliation Of Effective Income Tax Expense [Line Items]
Loss from continuing operations before income tax	$ (82,101)	$ (91,586)	$ (99,630)
Share-based payments expense	1,089	1,588	2,836
Research and development tax concessions	(730)	(869)	(894)
Foreign exchange translation gains/(losses)	501	159	313
Contingent consideration	(2,631)	(274)	(5,606)
Other sundry items	695	(2,036)	121
Subtotal	(25,706)	(28,908)	(33,119)
Adjustments for current tax of prior periods	274	(923)	(1)
Differences in overseas tax rates	8,537	8,407	13,218
Tax benefit not recognized	16,683	21,185	19,083
Change in tax rate on Deferred tax assets	0	(8,326)	(482)
Change in tax rate on Deferred tax liability	0	8,326	482
Income tax benefit attributable to loss before income tax	(212)	(239)	(819)
Australian Government
Disclosure Of Reconciliation Of Effective Income Tax Expense [Line Items]
Tax benefit at the Australian tax rate	$ (24,630)	$ (27,476)	$ (29,889)

Income tax benefit_(expense) _2

Income tax benefit/(expense) - Summary of Reconciliation of Income Tax to Prima Facie Tax Payable (Parenthetical) (Details)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Disclosure Of Reconciliation Of Effective Income Tax Expense [Line Items]
Difference in tax rate	30%	30%	30%
Singapore
Disclosure Of Reconciliation Of Effective Income Tax Expense [Line Items]
Statutory tax rate	17%

Income tax benefit_(expense) _3

Income tax benefit/(expense) - Summary of Income Tax Expense/(Benefit) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Current tax
Current tax	$ 0	$ 0	$ 0
Total current tax (benefit)/expense	0	0	0
Deferred tax
(Increase)/decrease in deferred tax assets	38	(8,317)	(1,158)
(Decrease)/increase in deferred tax liabilities	(250)	8,078	339
Total deferred tax (benefit)/expense	(212)	(239)	(819)
Income tax benefit attributable to loss before income tax	$ (212)	$ (239)	$ (819)

Income tax benefit_(expense) _4

Income tax benefit/(expense) - Summary of Amounts That Would Be Recognized Directly in Equity if Brought to Account (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Amounts that would be recognized directly in equity if brought to account
Current tax recorded in equity (if brought to account)	$ (1,716)	$ (142)	$ (525)
Deferred tax recorded in equity (if brought to account)	839	715	905
Current and deferred tax relating to items credited (charged) directly to equity	$ (877)	$ 573	$ 380

Income tax benefit_(expense) _5

Income tax benefit/(expense) - Summary of Amounts That Would Be Recognized Directly in Equity (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Amounts recognized directly in equity
Current tax recorded in equity	$ 0	$ 0	$ 0
Deferred tax recorded in equity	212	239,000	91,000
Current and deferred tax relating to items credited (charged) directly to equity	$ 212	$ 239,000	$ 91,000

Income tax benefit_(expense) _6

Income tax benefit/(expense) - Summary of Deferred Tax Assets Not Brought to Account (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Unused tax losses
Potential tax benefit at local tax rates	$ 125,728	$ 111,283,000	$ 77,738,000
Other temporary differences
Potential tax benefit at local tax rates	12,318	11,046,000	7,424,000
Other tax credits
Potential tax benefit at local tax rates	3,220	3,220,000	3,220,000
Deferred tax assets not brought to account	$ 141,266	$ 125,549,000	$ 88,382,000

Income tax benefit_(expense) _7

Income tax benefit/(expense) - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Deferred tax asset	$ 87,992	$ 88,242
Unused Tax Losses
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Tax effect of gross tax losses	553,000	$ 477,800	$ 424,900
Deferred tax asset	$ 44,500
Unused Tax Losses \| Bottom of range
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Deferred tax asset expiration period	9 years
Unused Tax Losses \| Top of range
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Deferred tax asset expiration period	15 years

Financial Assets and Liabilit_3

Financial Assets and Liabilities - Summary of Financial Instruments (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Disclosure Of Financial Assets And Liabilities [Line Items]
Cash & cash equivalents	$ 71,318	$ 60,447	$ 136,881	$ 129,328
Trade & other receivables	6,998	4,403
Financial assets at fair value through other comprehensive income	1,757	1,758
Other non-current assets	2,326	1,930
Financial assets, Total	82,399	68,538
Trade and other payables	20,145	23,079
Borrowings	108,763	96,634
Contingent consideration	17,199	23,284
Warrant liability	5,426	2,185	$ 0
Financial liabilities, Total	151,533	145,182
Liabilities at amortized cost
Disclosure Of Financial Assets And Liabilities [Line Items]
Trade and other payables	20,145	23,079
Borrowings	108,763	96,634
Financial liabilities, Total	128,908	119,713
Liabilities at FVTPL
Disclosure Of Financial Assets And Liabilities [Line Items]
Contingent consideration	17,199	23,284
Warrant liability	5,426	2,185
Financial liabilities, Total	22,625	25,469
Assets at amortized cost
Disclosure Of Financial Assets And Liabilities [Line Items]
Cash & cash equivalents	71,318	60,447
Trade & other receivables	6,998	4,403
Other non-current assets	2,326	1,930
Financial assets, Total	80,642	66,780
Assets at FVOCI
Disclosure Of Financial Assets And Liabilities [Line Items]
Financial assets at fair value through other comprehensive income	1,757	1,758
Financial assets, Total	$ 1,757	$ 1,758

Financial Assets and Liabilit_4

Financial Assets and Liabilities - Summary of Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Disclosure Of Financial Assets And Liabilities [Abstract]
Cash at bank	$ 70,920	$ 60,034	$ 136,430
Deposits at call	398	413	451
Cash and cash equivalents	$ 71,318	$ 60,447	$ 136,881	$ 129,328

Financial Assets and Liabilit_5

Financial Assets and Liabilities - Summary of Cash and Cash Equivalents (Parenthetical) (Details) - USD ($) $ in Millions	Jun. 30, 2023	Jun. 30, 2022
Disclosure Of Financial Assets And Liabilities [Abstract]
Interest-bearing deposits at call held as security	$ 0.4	$ 0.4

Financial Assets and Liabilit_6

Financial Assets and Liabilities - Summary of Trade and Other Receivables (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022
Disclosure Of Financial Assets And Liabilities [Abstract]
Trade debtors	$ 2,276	$ 2,224
Tax incentives recoverable	2,363	0
Foreign withholding tax recoverable	471	471
U.S. Tax credits	1,473	1,473
Net investment in sublease	195	0
Interest receivables	18	0
Other recoverable taxes (Goods and services tax and value-added tax)	202	235
Trade and other receivables	$ 6,998	$ 4,403

Financial Assets and Liabilit_7

Financial Assets and Liabilities - Summary of Prepayments (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022
Disclosure Of Financial Assets And Liabilities [Abstract]
Clinical trial research and development expenditure	$ 950	$ 1,313
Prepaid insurance and subscriptions	2,025	2,420
Other	367	1,254
Prepayments	$ 3,342	$ 4,987

Financial Assets and Liabilit_8

Financial Assets and Liabilities - Additional Information (Details) - USD ($)					1 Months Ended	12 Months Ended
	Mar. 08, 2023	Dec. 21, 2022	Nov. 19, 2021	Jun. 29, 2018	Nov. 30, 2021	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021	Sep. 30, 2023	Dec. 31, 2022
Disclosure Of Financial Assets And Liabilities [Line Items]
Gain (loss) recognized in comprehensive income, for change in fair value of financial assets						$ 0	$ (300,000)	$ 200,000
Borrowings						108,763,000	96,634,000
Foreign currency balance held						82,399,000	68,538,000
Financial liabilities						151,533,000	145,182,000
Warrants fair value at grant date						5,400,000	2,200,000
Gain (loss) on remeasurement of warrant liability						$ 2,200,000	$ 5,900,000
Level 3 \| Unlisted Equity Securities
Disclosure Of Financial Assets And Liabilities [Line Items]
Percentage of assets measured at fair value						100%	100%
Fixed interest rate
Disclosure Of Financial Assets And Liabilities [Line Items]
Borrowings						$ 116,495,000	$ 106,905,000
Warrants
Disclosure Of Financial Assets And Liabilities [Line Items]
Number of shares warrants granted to purchase (in shares)						2,224,669	1,769,669
Oaktree Capital Management, L.P.
Disclosure Of Financial Assets And Liabilities [Line Items]
Borrowings term					5 years
Borrowings			$ 60,000,000
Borrowings, interest period					3 years
Borrowings principal amortization period					2 years
Percentage of premium for volume-weighted average price		15%	15%
Issuance warrants exercised period	7 years		7 years
Remeasurement of borrowing arrangements within finance gains (loss)						$ (1,600,000)	$ (1,600,000)
Finance costs gains (loss) on remeasurement due to additional warrants issued						1,000,000
Finance Costs Gains (Loss) On Adjustment Of Carrying Amount On Financial Liability						600,000
Oaktree Capital Management, L.P. \| Refinancing and Expansion of Senior Debt Facility
Disclosure Of Financial Assets And Liabilities [Line Items]
Percentage of share premium price										15%
Warrant exercise term	7 years
Oaktree Capital Management, L.P. \| American Depositary Shares
Disclosure Of Financial Assets And Liabilities [Line Items]
Exercise Price		$ 3.70	$ 7.26
Oaktree Capital Management, L.P. \| American Depositary Shares \| Refinancing and Expansion of Senior Debt Facility
Disclosure Of Financial Assets And Liabilities [Line Items]
Exercise Price										$ 3.70
Oaktree Capital Management, L.P. \| Warrants
Disclosure Of Financial Assets And Liabilities [Line Items]
Number of shares warrants granted to purchase (in shares)		455,000	1,769,669
Oaktree Capital Management, L.P. \| Warrants \| Refinancing and Expansion of Senior Debt Facility
Disclosure Of Financial Assets And Liabilities [Line Items]
Number of shares warrants granted to purchase (in shares)										455,000
Oaktree Capital Management, L.P. \| Tranche One
Disclosure Of Financial Assets And Liabilities [Line Items]
Borrowings			$ 60,000,000
Oaktree Capital Management, L.P.
Disclosure Of Financial Assets And Liabilities [Line Items]
Borrowings, interest rate					9.75%
Percentage of principal amortizes over two years					40%
Borrowings, unpaid interest portion per annum					1.75%
Borrowings principal amount					$ 90,000,000
Oaktree Capital Management, L.P. \| Tranche One
Disclosure Of Financial Assets And Liabilities [Line Items]
Borrowings					$ 60,000,000
Borrowings, interest rate					9.75%
Oaktree Capital Management, L.P. \| Tranche One \| Forecast
Disclosure Of Financial Assets And Liabilities [Line Items]
Borrowings									$ 30,000,000
Oaktree Capital Management, L.P. \| Tranche Two
Disclosure Of Financial Assets And Liabilities [Line Items]
Borrowings, interest rate					8%
NovaQuest Capital Management, L.L.C.
Disclosure Of Financial Assets And Liabilities [Line Items]
Remeasurement of borrowing arrangements within finance gains (loss)						(900,000)	500,000	$ 4,800,000
Percentage of entity's revenue, annual payment cap threshold				25%
Minimum unrestricted cash balance						35,000,000
NovaQuest Capital Management, L.L.C. \| Level 2
Disclosure Of Financial Assets And Liabilities [Line Items]
Foreign currency balance held						0	0
Financial liabilities						0	0
NovaQuest Capital Management, L.L.C. \| Level 1
Disclosure Of Financial Assets And Liabilities [Line Items]
Foreign currency balance held						0	0
Financial liabilities						$ 0	$ 0
NovaQuest Capital Management, L.L.C. \| Fixed interest rate
Disclosure Of Financial Assets And Liabilities [Line Items]
Borrowings term				8 years		8 years
Borrowings, interest period				4 years
Borrowings, interest rate				15%
Borrowings principal amortization period				4 years
Borrowings principal amount				$ 40,000,000
NovaQuest Capital Management, L.L.C. \| Contingent Consideration Provision \| Level 3
Disclosure Of Financial Assets And Liabilities [Line Items]
Percentage of liabilities measured at fair value						100%	100%
NovaQuest Capital Management, L.L.C. \| Tranche One \| Fixed interest rate
Disclosure Of Financial Assets And Liabilities [Line Items]
Borrowings				$ 30,000,000
Top of range
Disclosure Of Financial Assets And Liabilities [Line Items]
Trade receivables settlement period						60 days

Financial Assets and Liabilit_9

Financial Assets and Liabilities - Summary of Financial Assets at Fair Value through Other Comprehensive Income (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022
Disclosure Of Financial Assets And Liabilities [Line Items]
Financial assets at fair value through other comprehensive income	$ 1,757	$ 1,758
Equity securities
Disclosure Of Financial Assets And Liabilities [Line Items]
Financial assets at fair value through other comprehensive income	$ 1,757	$ 1,758

Financial Assets and Liabili_10

Financial Assets and Liabilities - Summary of Other Non-current Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022
Disclosure Of Financial Assets And Liabilities [Line Items]
Other non-current assets	$ 2,326	$ 1,930
Bank guarantee
Disclosure Of Financial Assets And Liabilities [Line Items]
Other non-current assets	481	500
Net investment in sublease
Disclosure Of Financial Assets And Liabilities [Line Items]
Other non-current assets	414	0
Letter of credit
Disclosure Of Financial Assets And Liabilities [Line Items]
Other non-current assets	1,179	1,178
Security deposit
Disclosure Of Financial Assets And Liabilities [Line Items]
Other non-current assets	$ 252	$ 252

Financial Assets and Liabili_11

Financial Assets and Liabilities - Summary of Trade and Other Payables (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022
Disclosure Of Financial Assets And Liabilities [Abstract]
Trade and other payables	$ 20,145	$ 23,079
Trade and other payables	$ 20,145	$ 23,079

Financial Assets and Liabili_12

Financial Assets and Liabilities - Summary of Borrowings (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Borrowings
Borrowing arrangements	$ 81,919	$ 81,919
Less: transaction costs	(8,740)	(8,247)
Amortization of carrying amount, net of payments made	35,584	22,962
Principal amount of loans	108,763	96,634
Non-current
Current borrowings	5,952	5,017
Borrowings, Non-current	102,811	91,617
Total borrowings	108,763	96,634
Borrowings - NovaQuest
Non-current
Current borrowings	336	372
Borrowings, Non-current	55,739	47,898
Borrowings - Oaktree
Non-current
Current borrowings	5,616	4,645
Borrowings, Non-current	$ 47,072	$ 43,719

Financial Assets and Liabili_13

Financial Assets and Liabilities - Summary of Net Debt (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Line Items]
Cash and cash equivalents	$ 71,318	$ 60,447	$ 136,881	$ 129,328
Borrowings	(108,763)	(96,634)
Lease liabilities	(7,732)	(10,271)
Warrant liability	(5,426)	(2,185)	$ 0
Net Debt	(50,603)	(48,643)
Fixed interest rate
Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Line Items]
Borrowings	(116,495)	(106,905)
variable interest rates
Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Line Items]
Borrowings	$ 0	$ 0

Financial Assets and Liabili_14

Financial Assets and Liabilities - Summary of Net Debt Reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Disclosure of reconciliation of liabilities arising from financing activities [abstract]
Borrowings at beginning of period	$ (96,634)
Leases at beginning of period	(10,271)
Warrant liability at beginning of period	(2,185)	$ 0
Sub-total at beginning of period	(109,090)
Cash and cash equivalents at beginning of period	60,447	136,881	$ 129,328
Net debt total at beginning of period	(48,643)
Cash Flows	5,926
Liabilities from financing activities, Leases	3,170
Liabilities from financing activities, Sub-total	0
Liabilities from financing activities, Sub-total	9,096
Net increase/(decrease) in cash and cash equivalents	11,039	(75,884)	6,138
Cash Flows, Total	20,135
Remeasurement adjustments	358
Remeasurement adjustments, Warrants	(2,205)
Remeasurement adjustments	(1,847)
Increase decrease in borrowing liabilities classified as financing activities	(18,413)
Increase (decrease)in lease liabilities arising from financing activities	(738)
Other Changes	(19,151)
Issuance of warrants, warrant liability	(1,036)
Issuance Of Warrants	(1,036)
Increase (decrease) in acquisition of lease liabilities arising from financing activities	0
Acquisition – leases	0
Foreign exchange adjustments, Leases	107
Foreign exchange adjustments, Sub-total	107
Foreign exchange adjustments	(168)	(550)	1,415
Foreign exchange adjustments	(61)
Borrowings at end of period	(108,763)	(96,634)
Leases at end of period	(7,732)	(10,271)
Warrant liability at end of period	(5,426)	(2,185)	0
Sub-total at end of period	(121,921)	(109,090)
Cash and cash equivalents at end of period	71,318	60,447	$ 136,881
Net debt total at end of period	$ (50,603)	$ (48,643)

Financial Assets and Liabili_15

Financial Assets and Liabilities - Summary of Financial Assets and Liabilities Measured and Recognized at Fair Value (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Financial assets at fair value through other comprehensive income:
Total Financial Assets	$ 1,757	$ 1,758
Financial liabilities at fair value through profit or loss:
Contingent consideration	17,199	23,284
Warrant liabilities	5,426	2,185	$ 0
Total Financial Liabilities	22,625	25,469
Level 1
Financial assets at fair value through other comprehensive income:
Total Financial Assets	0	0
Financial liabilities at fair value through profit or loss:
Contingent consideration	0	0
Warrant liabilities	0	0
Total Financial Liabilities	0	0
Level 2
Financial assets at fair value through other comprehensive income:
Total Financial Assets	0	0
Financial liabilities at fair value through profit or loss:
Contingent consideration	0	0
Warrant liabilities	0	0
Total Financial Liabilities	0	0
Level 3
Financial assets at fair value through other comprehensive income:
Total Financial Assets	1,757	1,758
Financial liabilities at fair value through profit or loss:
Contingent consideration	17,199	23,284
Warrant liabilities	5,426	2,185
Total Financial Liabilities	22,625	25,469
Equity securities
Financial assets at fair value through other comprehensive income:
Total Financial Assets	1,757	1,758
Equity securities \| Level 1
Financial assets at fair value through other comprehensive income:
Total Financial Assets	0	0
Equity securities \| Level 2
Financial assets at fair value through other comprehensive income:
Total Financial Assets	0	0
Equity securities \| Level 3
Financial assets at fair value through other comprehensive income:
Total Financial Assets	$ 1,757	$ 1,758

Financial Assets and Liabili_16

Financial Assets and Liabilities - Summary of Changes in the Contingent Consideration Fair Value of Level 3 Instruments (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Disclosure Of Financial Instruments [Line Items]
Remeasurement of contingent consideration	$ (8,771)	$ (913)	$ (18,687)
Level 3
Disclosure Of Financial Instruments [Line Items]
Opening balance	23,284	25,409
Amount used during the period	2,686	(1,212)
Remeasurement of contingent consideration	(8,771)	(913)
Closing balance	$ 17,199	$ 23,284	$ 25,409

Financial Assets and Liabili_17

Financial Assets and Liabilities - Summary of Changes in the Contingent Consideration Fair Value of Level 3 Instruments (Parenthetical) (Details) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Level 3
Disclosure Of Financial Instruments [Line Items]
Gain on re-measurement of contingent consideration provision	$ 8.8	$ 0.9

Financial Assets and Liabili_18

Financial Assets and Liabilities - Summary of Quantitative Information About the Significant Unobservable Inputs Used in Level 3 Fair Value Measurements (Details) - Level 3 - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Disclosure Of Financial Instruments [Line Items]
Contingent consideration provision	$ 17,199	$ 23,284	$ 25,409
Expected unit sales price
Disclosure Of Financial Instruments [Line Items]
Percentage of reasonably possible increase (decrease) in unobservable input, liabilities	0.10	0.10
Percentage of reasonably possible increase (decrease) in fair value measurement due to change in unobservable input, liabilities	0.001	0.02
Discounted cash flow
Disclosure Of Financial Instruments [Line Items]
Contingent consideration provision	$ 17,199	$ 23,284
Discounted cash flow \| Discounted cash flows
Disclosure Of Financial Instruments [Line Items]
Percentage of reasonably possible increase (decrease) in unobservable input, liabilities	0.005	0.005
Percentage of reasonably possible increase (decrease) in fair value measurement due to change in unobservable input, liabilities	0.0001	0.002
Weighted Average \| Discounted cash flow
Disclosure Of Financial Instruments [Line Items]
Range of inputs (weighted average)	(12.50%)	(12.50%)
Bottom of range \| Discounted cash flow
Disclosure Of Financial Instruments [Line Items]
Range of inputs (weighted average)	11%	11%
Top of range \| Discounted cash flow
Disclosure Of Financial Instruments [Line Items]
Range of inputs (weighted average)	13%	13%
Expected Sales Volume \| Expected sales volumes
Disclosure Of Financial Instruments [Line Items]
Percentage of reasonably possible increase (decrease) in unobservable input, liabilities	0.10	0.10
Percentage of reasonably possible increase (decrease) in fair value measurement due to change in unobservable input, liabilities	0.001	0.02
Probability of Success \| Probability of success measurement input
Disclosure Of Financial Instruments [Line Items]
Percentage of reasonably possible increase (decrease) in unobservable input, liabilities	0.10	0.10
Percentage of reasonably possible increase (decrease) in fair value measurement due to change in unobservable input, liabilities	0.08	0.086
Probability of Success \| Payment assumptions measurement input
Disclosure Of Financial Instruments [Line Items]
Percentage of reasonably possible increase (decrease) in unobservable input, liabilities	0.20	0.20
Percentage of reasonably possible increase (decrease) in fair value measurement due to change in unobservable input, liabilities	0.16	0.172

Financial Assets and Liabili_19

Financial Assets and Liabilities - Summary of Valuation Processes of Contingent Consideration at Fair Value (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022
Disclosure of detailed information about financial instruments [abstract]
Fair value of cash or stock payable, dependent on achievement of future late-stage clinical or regulatory targets	$ 16,606	$ 17,827
Fair value of royalty payments from commercialization of the intellectual property acquired	593	5,457
Contingent Consideration	$ 17,199	$ 23,284

Financial Assets and Liabili_20

Financial Assets and Liabilities - Summary of Warrant Liability (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Disclosure Of Financial Instruments [Line Items]
Opening balance	$ 2,185	$ 0
Warrants fair value at grant date	5,400	2,200
Remeasurement of warrant liability	2,205	(5,896)
Closing Balance	5,426	2,185
Warrants fair value at grant date - November 19, 2021
Disclosure Of Financial Instruments [Line Items]
Warrants fair value at grant date	0	8,081
Warrants fair value at grant date - December 22, 2022
Disclosure Of Financial Instruments [Line Items]
Warrants fair value at grant date	$ 1,036	$ 0

Financial Assets and Liabili_21

Financial Assets and Liabilities - Summary of Fair Value of Warrants (Details)			12 Months Ended
	Mar. 18, 2021 USD ($) $ / shares	Mar. 18, 2021 $ / shares	Jun. 30, 2023 USD ($) Tranche Year $ / shares shares	Jun. 30, 2022 USD ($) Year $ / shares shares
Disclosure Of Financial Instruments [Line Items]
Dividend Yield	0%
Expected Volatility	66.88%
Risk Free Interest Rate	1.24%
Fair value per warrant (in dollars per share) \| (per share)	$ 0.863	$ 1.103
Fair value per warrant (in dollars per share) \| $	$ 12,968,583
Warrants
Disclosure Of Financial Instruments [Line Items]
Number of shares warrants granted to purchase (in shares) \| shares			2,224,669	1,769,669
Fair value per warrant (in dollars per share) \| $			$ 5,426,212	$ 2,185,476
Warrants
Disclosure Of Financial Instruments [Line Items]
Share Price (in usd per share)			$ 3.91	$ 2.22
Exercise price (in dollars per share)				$ 7.26
Expected Term			6.5	7
Dividend Yield			0%	0%
Expected Volatility			81.26%	83.22%
Risk Free Interest Rate			4.01%	3.08%
Fair value per warrant (in dollars per share)				$ 1.2350
Fair value per warrant (in dollars per share) \| $			$ 5,426,212	$ 2,185,476
Warrants \| Minimum
Disclosure Of Financial Instruments [Line Items]
Exercise price (in dollars per share)			$ 3.70
Expected Term \| Year			6
Fair value per warrant (in dollars per share)			$ 2.3103
Warrants \| Maximum
Disclosure Of Financial Instruments [Line Items]
Exercise price (in dollars per share)			$ 7.26
Expected Term \| Year			7
Fair value per warrant (in dollars per share)			$ 2.9401

Financial Assets and Liabili_22

Financial Assets and Liabilities - Summary of Fair Value of Warrants (Parenthetical) (Details) - shares	Jun. 30, 2023	Jun. 30, 2022
Warrants
Disclosure Of Financial Instruments [Line Items]
Number of shares warrants granted to purchase (in shares)	2,224,669	1,769,669

Non-financial Assets and Liab_3

Non-financial Assets and Liabilities - Additional Information (Details)		12 Months Ended
	Mar. 31, 2023 USD ($)	Jun. 30, 2023 USD ($) acquisition segment	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2015 USD ($)	Jun. 30, 2013 USD ($)	Jun. 30, 2010 USD ($)
Disclosure Of Non Financial Assets And Liabilities [Line Items]
Interest expense for leases		$ 500,000	$ 600,000	$ 600,000
Payments associated with lease liabilities		3,200,000	3,400,000
Short term leases expense		1,100,000	3,200,000
Depreciation, right-of-use assets		$ 1,661,000	1,717,000	$ 1,691,000
Number of acquisitions \| acquisition		2
Number of reportable operating segment \| segment		1
In process research and development recognized		$ 427,800,000	427,800,000
Employee benefits
Disclosure Of Non Financial Assets And Liabilities [Line Items]
Current provisions for accrued annual leave		1,100,000	$ 1,000,000
Angioblast Systems Inc in 2010
Disclosure Of Non Financial Assets And Liabilities [Line Items]
Goodwill							$ 118,400,000
In process research and development recognized							$ 387,000,000
Osiris MSC in 2013
Disclosure Of Non Financial Assets And Liabilities [Line Items]
Goodwill						$ 13,900,000
In process research and development recognized						$ 126,700,000
Osiris MSC in 2015
Disclosure Of Non Financial Assets And Liabilities [Line Items]
Goodwill		2,100,000
TEMCELL Asset \| Japan
Disclosure Of Non Financial Assets And Liabilities [Line Items]
In process research and development recognized					$ 24,000,000
MPC-MICRO-IO and MPC-CBE
Disclosure Of Non Financial Assets And Liabilities [Line Items]
In process research and development recognized		61,900,000
In-process research and development acquired
Disclosure Of Non Financial Assets And Liabilities [Line Items]
Impairment loss recognised in profit or loss	$ 0	0
Goodwill
Disclosure Of Non Financial Assets And Liabilities [Line Items]
Impairment loss recognised in profit or loss	$ 0	0
Manufacturing Service Agreement
Disclosure Of Non Financial Assets And Liabilities [Line Items]
Minimum financial commitment reduction amount on lease component		$ 1,100,000
Lonza Bioscience Singapore Pte Ltd \| Manufacturing Service Agreement
Disclosure Of Non Financial Assets And Liabilities [Line Items]
Non-cancellable term of lease and non lease components		2 years
Minimum financial commitment of the lease component		$ 3,000,000
Bottom of range \| Discounted cash flow
Disclosure Of Non Financial Assets And Liabilities [Line Items]
Real post-tax discount rate		13.80%
Expected patent expiry		9 years
Bottom of range \| Licenses to Patents
Disclosure Of Non Financial Assets And Liabilities [Line Items]
Useful life measured as period of time, intangible assets other than goodwill		7 years
Bottom of range \| Current Marketed Products
Disclosure Of Non Financial Assets And Liabilities [Line Items]
Useful life measured as period of time, intangible assets other than goodwill		15 years
Top of range \| Discounted cash flow
Disclosure Of Non Financial Assets And Liabilities [Line Items]
Real post-tax discount rate		15.50%
Expected patent expiry		25 years
Top of range \| Licenses to Patents
Disclosure Of Non Financial Assets And Liabilities [Line Items]
Useful life measured as period of time, intangible assets other than goodwill		16 years
Top of range \| Current Marketed Products
Disclosure Of Non Financial Assets And Liabilities [Line Items]
Useful life measured as period of time, intangible assets other than goodwill		20 years
Plant and Equipment \| Bottom of range
Disclosure Of Non Financial Assets And Liabilities [Line Items]
Estimated useful lives		3 years
Plant and Equipment \| Top of range
Disclosure Of Non Financial Assets And Liabilities [Line Items]
Estimated useful lives		15 years
Office Furniture and Equipment \| Bottom of range
Disclosure Of Non Financial Assets And Liabilities [Line Items]
Estimated useful lives		5 years
Office Furniture and Equipment \| Top of range
Disclosure Of Non Financial Assets And Liabilities [Line Items]
Estimated useful lives		10 years
Computer Hardware and Software \| Bottom of range
Disclosure Of Non Financial Assets And Liabilities [Line Items]
Estimated useful lives		3 years
Computer Hardware and Software \| Top of range
Disclosure Of Non Financial Assets And Liabilities [Line Items]
Estimated useful lives		5 years

Non-financial Assets and Liab_4

Non-financial Assets and Liabilities - Summary of Property, Plant and Equipment (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Disclosure Of Property Plant And Equipment [Line Items]
Beginning Balance	$ 2,045	$ 3,021
Additions	274	188
Exchange differences	(9)	(20)
Depreciation charge	(953)	(1,144)	$ (1,016)
Ending Balance	1,357	2,045	3,021
Cost
Disclosure Of Property Plant And Equipment [Line Items]
Beginning Balance	12,150
Ending Balance	12,337	12,150
Accumulated depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Beginning Balance	(10,105)
Ending Balance	(10,980)	(10,105)
Plant and Equipment
Disclosure Of Property Plant And Equipment [Line Items]
Beginning Balance	1,208	1,953
Additions	171	143
Exchange differences	(104)	54
Depreciation charge	(818)	(942)
Ending Balance	457	1,208	1,953
Plant and Equipment \| Cost
Disclosure Of Property Plant And Equipment [Line Items]
Beginning Balance	6,846
Ending Balance	6,910	6,846
Plant and Equipment \| Accumulated depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Beginning Balance	(5,638)
Ending Balance	(6,453)	(5,638)
Office Furniture and Equipment
Disclosure Of Property Plant And Equipment [Line Items]
Beginning Balance	692	811
Additions	43	3
Exchange differences	113	(70)
Depreciation charge	(45)	(52)
Ending Balance	803	692	811
Office Furniture and Equipment \| Cost
Disclosure Of Property Plant And Equipment [Line Items]
Beginning Balance	1,925
Ending Balance	2,074	1,925
Office Furniture and Equipment \| Accumulated depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Beginning Balance	(1,233)
Ending Balance	(1,271)	(1,233)
Computer Hardware and Software
Disclosure Of Property Plant And Equipment [Line Items]
Beginning Balance	145	257
Additions	60	42
Exchange differences	(18)	(4)
Depreciation charge	(90)	(150)
Ending Balance	97	145	$ 257
Computer Hardware and Software \| Cost
Disclosure Of Property Plant And Equipment [Line Items]
Beginning Balance	3,379
Ending Balance	3,353	3,379
Computer Hardware and Software \| Accumulated depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Beginning Balance	(3,234)
Ending Balance	$ (3,256)	$ (3,234)

Non-financial Assets and Liab_5

Non-financial Assets and Liabilities - Schedule of Right-of-Use Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Disclosure Of Right Of Use Assets Line Item
Beginning balance	$ 7,920
Depreciation charge	(1,661)	$ (1,717)	$ (1,691)
Ending balance	5,134	7,920
Right-of-use Assets
Disclosure Of Right Of Use Assets Line Item
Beginning balance	7,920	9,119
Additions		1,464
Additions/(derecognition)	(649)
Reassessment	224	591
Exchange differences	(15)	(165)
Depreciation charge	(2,346)	(3,089)
Ending balance	5,134	7,920	9,119
Right-of-use Assets \| Adjustment On Adoption Of I F R S16
Disclosure Of Right Of Use Assets Line Item
Beginning balance	7,920
Ending balance		7,920
Right-of-use Assets \| Cost
Disclosure Of Right Of Use Assets Line Item
Beginning balance	16,135
Ending balance	16,135	16,135
Right-of-use Assets \| Accumulated depreciation
Disclosure Of Right Of Use Assets Line Item
Beginning balance	(8,215)
Ending balance	(11,001)	(8,215)
Right-of-use Assets \| Buildings
Disclosure Of Right Of Use Assets Line Item
Beginning balance	5,096	5,417
Additions		1,464
Additions/(derecognition)	(649)
Reassessment	526	97
Exchange differences	(15)	(165)
Depreciation charge	(1,661)	(1,717)
Ending balance	3,297	5,096	5,417
Right-of-use Assets \| Buildings \| Adjustment On Adoption Of I F R S16
Disclosure Of Right Of Use Assets Line Item
Beginning balance	5,096
Ending balance		5,096
Right-of-use Assets \| Buildings \| Cost
Disclosure Of Right Of Use Assets Line Item
Beginning balance	9,957
Ending balance	9,957	9,957
Right-of-use Assets \| Buildings \| Accumulated depreciation
Disclosure Of Right Of Use Assets Line Item
Beginning balance	(4,861)
Ending balance	(6,660)	(4,861)
Right-of-use Assets \| Manufacturing
Disclosure Of Right Of Use Assets Line Item
Beginning balance	2,824	3,702
Reassessment	(302)	494
Depreciation charge	(685)	(1,372)
Ending balance	1,837	2,824	$ 3,702
Right-of-use Assets \| Manufacturing \| Adjustment On Adoption Of I F R S16
Disclosure Of Right Of Use Assets Line Item
Beginning balance	2,824
Ending balance		2,824
Right-of-use Assets \| Manufacturing \| Cost
Disclosure Of Right Of Use Assets Line Item
Beginning balance	6,178
Ending balance	6,178	6,178
Right-of-use Assets \| Manufacturing \| Accumulated depreciation
Disclosure Of Right Of Use Assets Line Item
Beginning balance	(3,354)
Ending balance	$ (4,341)	$ (3,354)

Non-financial Assets and Liab_6

Non-financial Assets and Liabilities - Schedule of Lease Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022
Lease liabilities [abstract]
Current	$ 4,060	$ 3,186
Non-current	3,672	7,085
Lease liabilities included in the balance sheet	$ 7,732	$ 10,271

Non-financial Assets and Liab_7

Non-financial Assets and Liabilities - Summary of Intangible Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Disclosure Of Intangible Assets [Line Items]
Opening net book amount	$ 578,652	$ 580,546
Additions/reversals	23	(450)
Exchange differences	1	75
Amortization charge	(1,493)	(1,519)
Closing net book amount	577,183	578,652
Cost
Disclosure Of Intangible Assets [Line Items]
Opening net book amount	651,138
Closing net book amount	651,143	651,138
Accumulated amortization
Disclosure Of Intangible Assets [Line Items]
Opening net book amount	(10,567)
Closing net book amount	(12,041)	(10,567)
Accumulated impairment
Disclosure Of Intangible Assets [Line Items]
Opening net book amount	(61,919)
Closing net book amount	(61,919)	(61,919)
Goodwill
Disclosure Of Intangible Assets [Line Items]
Opening net book amount	134,453	134,453
Closing net book amount	134,453	134,453
Goodwill \| Cost
Disclosure Of Intangible Assets [Line Items]
Opening net book amount	134,453
Closing net book amount	134,453	134,453
Acquired licenses to patents
Disclosure Of Intangible Assets [Line Items]
Opening net book amount	1,632	2,072
Additions/reversals	23	(450)
Exchange differences	1	74
Amortization charge	(38)	(64)
Closing net book amount	1,618	1,632
Acquired licenses to patents \| Cost
Disclosure Of Intangible Assets [Line Items]
Opening net book amount	2,987
Closing net book amount	2,993	2,987
Acquired licenses to patents \| Accumulated amortization
Disclosure Of Intangible Assets [Line Items]
Opening net book amount	(1,355)
Closing net book amount	(1,375)	(1,355)
In-process research and development acquired
Disclosure Of Intangible Assets [Line Items]
Opening net book amount	427,779	427,779
Closing net book amount	427,779	427,779
In-process research and development acquired \| Cost
Disclosure Of Intangible Assets [Line Items]
Opening net book amount	489,698
Closing net book amount	489,698	489,698
In-process research and development acquired \| Accumulated impairment
Disclosure Of Intangible Assets [Line Items]
Opening net book amount	(61,919)
Closing net book amount	(61,919)	(61,919)
Current marketed products
Disclosure Of Intangible Assets [Line Items]
Opening net book amount	14,788	16,242
Exchange differences	0	1
Amortization charge	(1,455)	(1,455)
Closing net book amount	13,333	14,788
Current marketed products \| Cost
Disclosure Of Intangible Assets [Line Items]
Opening net book amount	24,000
Closing net book amount	23,999	24,000
Current marketed products \| Accumulated amortization
Disclosure Of Intangible Assets [Line Items]
Opening net book amount	(9,212)
Closing net book amount	$ (10,666)	$ (9,212)

Non-financial Assets and Liab_8

Non-financial Assets and Liabilities - Summary of Carrying Value of In Process Research and Development Acquired by Product (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Disclosure Of Intangible Assets [Line Items]
Carrying value of in process research and development	$ 577,183	$ 578,652	$ 580,546
In-process research and development acquired
Disclosure Of Intangible Assets [Line Items]
Carrying value of in process research and development	427,779	427,779	$ 427,779
In-process research and development acquired \| Cardiovascular Products
Disclosure Of Intangible Assets [Line Items]
Carrying value of in process research and development	254,351	254,351
In-process research and development acquired \| Intravenous products for metabolic diseases and inflammatory/immunologic conditions
Disclosure Of Intangible Assets [Line Items]
Carrying value of in process research and development	70,730	70,730
In-process research and development acquired \| MSC Products
Disclosure Of Intangible Assets [Line Items]
Carrying value of in process research and development	$ 102,698	$ 102,698

Non-financial Assets and Liab_9

Non-financial Assets and Liabilities - Summary of Provisions (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022
Disclosure Of Other Provisions [Line Items]
Current provisions	$ 6,399	$ 17,906
Non-current provisions	16,612	12,523
Total provisions	23,011	30,429
Contingent consideration
Disclosure Of Other Provisions [Line Items]
Current provisions	636	10,823
Non-current provisions	16,563	12,461
Total provisions	17,199	23,284
Employee benefits
Disclosure Of Other Provisions [Line Items]
Current provisions	2,013	3,333
Non-current provisions	49	62
Total provisions	2,062	3,395
Provision for license agreements
Disclosure Of Other Provisions [Line Items]
Current provisions	3,750	3,750
Non-current provisions	0	0
Total provisions	$ 3,750	$ 3,750

Non-financial Assets and Lia_10

Non-financial Assets and Liabilities - Summary of Deferred Tax Balances (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022
Deferred tax assets
Tax losses	$ 76,020	$ 80,411
Other temporary differences	11,972	7,831
Total deferred tax assets	87,992	88,242
Deferred tax liabilities
Intangible assets	87,992	88,242
Total deferred tax liabilities	87,992	88,242
Net deferred tax liabilities	$ 0	$ 0

Non-financial Assets and Lia_11

Non-financial Assets and Liabilities - Schedule of Movements Related to Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Deferred Tax Assets And Liabilities [Line Items]
Beginning balance	$ 0	$ 0
Charged/(credited) to:
- profit or loss	(212)	(239)
- directly to equity	212	239
Ending balance	0	0
Tax losses (DTA)
Deferred Tax Assets And Liabilities [Line Items]
Beginning balance	(80,411)	(71,916)
Charged/(credited) to:
- profit or loss	4,179	(8,742)
- directly to equity	212	247
Ending balance	(76,020)	(80,411)
Other Temporary Differences (DTA)
Deferred Tax Assets And Liabilities [Line Items]
Beginning balance	(7,831)	(8,248)
Charged/(credited) to:
- profit or loss	(4,141)	425
- directly to equity	0	(8)
Ending balance	(11,972)	(7,831)
Intangible Assets (DTL)
Deferred Tax Assets And Liabilities [Line Items]
Beginning balance	88,242	80,164
Charged/(credited) to:
- profit or loss	(250)	8,078
Ending balance	$ 87,992	$ 88,242

Non-financial Assets and Lia_12

Non-financial Assets and Liabilities - Schedule of Deferred Consideration (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Disclosure Of Non Financial Assets And Liabilities [Abstract]
Opening balance	$ 2,500	$ 2,500
Amount recognized as revenue during the period	0	0
End of the period	$ 2,500	$ 2,500

Non-financial Assets and Lia_13

Non-financial Assets and Liabilities - Schedule of Deferred Consideration (Parenthetical) (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Dec. 31, 2019	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Disclosure Of Non Financial Assets And Liabilities [Abstract]
Milestone revenue	$ 2,500	$ 0	$ 1,172	$ 0

Equity - Schedule of Share Capi

Equity - Schedule of Share Capital (Details) - USD ($)	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Contributed equity
Total Equity	$ 501,838,000	$ 497,044,000	$ 581,397,000	$ 549,326,000
Ordinary Shares
Contributed equity
Ordinary shares (in shares)	814,204,825	650,454,551	648,696,070	583,949,612
Less: Treasury Shares (in shares)	(542,903)	(542,903)	(771,983)
Total Contributed Equity (in shares)	813,661,922	649,911,648	647,924,087
Ordinary shares value	$ 1,249,123,000	$ 1,165,309,000	$ 1,163,153,000
Less: Treasury Shares value	0	0	0
Total Equity	$ 1,249,123,000	$ 1,165,309,000	$ 1,163,153,000	$ 1,051,450,000

Equity - Summary of Movements i

Equity - Summary of Movements in Ordinary Share Capital (Details) $ in Thousands	12 Months Ended
	Jun. 30, 2023 USD ($) shares	Jun. 30, 2022 USD ($) shares	Jun. 30, 2021 USD ($) shares
Disclosure Of Classes Of Share Capital [Line Items]
Beginning balance	$ 497,044	$ 581,397	$ 549,326
Issues of ordinary shares during the period
Exercise of share options, (in shares) \| shares	0
Issued Capital
Disclosure Of Classes Of Share Capital [Line Items]
Beginning balance, (in shares) \| shares	650,454,551	648,696,070	583,949,612
Beginning balance	$ 1,165,309	$ 1,163,153	$ 1,051,450
Issues of ordinary shares during the period
Exercise of share options		$ 209	$ 9,223
Transfer to employee share trust, (in shares) \| shares			3,450,000
Share based compensation for services rendered, (in shares) \| shares		1,758,481	1,187,168
Share based compensation for services rendered		$ 1,698	$ 1,867
Transaction costs arising on share issue	$ (5,327)	$ 21	$ (1,312)
Total contributions of equity during the period, (in shares) \| shares	163,750,274	1,758,481	64,746,458
Total contributions of equity during the period	$ 83,814	$ 1,928	$ 106,809
Share options reserve transferred to equity on exercise of options		$ 228	$ 4,894
Placement Agreement \| Issued Capital
Issues of ordinary shares during the period
Placement of shares under a share placement agreement, (in shares) \| shares	163,750,274		60,109,290
Placement of shares under a share placement agreement	$ 89,141		$ 97,031

Equity - Summary of Movements_2

Equity - Summary of Movements in Ordinary Share Capital (Parenthetical) (Details) $ / shares in Units, $ in Millions, $ in Millions			1 Months Ended
	Apr. 25, 2023 USD ($)	Aug. 31, 2022 $ / shares shares	Apr. 30, 2023 $ / shares shares	Mar. 31, 2021 AUD ($) $ / shares shares
Disclosure Of Classes Of Share Capital [Line Items]
Proceeds from issue of shares \| $	$ 40
Number of shares issued and fully paid (in shares) \| shares			77,083,607
Fully-paid ordinary shares price (in dollars per share) \| $ / shares			0.85
Discount percentage used to calculate equity purchase price per share			15%
Warrants
Disclosure Of Classes Of Share Capital [Line Items]
Ordinary shares (in shares) \| shares				15,000,000
Warrant exercise price (in dollars per share) \| $ / shares				$ 2.88
Ratio of issuance of warrants to ordinary shares				25%
Warrants \| Top of range
Disclosure Of Classes Of Share Capital [Line Items]
Maximum amount of capital that can be raised from warrants \| $				$ 43.2
Equity Purchase Fee \| Tasly
Disclosure Of Classes Of Share Capital [Line Items]
Discount percentage used to calculate equity purchase price per share		5%		6.50%
Sale of equity price (in dollars per share) \| $ / shares		$ 0.75		$ 2.30
Ordinary shares (in shares) \| shares		86,666,667		60,109,290

Equity - Summary of Movements o

Equity - Summary of Movements of Shares in Share Trust (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Jul. 31, 2020	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Disclosure Of Movements Of Shares In Share Trust [Line Items]
Exercise of share options, (in shares)		0
Mesoblast Employee Share Trust
Disclosure Of Movements Of Shares In Share Trust [Line Items]
Opening balance, (in shares)	3,500,000	542,903	771,983	3,500,000
Transfer to employee share trust, (in shares)	3,500,000	0	0	3,450,000
Exercise of share options, (in shares)		0	(229,080)	(6,178,017)
Ending balance, (in shares)		542,903	542,903	771,983
Opening balance	$ 0	$ 0	$ 0	$ 0
Transfer to employee share trust		0	0	0
Exercise of share options		0	0	0
Ending balance		$ 0	$ 0	$ 0

Equity - Summary of Movements_3

Equity - Summary of Movements of Shares in Share Trust (Parenthetical) (Details) - shares	1 Months Ended	12 Months Ended
	Jul. 31, 2020	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Mesoblast Employee Share Trust
Disclosure Of Movements Of Shares In Share Trust [Line Items]
Transfer to employee share trust, (in shares)	3,500,000	0	0	3,450,000

Equity - Additional Information

Equity - Additional Information (Details) $ / shares in Units, $ in Thousands, $ in Millions	1 Months Ended		12 Months Ended
	Mar. 31, 2021 USD ($) $ / shares	Mar. 31, 2021 AUD ($) $ / shares shares	Jun. 30, 2023 USD ($) shares	Jun. 30, 2022 USD ($) shares	Jun. 30, 2021 USD ($) shares	Apr. 30, 2023 shares	Mar. 31, 2022 shares	Jun. 30, 2020 shares
Disclosure Of Classes Of Share Capital [Line Items]
Proceeds from issue of shares \| $			$ 88,635	$ 209	$ 106,268
Fully-paid ordinary shares						77,083,607
Warrants
Disclosure Of Classes Of Share Capital [Line Items]
Ordinary shares (in shares)		15,027,327
Warrant exercise price (in dollars per share) \| $ / shares		$ 2.88
Warrant exercise term	7 years	7 years
Share price, minimum consecutive day		45 days
Warrants \| Bottom of range
Disclosure Of Classes Of Share Capital [Line Items]
Share price for right exercise of the warrants (in aud per share) \| $ / shares	4.32	4.32
Private Placement of Shares
Disclosure Of Classes Of Share Capital [Line Items]
Exercise price (in dollars per share) \| $ / shares		$ 2.30
Proceeds from issue of shares	$ 110,000	$ 138
Fully-paid ordinary shares							60,109,290
Ordinary Shares
Disclosure Of Classes Of Share Capital [Line Items]
Ordinary shares (in shares)			814,204,825	650,454,551	648,696,070			583,949,612

Equity - Summary of Reserves (D

Equity - Summary of Reserves (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Disclosure Of Reserves Within Equity [Line Items]
Reserves	$ 73,520	$ 70,651
Share-based payments reserve
Disclosure Of Reserves Within Equity [Line Items]
Reserves	101,367	97,924	$ 92,855
Investment revaluation reserve
Disclosure Of Reserves Within Equity [Line Items]
Reserves	(543)	(542)	(220)
Foreign Currency Translation Reserve
Disclosure Of Reserves Within Equity [Line Items]
Reserves	(40,273)	(39,700)	(39,791)
Warrants reserve
Disclosure Of Reserves Within Equity [Line Items]
Reserves	$ 12,969	$ 12,969	$ 12,969

Equity - Summary of Reconciliat

Equity - Summary of Reconciliation of Reserves (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Disclosure Of Reserves Within Equity [Line Items]
Opening balance	$ 70,651
Fair value of share-based payments	3,655	$ 5,536	$ 12,510
Changes in the fair value of financial assets through other comprehensive income	1	322	(209)
Closing Balance	73,520	70,651
Share-based payments reserve
Disclosure Of Reserves Within Equity [Line Items]
Opening balance	97,924	92,855
Tax credited / (debited) to equity	(212)	(239)
Transfer to ordinary shares on exercise of options	0	(228)
Fair value of share-based payments	3,655	5,536
Closing Balance	101,367	97,924	92,855
Investment revaluation reserve
Disclosure Of Reserves Within Equity [Line Items]
Opening balance	(542)	(220)
Changes in the fair value of financial assets through other comprehensive income	(1)	(322)
Closing Balance	(543)	(542)	(220)
Foreign Currency Translation Reserve
Disclosure Of Reserves Within Equity [Line Items]
Opening balance	(39,700)	(39,791)
Currency gain/(loss) on translation of foreign operations net assets	(573)	91
Closing Balance	(40,273)	(39,700)	(39,791)
Warrants reserve
Disclosure Of Reserves Within Equity [Line Items]
Opening balance	12,969	12,969
Movements during the period	0	0
Closing Balance	$ 12,969	$ 12,969	$ 12,969

Equity - Summary of Assumptions

Equity - Summary of Assumptions Based on Observable Market Conditions Existed at Issue Date (Details) - Mar. 18, 2021	USD ($) $ / shares	$ / shares
Disclosure of classes of share capital [abstract]
Share Price (in dollars per share)		$ 2.41
Exercise Price (in dollars per share)		2.88
Expected Term	7 years
Dividend Yield	0%
Expected Volatility	66.88%
A$-US$ FX Spot Rate		0.7827
Risk Free Interest Rate	1.24%
Fair value per warrant (in dollars per share) \| (per share)	$ 0.863	$ 1.103
Fair value per warrant (in dollars per share) \| $	$ 12,968,583

Equity - Summary of Assumptio_2

Equity - Summary of Assumptions Based on Observable Market Conditions Existed at Issue Date (Parenthetical) (Details)	Mar. 18, 2021 shares
Warrants
Disclosure Of Classes Of Share Capital [Line Items]
Number of warrants at issue date	15,027,327
Bottom of range
Disclosure Of Classes Of Share Capital [Line Items]
Term of bond issued	5 years
Top of range
Disclosure Of Classes Of Share Capital [Line Items]
Term of bond issued	10 years

Cash Flow Information - Summary

Cash Flow Information - Summary of Cash Flow Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Reconciliation of cash and cash equivalents
Cash at bank	$ 70,920	$ 60,034	$ 136,430
Deposits at call	398	413	451
Cash and cash equivalents	71,318	60,447	136,881	$ 129,328
Cash flows from operating activities
Loss for the period	(81,889)	(91,347)	(98,811)
Add/(deduct) net loss for non-cash items as follows:
Depreciation and amortization	4,107	4,380	4,264
Foreign exchange losses/(gains)	62	536	(1,499)
Finance costs	20,122	17,288	10,711
Remeasurement of contingent consideration	(8,771)	(913)	(18,687)
Remeasurement of warrant liabilities	2,205	(5,896)	0
Equity settled share-based payment	3,655	5,536	12,510
Deferred tax benefit	(212)	(235)	(819)
Gain on derecognition of right-of-use assets	(76)	0	0
Change in operating assets and liabilities:
Decrease/(increase) in trade and other receivables	(118)	140	(1,739)
Decrease/(increase) in prepayments	1,650	1,555	(213)
Increase/(decrease) in trade creditors and accruals	(398)	4,777	(5,061)
Decrease/(increase) in tax incentive recoverable	(2,388)	0	0
Increase/(decrease) in provisions	(1,218)	(1,603)	(1,405)
Net cash (outflows) in operating activities	$ (63,269)	$ (65,782)	$ (100,749)

Financial Risk Management - Add

Financial Risk Management - Additional Information (Details)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Disclosure - Financial Risk Management - Additional Information (Details) [Line Items]
Percentage of forecast net sales	20%
Interest Rate Risk
Disclosure - Financial Risk Management - Additional Information (Details) [Line Items]
Effect on profit from change in tax rate	10%	10%
Liquidity Risk
Disclosure - Financial Risk Management - Additional Information (Details) [Line Items]
Non-interest bearing financial liabilities maturing period	6 months	6 months
USD \| Currency Risk
Disclosure - Financial Risk Management - Additional Information (Details) [Line Items]
Percentage of cash held	67%	97%
(in Australian dollars, in thousands, except percent data) \| Currency Risk
Disclosure - Financial Risk Management - Additional Information (Details) [Line Items]
Percentage of cash held	33%	3%

Financial Risk Management - Sch

Financial Risk Management - Schedule of Balances Held at the End of Year with an Analysis which Assesses Impact on Profit and Loss Due to Change in Exchange Rate (Details) € in Thousands, £ in Thousands, SFr in Thousands, $ in Thousands, $ in Thousands, $ in Thousands

12 Months Ended

Jun. 30, 2023 USD ($)

Jun. 30, 2022 USD ($)

Jun. 30, 2021 USD ($)

Jun. 30, 2023 CHF (SFr)

Jun. 30, 2023 SGD ($)

Jun. 30, 2023 EUR (€)

Jun. 30, 2023 AUD ($)

Jun. 30, 2023 GBP (£)

Jun. 30, 2022 CHF (SFr)

Jun. 30, 2022 SGD ($)

Jun. 30, 2022 EUR (€)

Jun. 30, 2022 AUD ($)

Jun. 30, 2022 GBP (£)

Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]

Loss for the period

$ (81,889)

$ (91,347)

$ (98,811)

Foreign currency balance held

82,399

68,538

+20% | Currency Risk

Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]

Loss for the period

(648)

(434)

-20% | Currency Risk

Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]

Loss for the period

648

434

Bank Accounts | USD | Currency Risk

Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]

Foreign currency balance held

Bank Accounts | USD | +20% | Currency Risk

Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]

Loss for the period

Bank Accounts | USD | -20% | Currency Risk

Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]

Loss for the period

(12)

Bank Accounts | CHF | Currency Risk

Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]

Foreign currency balance held | SFr

SFr 79

SFr 55

Bank Accounts | CHF | +20% | Currency Risk

Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]

Loss for the period

Bank Accounts | CHF | -20% | Currency Risk

Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]

Loss for the period

(18)

(12)

Bank Accounts | SGD | Currency Risk

Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]

Foreign currency balance held

$ 80

$ 140

Bank Accounts | SGD | +20% | Currency Risk

Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]

Loss for the period

Bank Accounts | SGD | -20% | Currency Risk

Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]

Loss for the period

(12)

(20)

Bank Accounts | EUR | Currency Risk

Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]

Foreign currency balance held | €

€ 4

€ 289

Bank Accounts | EUR | +20% | Currency Risk

Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]

Loss for the period

Bank Accounts | EUR | -20% | Currency Risk

Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]

Loss for the period

(1)

(60)

Trade and Other Receivables | USD | Currency Risk

Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]

Foreign currency balance held

400

Trade and Other Receivables | USD | +20% | Currency Risk

Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]

Loss for the period

Trade and Other Receivables | USD | -20% | Currency Risk

Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]

Loss for the period

(80)

Trade and Other Receivables | CHF | Currency Risk

Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]

Foreign currency balance held | SFr

Trade and Other Receivables | CHF | +20% | Currency Risk

Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]

Loss for the period

Trade and Other Receivables | CHF | -20% | Currency Risk

Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]

Loss for the period

(1)

Trade and Other Receivables | SGD | Currency Risk

Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]

Foreign currency balance held

106

205

Trade and Other Receivables | SGD | +20% | Currency Risk

Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]

Loss for the period

Trade and Other Receivables | SGD | -20% | Currency Risk

Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]

Loss for the period

(16)

(30)

Trade and Other Receivables | EUR | Currency Risk

Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]

Foreign currency balance held | €

292

153

Trade and Other Receivables | EUR | +20% | Currency Risk

Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]

Loss for the period

Trade and Other Receivables | EUR | -20% | Currency Risk

Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]

Loss for the period

(63)

(32)

Trade Payables and Accruals | USD | Currency Risk

Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]

Foreign currency balance held

(1,361)

(274)

Trade Payables and Accruals | USD | +20% | Currency Risk

Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]

Loss for the period

(272)

(55)

Trade Payables and Accruals | USD | -20% | Currency Risk

Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]

Loss for the period

272

Trade Payables and Accruals | CHF | Currency Risk

Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]

Foreign currency balance held | SFr

SFr (40)

SFr (36)

Trade Payables and Accruals | CHF | +20% | Currency Risk

Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]

Loss for the period

(9)

(7)

Trade Payables and Accruals | CHF | -20% | Currency Risk

Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]

Loss for the period

Trade Payables and Accruals | SGD | Currency Risk

Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]

Foreign currency balance held

$ (422)

(429)

Trade Payables and Accruals | SGD | +20% | Currency Risk

Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]

Loss for the period

(62)

Trade Payables and Accruals | SGD | -20% | Currency Risk

Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]

Loss for the period

Trade Payables and Accruals | EUR | Currency Risk

Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]

Foreign currency balance held | €

€ (26)

€ (42)

Trade Payables and Accruals | EUR | +20% | Currency Risk

Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]

Loss for the period

(6)

(9)

Trade Payables and Accruals | EUR | -20% | Currency Risk

Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]

Loss for the period

Trade Payables and Accruals | (in Australian dollars, in thousands, except percent data) | Currency Risk

Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]

Foreign currency balance held

$ (1,064)

$ (752)

Trade Payables and Accruals | (in Australian dollars, in thousands, except percent data) | +20% | Currency Risk

Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]

Loss for the period

(141)

(104)

Trade Payables and Accruals | (in Australian dollars, in thousands, except percent data) | -20% | Currency Risk

Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]

Loss for the period

141

104

Trade Payables and Accruals | GBP | Currency Risk

Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]

Foreign currency balance held | £

£ (45)

£ (50)

Trade Payables and Accruals | GBP | +20% | Currency Risk

Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]

Loss for the period

(11)

(12)

Trade Payables and Accruals | GBP | -20% | Currency Risk

Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]

Loss for the period

Provisions | USD | Currency Risk

Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]

Foreign currency balance held

(1,750)

Provisions | USD | +20% | Currency Risk

Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]

Loss for the period

(350)

Provisions | USD | -20% | Currency Risk

Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]

Loss for the period

$ 350

350

Provisions | SGD | Currency Risk

Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]

Foreign currency balance held

$ (62)

Provisions | SGD | +20% | Currency Risk

Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]

Loss for the period

(9)

Provisions | SGD | -20% | Currency Risk

Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]

Loss for the period

$ 9

Financial Risk Management - S_2

Financial Risk Management - Schedule of Deposits Held which Derive Interest Revenue Together with the Maximum and Minimum Interest Rates Being Earned (Details) - Interest Rate Risk $ in Thousands, $ in Thousands	12 Months Ended
	Jun. 30, 2023 USD ($)	Jun. 30, 2023 AUD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2022 AUD ($)
USD
Disclosure of Financial Risk Management [Line Items]
Funds invested	$ 40,569		$ 49,383
Rate increase on funds invested	73		15
Rate decrease on funds invested	$ (73)		$ (15)
(in Australian dollars, in thousands, except percent data)
Disclosure of Financial Risk Management [Line Items]
Funds invested		$ 600		$ 600
Rate increase on funds invested		3		1
Rate decrease on funds invested		$ (3)		$ 1
Bottom of range \| USD
Disclosure of Financial Risk Management [Line Items]
Funds invested percentage	1.79%	1.79%	0%	0%
Rate increase	1.97%	1.97%	0.03%	0.03%
Rate decrease	1.61%	1.61%	0.03%	0.03%
Bottom of range \| (in Australian dollars, in thousands, except percent data)
Disclosure of Financial Risk Management [Line Items]
Funds invested percentage	4.59%	4.59%	1.50%	1.50%
Rate increase	5.05%	5.05%	1.65%	1.65%
Rate decrease	4.13%	4.13%	1.35%	1.35%
Top of range \| USD
Disclosure of Financial Risk Management [Line Items]
Funds invested percentage	1.79%	1.79%	0%	0%
Rate increase	1.97%	1.97%	0.03%	0.03%
Rate decrease	1.61%	1.61%	0.03%	0.03%
Top of range \| (in Australian dollars, in thousands, except percent data)
Disclosure of Financial Risk Management [Line Items]
Funds invested percentage	4.59%	4.59%	1.50%	1.50%
Rate increase	5.05%	5.05%	1.65%	1.65%
Rate decrease	4.13%	4.13%	1.35%	1.35%

Financial Risk Management - S_3

Financial Risk Management - Schedule of Deposits Held which Derive Interest Revenue Together with the Maximum and Minimum Interest Rates Being Earned (Parenthetical) (Details) - Interest Rate Risk	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
USD
Disclosure of Financial Risk Management [Line Items]
Effect on profit from change in interest rate increase or decrease	10%	10%
(in Australian dollars, in thousands, except percent data)
Disclosure of Financial Risk Management [Line Items]
Effect on profit from change in interest rate increase or decrease	10%	10%

Financial Risk Management - Sum

Financial Risk Management - Summary of Borrowing to Price Rate Changes (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022
Disclosure of Financial Risk Management [Line Items]
Current borrowings	$ 5,952	$ 5,017
Non-current borrowings	102,811	91,617
Total borrowings	108,763	96,634
Commodity price risk
Disclosure of Financial Risk Management [Line Items]
Current borrowings	336	372
Non-current borrowings	55,739	47,898
Total borrowings	$ 56,075	$ 48,270
Percent of current borrowings	0%	0%
Percent of non-current borrowings	51%	50%
Percent of total loans	51%	50%

Financial Risk Management - S_4

Financial Risk Management - Summary of Group's Receivables (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Disclosure Of Trade And Other Receivables [Line Items]
Deposits at call	$ 398	$ 413	$ 451
Cash at bank	70,920	60,034	$ 136,430
Other recoverable taxes (Goods and services tax and value-added tax)	202	235
U.S. Tax credits	1,473	1,473
Credit Risk \| Minimum A Rated
Disclosure Of Trade And Other Receivables [Line Items]
Deposits at call	398	413
Cash at bank	70,920	60,033
Receivable from minimum A rated bank deposits (interest)	18	0
Credit Risk \| Non-Rated
Disclosure Of Trade And Other Receivables [Line Items]
Receivable from other parties (non-rated)	2,276	2,382
Credit Risk \| Australian Government
Disclosure Of Trade And Other Receivables [Line Items]
Receivable from the Government (Income Tax)	2,363	5
Receivable from the Australian Government (Foreign Withholding Tax)	400	400
Other recoverable taxes (Goods and services tax and value-added tax)	121	102
Credit Risk \| United States Government
Disclosure Of Trade And Other Receivables [Line Items]
Receivable from the Government (Income Tax)	0	20
Other recoverable taxes (Goods and services tax and value-added tax)	71	0
U.S. Tax credits	1,473	1,475
Minimum A rated bank deposits (held as security)	1,912	1,930
Credit Risk \| Swiss Government
Disclosure Of Trade And Other Receivables [Line Items]
Receivable from the Swiss Government (Value-Added Tax)	3	105
Credit Risk \| SGD
Disclosure Of Trade And Other Receivables [Line Items]
Other recoverable taxes (Goods and services tax and value-added tax)	$ 78	$ 0

Financial Risk Management - S_5

Financial Risk Management - Schedule of Maturity Profile of Anticipated Future Contractual Cash Flows Carrying Value (Details) $ in Thousands	Jun. 30, 2023 USD ($)
Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]
Total contractual cash flows	$ (209,618)
Carrying amount	(137,233)
Within 1 year
Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]
Total contractual cash flows	(35,823)
Between 1-2 years
Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]
Total contractual cash flows	(19,166)
Between 2-5 years
Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]
Total contractual cash flows	(154,629)
Over 5 years
Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]
Total contractual cash flows	0
Borrowings
Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]
Total contractual cash flows	(174,678)
Carrying amount	(108,763)
Borrowings \| Within 1 year
Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]
Total contractual cash flows	(6,668)
Borrowings \| Between 1-2 years
Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]
Total contractual cash flows	(15,639)
Borrowings \| Between 2-5 years
Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]
Total contractual cash flows	(152,371)
Borrowings \| Over 5 years
Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]
Total contractual cash flows	0
Trade payables
Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]
Total contractual cash flows	(20,145)
Carrying amount	(20,145)
Trade payables \| Within 1 year
Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]
Total contractual cash flows	(20,145)
Trade payables \| Between 1-2 years
Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]
Total contractual cash flows	0
Trade payables \| Between 2-5 years
Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]
Total contractual cash flows	0
Trade payables \| Over 5 years
Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]
Total contractual cash flows	0
Lease liabilities
Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]
Total contractual cash flows	(8,237)
Carrying amount	(7,732)
Lease liabilities \| Within 1 year
Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]
Total contractual cash flows	(4,393)
Lease liabilities \| Between 1-2 years
Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]
Total contractual cash flows	(2,592)
Lease liabilities \| Between 2-5 years
Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]
Total contractual cash flows	(1,252)
Lease liabilities \| Over 5 years
Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]
Total contractual cash flows	0
Contingent consideration
Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]
Total contractual cash flows	(6,558)
Carrying amount	(593)
Contingent consideration \| Within 1 year
Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]
Total contractual cash flows	(4,617)
Contingent consideration \| Between 1-2 years
Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]
Total contractual cash flows	(935)
Contingent consideration \| Between 2-5 years
Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]
Total contractual cash flows	(1,006)
Contingent consideration \| Over 5 years
Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]
Total contractual cash flows	$ 0

Interests in other entities - S

Interests in other entities - Summary of Group's Principal Subsidiaries (Details) - Ordinary Shares	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Mesoblast, Inc.
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Equity holding	100%	100%
Mesoblast International Sàrl (includes Mesoblast International Sàrl Singapore Branch)
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Equity holding	100%	100%
Mesoblast Australia Pty Ltd
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Equity holding	100%	100%
Mesoblast UK Ltd
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Equity holding	100%	100%
BeiCell Ltd
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Equity holding	100%	100%

Contingent Assets and Liabili_2

Contingent Assets and Liabilities - Additional Information (Details) - USD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Disclosure Of Contingent Assets And Liabilities [Line Items]
Contingent assets outstanding	$ 0	$ 0
CALHNI \| Top of range
Disclosure Of Contingent Assets And Liabilities [Line Items]
Aggregated milestone payments	$ 2,200,000

Commitments - Additional Inform

Commitments - Additional Information (Details) - USD ($)	Jun. 30, 2023	Jun. 30, 2022
Commitments [Line Items]
Future capital expenditure commitments outstanding	$ 0	$ 0
Non-cancellable purchase commitments related to raw materials, manufacturing agreements and other goods and services	9,100,000
Other purchase commitments	0
Manufacturing Service Agreement
Commitments [Line Items]
Minimum financial commitment reduction amount	12,200,000
Minimum financial commitment reduction amount on lease component	1,100,000
Minimum financial commitment reduction amount on non lease component	11,100,000
Lonza Bioscience Singapore Pte Ltd \| Manufacturing Service Agreement
Commitments [Line Items]
Minimum remaining financial commitment of non-lease component on exercise of option to extend non-cancellable term	16,800,000
Minimum financial commitment of lease component on exercise of option to extend non-cancellable term	$ 3,000,000

Related party transactions - Su

Related party transactions - Summary of Aggregate Compensation made to Directors and other Members of key Management Personnel (Details) - USD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Disclosure of transactions between related parties [line items]
Short-term employee benefits	$ 2,153,181	$ 2,294,897
Long-term employee benefits	11,326	12,206
Post-employment benefits	23,935	31,346
Share based payments	881,342	391,592
Key management personnel compensation	3,069,784	$ 2,730,041
Strategic Advisory Role
Disclosure of transactions between related parties [line items]
Key management personnel compensation	$ 110,383

Share-Based Payments - Addition

Share-Based Payments - Additional Information (Details)			12 Months Ended
Share-Based Payments - Additional Information (Details)	Jul. 01, 2015	Jun. 30, 2015 acquisition	Jun. 30, 2023 Tranche $ / shares shares	Jun. 30, 2022 $ / shares	Jun. 30, 2021 $ / shares	Jun. 30, 2020
Disclosure Of Sharebased Payment Arrangements [Line Items]
Weighted average remaining contractual life of outstanding share options	7 years	5 years
Number of tranches \| acquisition		3
Percentage of premium attached with time based vesting condition options			10%
Percentage of premium attached with performance based vesting condition options			0%
Employee share option plan, maximum number of options available for issuance \| shares			10,000,000
Weighted average remaining contractual life of outstanding share options and loan funded			4 years 1 month 17 days	4 years 1 month 28 days	4 years 5 months 26 days
Number of tranches			3
Option exercise term in connection with cessation of employment			60 days
Modification made to share based payment arrangements				no	no	no
Weighted average share purchase price, granted no. (during the year) \| $ / shares			$ 0.66	$ 0.56	$ 1.42
Dividend yield on shares underlying options			0%
Closing share market price of ordinary share \| $ / shares			$ 1.14	0.61	1.98
Issues Granted Since July 1, 2015
Disclosure Of Sharebased Payment Arrangements [Line Items]
Expiry term of options			7 years
Tranche One
Disclosure Of Sharebased Payment Arrangements [Line Items]
Share options vesting to maximum in time-based conditions			0.3333
Period of vesting requirements for share based payment arrangement			12 months
Tranche vesting term			1 year
Tranche One \| Two or Three Equal Tranches
Disclosure Of Sharebased Payment Arrangements [Line Items]
Share options vesting to maximum in time-based conditions			0.3333
Period of vesting requirements for share based payment arrangement			12 months
Tranche One \| Three or Eight Tranches
Disclosure Of Sharebased Payment Arrangements [Line Items]
Share options vesting to maximum in time-based conditions			0.3333
Period of vesting requirements for share based payment arrangement			12 months
Tranche One \| One, Two, Three or Five Tranches
Disclosure Of Sharebased Payment Arrangements [Line Items]
Share options vesting to maximum in time-based conditions			0.3333
Period of vesting requirements for share based payment arrangement			12 months
Tranche One \| Two, Three, Four or Five Tranches
Disclosure Of Sharebased Payment Arrangements [Line Items]
Share options vesting to maximum in time-based conditions			0.3333
Period of vesting requirements for share based payment arrangement			12 months
Tranche One \| Bottom of range
Disclosure Of Sharebased Payment Arrangements [Line Items]
Number of equal tranches vest on date			1
Tranche Two
Disclosure Of Sharebased Payment Arrangements [Line Items]
Share options vesting to maximum in time-based conditions			0.6667
Period of vesting requirements for share based payment arrangement			24 months
Tranche vesting term			2 years
Tranche Two \| Two or Three Equal Tranches
Disclosure Of Sharebased Payment Arrangements [Line Items]
Share options vesting to maximum in time-based conditions			0.6667
Period of vesting requirements for share based payment arrangement			24 months
Tranche Two \| Three or Eight Tranches
Disclosure Of Sharebased Payment Arrangements [Line Items]
Share options vesting to maximum in time-based conditions			0.6667
Period of vesting requirements for share based payment arrangement			24 months
Tranche Two \| One, Two, Three or Five Tranches
Disclosure Of Sharebased Payment Arrangements [Line Items]
Share options vesting to maximum in time-based conditions			0.6667
Period of vesting requirements for share based payment arrangement			24 months
Tranche Two \| Two, Three, Four or Five Tranches
Disclosure Of Sharebased Payment Arrangements [Line Items]
Share options vesting to maximum in time-based conditions			0.6667
Period of vesting requirements for share based payment arrangement			24 months
Tranche Two \| Bottom of range
Disclosure Of Sharebased Payment Arrangements [Line Items]
Number of equal tranches vest on date			2
Tranche Three
Disclosure Of Sharebased Payment Arrangements [Line Items]
Period of vesting requirements for share based payment arrangement			36 months
Tranche vesting term			3 years
Tranche Three \| Two or Three Equal Tranches
Disclosure Of Sharebased Payment Arrangements [Line Items]
Period of vesting requirements for share based payment arrangement			36 months
Tranche Three \| Three or Eight Tranches
Disclosure Of Sharebased Payment Arrangements [Line Items]
Period of vesting requirements for share based payment arrangement			36 months
Tranche Three \| One, Two, Three or Five Tranches
Disclosure Of Sharebased Payment Arrangements [Line Items]
Period of vesting requirements for share based payment arrangement			36 months
Tranche Three \| Two, Three, Four or Five Tranches
Disclosure Of Sharebased Payment Arrangements [Line Items]
Period of vesting requirements for share based payment arrangement			36 months
Tranche Three \| Bottom of range
Disclosure Of Sharebased Payment Arrangements [Line Items]
Number of equal tranches vest on date			3
Series 36(a&b) \| Bottom of range
Disclosure Of Sharebased Payment Arrangements [Line Items]
Number of equal tranches vest on date			2
Series 36(a&b) \| Top of range
Disclosure Of Sharebased Payment Arrangements [Line Items]
Number of equal tranches vest on date			3
49a, 49b, 50, 50a, 53, 64b, 64c, 64d, 64e, 71, 74a, 74b, 74c \| Bottom of range
Disclosure Of Sharebased Payment Arrangements [Line Items]
Number of equal tranches prior to vesting			2
49a, 49b, 50, 50a, 53, 64b, 64c, 64d, 64e, 71, 74a, 74b, 74c \| Top of range
Disclosure Of Sharebased Payment Arrangements [Line Items]
Number of equal tranches prior to vesting			3
Series 38a, 40a, 57 & 66
Disclosure Of Sharebased Payment Arrangements [Line Items]
Number of equal tranches vest on date			1
Series 39a \| Bottom of range
Disclosure Of Sharebased Payment Arrangements [Line Items]
Number of equal tranches vest on date			1
Series 39a \| Top of range
Disclosure Of Sharebased Payment Arrangements [Line Items]
Number of equal tranches vest on date			2
Series 51 & 75
Disclosure Of Sharebased Payment Arrangements [Line Items]
Number of equal tranches vest on date			2
Series 55
Disclosure Of Sharebased Payment Arrangements [Line Items]
Number of equal tranches vest on date			5
Series 63a \| Bottom of range
Disclosure Of Sharebased Payment Arrangements [Line Items]
Number of equal tranches vest on date			3
Series 63a \| Top of range
Disclosure Of Sharebased Payment Arrangements [Line Items]
Number of equal tranches vest on date			8
Tranche Five \| Top of range
Disclosure Of Sharebased Payment Arrangements [Line Items]
Number of equal tranches vest on date			5
(in Australian dollars, in thousands, except percent data)
Disclosure Of Sharebased Payment Arrangements [Line Items]
Weighted average exercise price of share options exercised in share-based payment arrangement \| $ / shares			$ 0	1.82	4.42
Weighted average share purchase price, granted no. (during the year) \| $ / shares			$ 1.08	$ 1.77	$ 3.56

Share-Based Payments - Reconcil

Share-Based Payments - Reconciliation of Outstanding Share Based Payments (Details)		12 Months Ended
	Mar. 18, 2021 $ / shares	Jun. 30, 2023 shares $ / shares	Jun. 30, 2022 shares $ / shares	Jun. 30, 2021 shares $ / shares	Jun. 30, 2020 shares $ / shares	Jun. 30, 2021 shares $ / shares
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Opening Balance		49,650,468
Granted No. (during the year)		16,974,500
Exercise of share options, (in shares)		0
Lapsed/Forfeited* No. (during the year)		(9,190,647)
Closing Balance		57,434,321	49,650,468
Vested and exercisable No (end of year)		26,464,507
Share Price (in dollars per share) \| $ / shares	$ 2.41
Weighted average share purchase price, granted no. (during the year) \| $ / shares		$ 0.66	$ 0.56	$ 1.42
Series 61
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares				2.51
Series 63
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares				4.02
Series 63a
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares				3.65
Series 64
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares				3.75
Series 64a
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares				3.41
Series 64b
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares				3.41
Series 64c
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares				3.41
Series 64d
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares				3.41
Series 64e
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares				3.41
Series 65
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares				5.76
Series 66
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares				4.78
Series 67
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares				3.84
Series 68
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares				3.60
Series 69
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares				3.60
Series 71
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares				2.67
Series 73
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares				$ 0
Series 72
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares			2.28
Series 74
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares			1.95
Series 74a
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares			1.77
Series 74b
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares			1.77
Series 74c
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares			1.77
Series 75
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares			$ 1.42
Series 76
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		1.03
Series 77
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		1.01
Series 78
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		0.85
Series 79
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		1.13
Series79 A
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		1.03
Series 79 B
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		1.13
Series 79 C
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		1.03
Series 79 D
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		1.03
Series 80
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		0.93
Series 81
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		4.60
Series 82
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		1.12
Series 83
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 1.03
(in Australian dollars, in thousands, except percent data)
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Opening Balance		49,650,468	45,333,216	38,911,491
Granted No. (during the year)			10,723,000	18,193,406
Exercise of share options, (in shares)			(229,080)	(7,078,017)
Lapsed/Forfeited* No. (during the year)			(6,176,668)	(4,693,664)
Closing Balance			49,650,468	45,333,216	38,911,491
Vested and exercisable No (end of year)			23,084,908	18,389,623		18,389,623
Share Price (in dollars per share) \| $ / shares		$ 1.85	$ 2.21	$ 2.42	$ 1.86
Weighted average share purchase price, granted no. (during the year) \| $ / shares		1.08	1.77	3.56
Weighted average share purchase price, Exercised No. (during the year) \| $ / shares		0	1.25	2.06
Weighted average share purchase price, Lapsed/Forfeited* No. (during the year) \| $ / shares		2.39	2.99	2.76
Weighted average share purchase price, Vested and exercisable No (end of year) \| $ / shares		2.12	2.06	$ 2.15
(in Australian dollars, in thousands, except percent data) \| Series 32
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares			$ 4.20
Opening Balance			1,753,334
Lapsed/Forfeited* No. (during the year)			(1,753,334)
Closing Balance				1,753,334
(in Australian dollars, in thousands, except percent data) \| Series 33
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares			$ 4.05	$ 4.05
Opening Balance			75,000	75,000
Lapsed/Forfeited* No. (during the year)			(75,000)
Closing Balance				75,000	75,000
Vested and exercisable No (end of year)				75,000		75,000
(in Australian dollars, in thousands, except percent data) \| Series 34
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 2.80	$ 2.80	$ 2.80
Opening Balance		1,678,979	1,858,979	2,638,334
Exercise of share options, (in shares)				(769,355)
Lapsed/Forfeited* No. (during the year)		(1,678,979)	(180,000)	(10,000)
Closing Balance			1,678,979	1,858,979	2,638,334
Vested and exercisable No (end of year)			1,678,979	1,858,979		1,858,979
(in Australian dollars, in thousands, except percent data) \| Series 34a
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares				$ 2.74
Opening Balance				200,000
Exercise of share options, (in shares)				(116,666)
Lapsed/Forfeited* No. (during the year)				(83,334)
Closing Balance					200,000
(in Australian dollars, in thousands, except percent data) \| Series 34b
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 2.80	$ 2.80	$ 2.80
Opening Balance		200,000	200,000	200,000
Lapsed/Forfeited* No. (during the year)		(200,000)
Closing Balance			200,000	200,000	200,000
Vested and exercisable No (end of year)			200,000	200,000		200,000
(in Australian dollars, in thousands, except percent data) \| Series 35
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares				$ 2.20
Opening Balance				900,000
Exercise of share options, (in shares)				(900,000)
Closing Balance					900,000
(in Australian dollars, in thousands, except percent data) \| Series 35a
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 2.86	$ 2.86	$ 2.86
Opening Balance		1,500,000	1,500,000
Granted No. (during the year)				1,500,000
Closing Balance		1,500,000	1,500,000	1,500,000
Vested and exercisable No (end of year)		1,500,000	1,500,000	1,500,000		1,500,000
(in Australian dollars, in thousands, except percent data) \| Series 36
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 1.31	$ 1.31	$ 1.31
Opening Balance		533,000	623,000	923,000
Exercise of share options, (in shares)			(50,000)	(300,000)
Lapsed/Forfeited* No. (during the year)			(40,000)
Closing Balance		533,000	533,000	623,000	923,000
Vested and exercisable No (end of year)		533,000	533,000	623,000		623,000
(in Australian dollars, in thousands, except percent data) \| Series 36a
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 1.19	$ 1.19	$ 1.19
Opening Balance		1,950,730	1,950,730	2,519,064
Exercise of share options, (in shares)				(426,668)
Lapsed/Forfeited* No. (during the year)				(141,666)
Closing Balance		1,950,730	1,950,730	1,950,730	2,519,064
Vested and exercisable No (end of year)		1,809,064	1,809,064	1,809,064		1,809,064
(in Australian dollars, in thousands, except percent data) \| Series 36b
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares				$ 1.65
Opening Balance				300,000
Exercise of share options, (in shares)				(300,000)
Closing Balance					300,000
(in Australian dollars, in thousands, except percent data) \| Series 37
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares				$ 2.23
Opening Balance				150,000
Exercise of share options, (in shares)				(150,000)
Closing Balance					150,000
(in Australian dollars, in thousands, except percent data) \| Series 38
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 1.54	$ 1.54	$ 1.54
Opening Balance		50,000	50,000	66,666
Exercise of share options, (in shares)				(16,666)
Lapsed/Forfeited* No. (during the year)		(150,000)
Closing Balance		50,000	50,000	50,000	66,666
Vested and exercisable No (end of year)		50,000	50,000	50,000		50,000
(in Australian dollars, in thousands, except percent data) \| Series 38a
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 1.40	$ 1.40	$ 1.40
Opening Balance		150,000	150,000	150,000
Closing Balance			150,000	150,000	150,000
Vested and exercisable No (end of year)			150,000	150,000		150,000
(in Australian dollars, in thousands, except percent data) \| Series 39
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 1.94	$ 1.94	$ 1.94
Opening Balance		975,000	1,090,000	1,655,000
Exercise of share options, (in shares)				(565,000)
Lapsed/Forfeited* No. (during the year)			(115,000)
Closing Balance		975,000	975,000	1,090,000	1,655,000
Vested and exercisable No (end of year)		975,000	975,000	1,090,000		1,090,000
(in Australian dollars, in thousands, except percent data) \| Series 39a
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 1.76	$ 1.76	$ 1.76
Opening Balance		902,425	902,425	1,302,425
Exercise of share options, (in shares)				(400,000)
Closing Balance		902,425	902,425	902,425	1,302,425
Vested and exercisable No (end of year)		902,425	902,425	902,425		902,425
(in Australian dollars, in thousands, except percent data) \| Series 40
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 1.41	$ 1.41	$ 1.41
Opening Balance		750,000	750,000	750,000
Closing Balance		750,000	750,000	750,000	750,000
Vested and exercisable No (end of year)		750,000	750,000	750,000		750,000
(in Australian dollars, in thousands, except percent data) \| Series 40a
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 1.28	$ 1.28	$ 1.28
Opening Balance		750,000	750,000	750,000
Closing Balance		750,000	750,000	750,000	750,000
(in Australian dollars, in thousands, except percent data) \| Series 41
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 1.52	$ 1.52	$ 1.52
Opening Balance		200,000	200,000	200,000
Closing Balance		200,000	200,000	200,000	200,000
Vested and exercisable No (end of year)		200,000	200,000	200,000		200,000
(in Australian dollars, in thousands, except percent data) \| Series 42
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 1.56	$ 1.56	$ 1.56
Opening Balance		200,000	200,000	200,000
Closing Balance		200,000	200,000	200,000	200,000
Vested and exercisable No (end of year)		200,000	200,000	133,334		133,334
(in Australian dollars, in thousands, except percent data) \| Series 43
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 1.87	$ 1.87	$ 1.87
Opening Balance		3,793,332	4,201,666	5,398,334
Exercise of share options, (in shares)			(20,000)	(944,998)
Lapsed/Forfeited* No. (during the year)		(660,000)	(388,334)	(251,670)
Closing Balance		3,133,332	3,793,332	4,201,666	5,398,334
Vested and exercisable No (end of year)		3,133,332	3,793,332	2,526,653		2,526,653
(in Australian dollars, in thousands, except percent data) \| Series 43b
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 1.87	$ 1.87	$ 1.87
Opening Balance		350,000	350,000	350,000
Closing Balance		350,000	350,000	350,000	350,000
Vested and exercisable No (end of year)		350,000	350,000	233,334		233,334
(in Australian dollars, in thousands, except percent data) \| Series 44
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares			$ 1.72	$ 1.72
Opening Balance			150,000	300,000
Exercise of share options, (in shares)				(150,000)
Lapsed/Forfeited* No. (during the year)			(150,000)
Closing Balance				150,000	300,000
Vested and exercisable No (end of year)				50,000		50,000
(in Australian dollars, in thousands, except percent data) \| Series 45
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 1.33	$ 1.33	$ 1.33
Opening Balance		590,000	590,000	590,000
Closing Balance		590,000	590,000	590,000	590,000
Vested and exercisable No (end of year)		590,000	590,000	393,332		393,332
(in Australian dollars, in thousands, except percent data) \| Series 46
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 1.45	$ 1.45	$ 1.45
Opening Balance		3,333	3,333	5,000
Exercise of share options, (in shares)				(1,667)
Closing Balance		3,333	3,333	3,333	5,000
Vested and exercisable No (end of year)		3,333	3,333	1,667		1,667
(in Australian dollars, in thousands, except percent data) \| Series 47
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 1.45	$ 1.45	$ 1.45
Opening Balance		150,000	150,000	150,000
Closing Balance		150,000	150,000	150,000	150,000
Vested and exercisable No (end of year)		150,000	150,000	150,000		150,000
(in Australian dollars, in thousands, except percent data) \| Series 48
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 1.48	$ 1.48	$ 1.48
Opening Balance		300,000	300,000	300,000
Closing Balance		300,000	300,000	300,000	300,000
Vested and exercisable No (end of year)		300,000	300,000	200,000		200,000
(in Australian dollars, in thousands, except percent data) \| Series 49
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 1.62	$ 1.62	$ 1.62
Opening Balance		3,098,670	3,638,671	4,690,000
Exercise of share options, (in shares)			(113,334)	(523,661)
Lapsed/Forfeited* No. (during the year)		(66,667)	(277,999)	(6,666)
Closing Balance		3,018,669	3,098,670	3,638,671	4,690,000
Vested and exercisable No (end of year)		3,018,669	1,940,654	1,030,310		1,030,310
(in Australian dollars, in thousands, except percent data) \| Series 49
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 1.62	$ 1.62	$ 1.62
Lapsed/Forfeited* No. (during the year)		(13,334)	(148,668)	(521,002)
(in Australian dollars, in thousands, except percent data) \| Series 49a
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 1.47	$ 1.47	$ 1.47
Opening Balance		3,499,998	3,999,998	5,500,000
Exercise of share options, (in shares)				(800,002)
Lapsed/Forfeited* No. (during the year)		(466,666)	(333,334)	(700,000)
Closing Balance		2,833,332	3,499,998	3,999,998	5,500,000
Vested and exercisable No (end of year)		1,883,332	1,316,665	400,001		400,001
(in Australian dollars, in thousands, except percent data) \| Series 49a
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 1.47	$ 1.47
Lapsed/Forfeited* No. (during the year)		(200,000)	(166,666)
(in Australian dollars, in thousands, except percent data) \| Series 49b
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 1.47	$ 1.47	$ 1.47
Opening Balance		1,346,667	1,346,667	1,346,667
Closing Balance		1,346,667	1,346,667	1,346,667	1,346,667
Vested and exercisable No (end of year)		673,334	673,334	448,889		448,889
(in Australian dollars, in thousands, except percent data) \| Series 49c
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 1.47	$ 1.47	$ 1.47
Opening Balance		538,667	538,667	538,667
Closing Balance		538,667	538,667	538,667	538,667
Vested and exercisable No (end of year)		538,667	359,112	179,556		179,556
(in Australian dollars, in thousands, except percent data) \| Series 50
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 1.47	$ 1.47	$ 1.47
Opening Balance		700,000	700,000	700,000
Closing Balance		700,000	700,000	700,000	700,000
Vested and exercisable No (end of year)		175,000
(in Australian dollars, in thousands, except percent data) \| Series 50a
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 1.47	$ 1.47	$ 1.47
Opening Balance		400,000	400,000	400,000
Lapsed/Forfeited* No. (during the year)		(400,000)
Closing Balance			400,000	400,000	400,000
(in Australian dollars, in thousands, except percent data) \| Series 51
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares			$ 1.47	$ 1.47
Opening Balance			150,000	150,000
Lapsed/Forfeited* No. (during the year)			(150,000)
Closing Balance				150,000	150,000
(in Australian dollars, in thousands, except percent data) \| Series 52
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 1.62	$ 1.62	$ 1.62
Opening Balance		400,000	400,000	400,000
Lapsed/Forfeited* No. (during the year)		(400,000)
Closing Balance			400,000	400,000	400,000
Vested and exercisable No (end of year)			266,666	133,333		133,333
(in Australian dollars, in thousands, except percent data) \| Series 53
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 1.47	$ 1.47	$ 1.47
Opening Balance		800,000	800,000	800,000
Lapsed/Forfeited* No. (during the year)		(800,000)
Closing Balance			800,000	800,000	800,000
Vested and exercisable No (end of year)			533,334	266,667		266,667
(in Australian dollars, in thousands, except percent data) \| Series 54
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 1.98	$ 1.98	$ 1.98
Opening Balance		153,334	295,000	845,000
Exercise of share options, (in shares)				(98,334)
Lapsed/Forfeited* No. (during the year)		(133,334)	(25,000)	(11,667)
Closing Balance		20,000	153,334	295,000	845,000
Vested and exercisable No (end of year)		20,000	146,668	98,334		98,334
(in Australian dollars, in thousands, except percent data) \| Series 54
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares			$ 1.98	$ 1.98
Opening Balance
Lapsed/Forfeited* No. (during the year)			(116,666)	(439,999)
Closing Balance
Vested and exercisable No (end of year)
(in Australian dollars, in thousands, except percent data) \| Series 55
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 1.48	$ 1.48	$ 1.48
Opening Balance		350,000	350,000	450,000
Exercise of share options, (in shares)				(100,000)
Closing Balance		350,000	350,000	350,000	450,000
Vested and exercisable No (end of year)		300,000	300,000	300,000		300,000
(in Australian dollars, in thousands, except percent data) \| Series 56
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 1.83	$ 1.83	$ 1.83
Opening Balance		200,000	200,000	200,000
Exercise of share options, (in shares)				0
Closing Balance		200,000	200,000	200,000	200,000
Vested and exercisable No (end of year)		200,000	133,332	66,666		66,666
(in Australian dollars, in thousands, except percent data) \| Series 57
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 1.80	$ 1.80	$ 1.80
Opening Balance		100,000	100,000	100,000
Closing Balance		100,000	100,000	100,000	100,000
Vested and exercisable No (end of year)		100,000	100,000	100,000		100,000
(in Australian dollars, in thousands, except percent data) \| Series 58
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 1.98	$ 1.98	$ 1.98
Opening Balance		450,000	450,000	450,000
Lapsed/Forfeited* No. (during the year)		(200,000)
Closing Balance		150,000	450,000	450,000	450,000
Vested and exercisable No (end of year)		150,000	300,000	150,000		150,000
(in Australian dollars, in thousands, except percent data) \| Series 58
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 1.98
Lapsed/Forfeited* No. (during the year)		(100,000)
(in Australian dollars, in thousands, except percent data) \| Series 59
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 3.38	$ 3.38	$ 3.38
Opening Balance		10,000	10,000
Granted No. (during the year)				65,000
Lapsed/Forfeited* No. (during the year)				(55,000)
Closing Balance		10,000	10,000	10,000
Vested and exercisable No (end of year)		10,000	10,000	3,333		3,333
(in Australian dollars, in thousands, except percent data) \| Series 60
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares				$ 2.51
Granted No. (during the year)				57,660
Lapsed/Forfeited* No. (during the year)				(57,660)
(in Australian dollars, in thousands, except percent data) \| Series 61
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares			$ 2.51	$ 2.51
Opening Balance			50,000
Granted No. (during the year)				250,000
Lapsed/Forfeited* No. (during the year)			(16,666)	(200,000)
Closing Balance				50,000
Vested and exercisable No (end of year)				16,666		16,666
(in Australian dollars, in thousands, except percent data) \| Series 61
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares			$ 2.51
Lapsed/Forfeited* No. (during the year)			(33,334)
(in Australian dollars, in thousands, except percent data) \| Series 63
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 4.02	$ 4.02	$ 4.02
Opening Balance		1,200,000	1,200,000
Granted No. (during the year)				1,200,000
Closing Balance		1,200,000	1,200,000	1,200,000
Vested and exercisable No (end of year)		1,200,000	800,000	400,000		400,000
(in Australian dollars, in thousands, except percent data) \| Series 63a
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 3.65	$ 3.65	$ 3.65
Opening Balance		2,400,000	2,400,000
Granted No. (during the year)				2,400,000
Lapsed/Forfeited* No. (during the year)		(800,000)
Closing Balance		1,200,000	2,400,000	2,400,000
Vested and exercisable No (end of year)		200,000	400,000
(in Australian dollars, in thousands, except percent data) \| Series 63 A
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 3.65
Lapsed/Forfeited* No. (during the year)		(400,000)
(in Australian dollars, in thousands, except percent data) \| Series 64
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 3.75	$ 3.75	$ 3.75
Opening Balance		3,498,333	4,280,000
Granted No. (during the year)				5,970,000
Lapsed/Forfeited* No. (during the year)		(176,668)	(225,003)	(1,690,000)
Closing Balance		3,253,333	3,498,333	4,280,000
Vested and exercisable No (end of year)		2,160,009	1,201,676
(in Australian dollars, in thousands, except percent data) \| Series 64
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 3.75	$ 3.75	$ 3.41
Opening Balance			300,000
Granted No. (during the year)				300,000
Lapsed/Forfeited* No. (during the year)		(68,332)	(556,664)
Closing Balance				300,000
(in Australian dollars, in thousands, except percent data) \| Series 64a
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 3.41	$ 3.41	$ 3.41
Opening Balance		2,700,000	3,050,000
Granted No. (during the year)				3,400,000
Lapsed/Forfeited* No. (during the year)		(965,000)	(350,000)	(350,000)
Closing Balance		1,735,000	2,700,000	3,050,000
Vested and exercisable No (end of year)		478,334	133,334
(in Australian dollars, in thousands, except percent data) \| Series 64b
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares			$ 3.41	$ 3.41
Opening Balance			325,000
Granted No. (during the year)				325,000
Lapsed/Forfeited* No. (during the year)			(325,000)
Closing Balance				325,000
(in Australian dollars, in thousands, except percent data) \| Series 64c
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 3.41	$ 3.41	$ 3.41
Opening Balance		350,000	350,000
Granted No. (during the year)				350,000
Closing Balance		350,000	350,000	350,000
Vested and exercisable No (end of year)		116,666
(in Australian dollars, in thousands, except percent data) \| Series 64d
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 3.41	$ 3.41
Opening Balance		300,000	300,000
Closing Balance		300,000	300,000	300,000
Vested and exercisable No (end of year)		100,000
(in Australian dollars, in thousands, except percent data) \| Series 64e
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 3.41	$ 3.41	$ 3.41
Opening Balance		1,200,000	1,200,000
Granted No. (during the year)				1,200,000
Closing Balance		1,200,000	1,200,000	1,200,000
Vested and exercisable No (end of year)		720,000
(in Australian dollars, in thousands, except percent data) \| Series 65
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 5.76	$ 5.76	$ 5.76
Opening Balance		5,000	5,000
Granted No. (during the year)				140,000
Lapsed/Forfeited* No. (during the year)		(3,334)		(135,000)
Closing Balance		0	5,000	5,000
Vested and exercisable No (end of year)			1,667
(in Australian dollars, in thousands, except percent data) \| Series 65
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 5.76
Lapsed/Forfeited* No. (during the year)		(1,666)
(in Australian dollars, in thousands, except percent data) \| Series 66
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 4.78	$ 4.78	$ 4.78
Opening Balance		200,000	200,000
Granted No. (during the year)				200,000
Closing Balance		200,000	200,000	200,000
Vested and exercisable No (end of year)		100,000	100,000
(in Australian dollars, in thousands, except percent data) \| Series 67
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Lapsed/Forfeited* No. (during the year)			(133,333)
(in Australian dollars, in thousands, except percent data) \| Series 67
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares			$ 3.84	$ 3.84
Opening Balance			200,000
Granted No. (during the year)				240,000
Lapsed/Forfeited* No. (during the year)			(66,667)	(40,000)
Closing Balance				200,000
(in Australian dollars, in thousands, except percent data) \| Series 68
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 3.60	$ 3.60	$ 3.60
Opening Balance		200,000	200,000
Granted No. (during the year)				200,000
Closing Balance		200,000	200,000	200,000
Vested and exercisable No (end of year)		133,333	66,666
(in Australian dollars, in thousands, except percent data) \| Series 69
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 3.60	$ 3.60	$ 3.60
Opening Balance		100,000	100,000
Granted No. (during the year)				100,000
Closing Balance		100,000	100,000	100,000
Vested and exercisable No (end of year)		100,000	100,000	100,000		100,000
(in Australian dollars, in thousands, except percent data) \| Series 71
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 2.67	$ 2.67	$ 2.67
Opening Balance		250,000	250,000
Granted No. (during the year)				250,000
Closing Balance		250,000	250,000	250,000
Vested and exercisable No (end of year)		166,667	0
(in Australian dollars, in thousands, except percent data) \| Series 73
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares			$ 0	$ 0
Opening Balance			45,746
Granted No. (during the year)				45,746
Exercise of share options, (in shares)			(45,746)
Closing Balance				45,746
Vested and exercisable No (end of year)				45,746		45,746
(in Australian dollars, in thousands, except percent data) \| Series 72
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 2.28	$ 2.28
Opening Balance		200,000
Granted No. (during the year)			200,000
Closing Balance		200,000	200,000
Vested and exercisable No (end of year)		133,334	66,667
(in Australian dollars, in thousands, except percent data) \| Series 74
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 1.77	$ 1.77
Opening Balance		3,423,000
Granted No. (during the year)			3,973,000
Lapsed/Forfeited* No. (during the year)		(50,001)	(550,000)
Closing Balance		3,186,333	3,423,000
Vested and exercisable No (end of year)		1,051,007
(in Australian dollars, in thousands, except percent data) \| Series 74a
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 1.77	$ 1.77
Opening Balance		4,150,000
Granted No. (during the year)			4,150,000
Lapsed/Forfeited* No. (during the year)		(300,000)
Closing Balance		3,850,000	4,150,000
Vested and exercisable No (end of year)		923,334
(in Australian dollars, in thousands, except percent data) \| Series 74b
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 1.77	$ 1.77
Opening Balance		1,550,000
Granted No. (during the year)			1,550,000
Closing Balance		1,550,000	1,550,000
(in Australian dollars, in thousands, except percent data) \| Series 74c
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 1.77	$ 1.77
Opening Balance		650,000
Granted No. (during the year)			650,000
Lapsed/Forfeited* No. (during the year)		(650,000)
Closing Balance			650,000
(in Australian dollars, in thousands, except percent data) \| Series 75
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 1.42	$ 1.42
Opening Balance		200,000
Granted No. (during the year)			200,000
Closing Balance		200,000	200,000
Vested and exercisable No (end of year)		100,000
(in Australian dollars, in thousands, except percent data) \| Series 74
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 1.77
Lapsed/Forfeited* No. (during the year)		(186,666)
(in Australian dollars, in thousands, except percent data) \| Series 76
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 1.03
Granted No. (during the year)		1,250,000
Closing Balance		1,250,000
(in Australian dollars, in thousands, except percent data) \| Series 77
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 1.01
Granted No. (during the year)		200,000
Closing Balance		200,000
Vested and exercisable No (end of year)		66,667
(in Australian dollars, in thousands, except percent data) \| Series 78
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 0.85
Granted No. (during the year)		200,000
Closing Balance		200,000
(in Australian dollars, in thousands, except percent data) \| Series 79
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 1.13
Granted No. (during the year)		5,844,500
Lapsed/Forfeited* No. (during the year)		(90,000)
Closing Balance		5,754,500
(in Australian dollars, in thousands, except percent data) \| Series79 A
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 1.03
Granted No. (during the year)		4,350,000
Closing Balance		4,350,000
(in Australian dollars, in thousands, except percent data) \| Series 79 B
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 1.13
Granted No. (during the year)		225,000
Closing Balance		225,000
(in Australian dollars, in thousands, except percent data) \| Series 79 C
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 1.03
Granted No. (during the year)		3,225,000
Closing Balance		3,225,000
(in Australian dollars, in thousands, except percent data) \| Series 79 D
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 1.03
Granted No. (during the year)		1,200,000
Closing Balance		1,200,000
(in Australian dollars, in thousands, except percent data) \| Series 80
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 0.93
Granted No. (during the year)		100,000
Closing Balance		100,000
Vested and exercisable No (end of year)		100,000
(in Australian dollars, in thousands, except percent data) \| Series 81
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 4.60
Granted No. (during the year)		100,000
Closing Balance		100,000
Vested and exercisable No (end of year)		100,000
(in Australian dollars, in thousands, except percent data) \| Series 82
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 1.12
Granted No. (during the year)		100,000
Closing Balance		100,000
(in Australian dollars, in thousands, except percent data) \| Series 83
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares		$ 1.03
Granted No. (during the year)		180,000
Lapsed/Forfeited* No. (during the year)		(30,000)
Closing Balance		150,000
USD \| Series 32
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share) \| $ / shares						$ 4.20
Opening Balance			1,753,334	2,268,334
Exercise of share options, (in shares)				(515,000)
Closing Balance				1,753,334	2,268,334
Vested and exercisable No (end of year)				1,753,334		1,753,334

Share-Based Payments - Summary

Share-Based Payments - Summary of Valuations of Options Approved and Granted (Details) - $ / shares		12 Months Ended
	Mar. 18, 2021	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Expected Volatility	66.88%
Dividend Yield	0%
Risk Free Interest Rate	1.24%
Series 76
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share)		$ 1.03
Share price at acceptance date		$ 0.99
Expected Volatility		65.37%
Expected life after factoring		6 years 3 months 18 days
Dividend Yield		0%
Risk Free Interest Rate		3.38%
Series 77
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share)		$ 1.01
Share price at acceptance date		$ 0.99
Expected Volatility		65.37%
Expected life after factoring		5 years 10 months 24 days
Dividend Yield		0%
Risk Free Interest Rate		3.38%
Series 78
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share)		$ 0.85
Share price at acceptance date		$ 0.99
Expected Volatility		65.37%
Expected life after factoring		6 years 1 month 6 days
Dividend Yield		0%
Risk Free Interest Rate		3.38%
Series 79
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share)		$ 1.13
Share price at acceptance date		$ 1.04
Expected Volatility		65.43%
Expected life after factoring		6 years 2 months 12 days
Dividend Yield		0%
Risk Free Interest Rate		3.11%
Series79 A
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share)		$ 1.03
Share price at acceptance date		$ 1.18
Expected Volatility		65.04%
Expected life after factoring		5 years 9 months 18 days
Dividend Yield		0%
Risk Free Interest Rate		3.88%
Series 79 B
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share)		$ 1.13
Share price at acceptance date		$ 0.97
Expected Volatility		65.29%
Expected life after factoring		6 years
Dividend Yield		0%
Risk Free Interest Rate		2.99%
Series 79 C
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share)		$ 1.03
Share price at acceptance date		$ 0.99
Expected Volatility		65.37%
Expected life after factoring		6 years 3 months 18 days
Dividend Yield		0%
Risk Free Interest Rate		3.38%
Series 79 D
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share)		$ 1.03
Share price at acceptance date		$ 1.15
Expected Volatility		64.98%
Expected life after factoring		5 years 8 months 12 days
Dividend Yield		0%
Risk Free Interest Rate		4.19%
Series 80
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share)		$ 0.93
Share price at acceptance date		$ 0.95
Expected Volatility		65.35%
Expected life after factoring		6 years 1 month 6 days
Dividend Yield		0%
Risk Free Interest Rate		3.35%
Series 81
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share)		$ 4.60
Share price at acceptance date		$ 0.95
Expected Volatility		65.35%
Expected life after factoring		4 years 7 months 6 days
Dividend Yield		0%
Risk Free Interest Rate		3.35%
Series 82
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share)		$ 1.12
Share price at acceptance date		$ 0.89
Expected Volatility		65.31%
Expected life after factoring		6 years 3 months 18 days
Dividend Yield		0%
Risk Free Interest Rate		3.70%
Series 83
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share)		$ 1.03
Share price at acceptance date		$ 0.97
Expected Volatility		65.17%
Expected life after factoring		6 years 4 months 24 days
Dividend Yield		0%
Risk Free Interest Rate		2.90%
Series 72
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share)			$ 2.28
Share price at acceptance date			$ 1.94
Expected Volatility			66.62%
Expected life after factoring			6 years 3 months 18 days
Dividend Yield			0%
Risk Free Interest Rate			0.69%
Series 74
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share)			$ 1.95
Share price at acceptance date			$ 1.69
Expected Volatility			65.85%
Expected life after factoring			6 years 2 months 12 days
Dividend Yield			0%
Risk Free Interest Rate			1.31%
Series 74a
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share)			$ 1.77
Share price at acceptance date			$ 0.93
Expected Volatility			65.41%
Expected life after factoring			5 years 3 months 18 days
Dividend Yield			0%
Risk Free Interest Rate			3.55%
Series 74b
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share)			$ 1.77
Share price at acceptance date			$ 0.93
Expected Volatility			65.41%
Expected life after factoring			5 years 3 months 18 days
Dividend Yield			0%
Risk Free Interest Rate			3.55%
Series 74c
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share)			$ 1.77
Share price at acceptance date			$ 1.16
Expected Volatility			65.89%
Expected life after factoring			5 years 10 months 24 days
Dividend Yield			0%
Risk Free Interest Rate			1.91%
Series 75
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share)			$ 1.42
Share price at acceptance date			$ 1.21
Expected Volatility			65.98%
Expected life after factoring			6 years 1 month 6 days
Dividend Yield			0%
Risk Free Interest Rate			2.18%
Series 61
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share)				$ 2.51
Share price at acceptance date				$ 3.60
Expected Volatility				60.95%
Expected life after factoring				6 years 1 month 6 days
Dividend Yield				0%
Risk Free Interest Rate				0.44%
Series 63
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share)				$ 4.02
Share price at acceptance date				$ 2.21
Expected Volatility				66.74%
Expected life after factoring				5 years 6 months
Dividend Yield				0%
Risk Free Interest Rate				0.65%
Series 63a
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share)				$ 3.65
Share price at acceptance date				$ 2.03
Expected Volatility				66.45%
Expected life after factoring				5 years 3 months 18 days
Dividend Yield				0%
Risk Free Interest Rate				0.72%
Series 64
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share)				$ 3.75
Share price at acceptance date				$ 3.60
Expected Volatility				60.95%
Expected life after factoring				6 years 3 months 18 days
Dividend Yield				0%
Risk Free Interest Rate				0.44%
Series 64a
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share)				$ 3.41
Share price at acceptance date				$ 2.03
Expected Volatility				66.45%
Expected life after factoring				5 years 6 months
Dividend Yield				0%
Risk Free Interest Rate				0.72%
Series 64b
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share)				$ 3.41
Share price at acceptance date				$ 2.09
Expected Volatility				66.48%
Expected life after factoring				5 years 6 months
Dividend Yield				0%
Risk Free Interest Rate				0.77%
Series 64c
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share)				$ 3.41
Share price at acceptance date				$ 4.12
Expected Volatility				65.36%
Expected life after factoring				6 years
Dividend Yield				0%
Risk Free Interest Rate				0.30%
Series 64d
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share)				$ 3.41
Share price at acceptance date				$ 0.65
Expected Volatility				65.55%
Expected life after factoring				4 years 7 months 6 days
Dividend Yield				0%
Risk Free Interest Rate				3.36%
Series 64e
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share)				$ 3.41
Share price at acceptance date				$ 2.03
Expected Volatility				66.45%
Expected life after factoring				5 years 6 months
Dividend Yield				0%
Risk Free Interest Rate				0.72%
Series 65
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share)				$ 5.76
Share price at acceptance date				$ 5.02
Expected Volatility				63.16%
Expected life after factoring				6 years 3 months 18 days
Dividend Yield				0%
Risk Free Interest Rate				0.34%
Series 66
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share)				$ 4.78
Share price at acceptance date				$ 3.24
Expected Volatility				65.17%
Expected life after factoring				6 years 3 months 18 days
Dividend Yield				0%
Risk Free Interest Rate				0.27%
Series 67
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share)				$ 3.84
Share price at acceptance date				$ 3.22
Expected Volatility				65.06%
Expected life after factoring				6 years 3 months 18 days
Dividend Yield				0%
Risk Free Interest Rate				0.30%
Series 68
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share)				$ 3.60
Share price at acceptance date				$ 2.38
Expected Volatility				67.22%
Expected life after factoring				6 years 3 months 18 days
Dividend Yield				0%
Risk Free Interest Rate				0.35%
Series 69
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share)				$ 3.60
Share price at acceptance date				$ 2.38
Expected Volatility				67.22%
Expected life after factoring				6 years 3 months 18 days
Dividend Yield				0%
Risk Free Interest Rate				0.35%
Series 71
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share)				$ 2.67
Share price at acceptance date				$ 2.35
Expected Volatility				66.81%
Expected life after factoring				6 years 2 months 12 days
Dividend Yield				0%
Risk Free Interest Rate				0.66%
Series 73
Disclosure Of Reconciliation Of Outstanding Share Based Payments [Line Items]
Exercise price per share AUD (in AUD per share)				$ 0
Share price at acceptance date				$ 2.09
Expected Volatility				66.48%
Expected life after factoring				2 months 12 days
Dividend Yield				0%
Risk Free Interest Rate				0.77%

Remuneration of auditors - Summ

Remuneration of auditors - Summary of Fees were Paid or Payable for Services Provided by the Auditor of the Parent Entity (Details) - USD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Audit and other assurance services
Total auditors' remuneration	$ 994,806	$ 945,568	$ 969,983
Price Water House Coopers \| Australia
Audit and other assurance services
Audit and review of financial reports	669,603	745,021	747,783
Other audit services	180,339	67,238	91,750
Total auditors' remuneration	849,942	812,259	839,533
Network Firms Of Price Water House Coopers \| Australia
Audit and other assurance services
Audit and review of financial reports	144,864	133,309	130,450
Total auditors' remuneration	$ 144,864	$ 133,309	$ 130,450

Losses per share - Summary of L

Losses per share - Summary of Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
(a) Basic (losses) per share
From continuing operations attributable to the ordinary equity holders of the company (in dollars per share)	$ (0.1108)	$ (0.1408)	$ (0.1633)
Total basic (losses) per share attributable to the ordinary equity holders of the company (in dollars per share)	(0.1108)	(0.1408)	(0.1633)
(b) Diluted (losses) per share
From continuing operations attributable to the ordinary equity holders of the company (in dollars per share)	(0.1108)	(0.1408)	(0.1633)
Total basic (losses) per share attributable to the ordinary equity holders of the company (in dollars per share)	$ (0.1108)	$ (0.1408)	$ (0.1633)
(c) Reconciliation of (losses) used in calculating (losses) per share
From continuing operations	$ (81,889)	$ (91,347)	$ (98,811)
Used in calculating basic (losses) per share	(81,889)	(91,347)	(98,811)
(Losses) attributable to the ordinary equity holders of the company used in calculating diluted losses per share	$ (81,889)	$ (91,347)	$ (98,811)
Weighted average number of ordinary shares used as the denominator in calculating basic losses per share (in shares)	739,039,547	648,899,589	605,064,036
Weighted average number of ordinary shares and potential ordinary shares used in calculating diluted losses per share (in shares)	739,039,547	648,899,589	605,064,036

Parent Entity Financial Infor_3

Parent Entity Financial Information - Summary of Parent Entity Financial Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Disclosure Of Parent Entity Financial Information [Line Items]
Current Assets	$ 81,658	$ 69,837
Total Assets	669,415	662,142
Current Liabilities	41,982	51,373
Total Liabilities	167,577	165,098
Shareholders' Equity
Issued Capital	1,249,123	1,165,309
Reserves
Accumulated losses	(820,805)	(738,916)
Total Equity	501,838	497,044	$ 581,397	$ 549,326
Loss for the period	(81,889)	(91,347)	(98,811)
Total comprehensive income/(loss) for the period	(82,463)	(91,578)	$ (100,126)
Parent
Disclosure Of Parent Entity Financial Information [Line Items]
Current Assets	28,850	4,948
Total Assets	890,120	853,380
Current Liabilities	11,941	9,210
Total Liabilities	15,282	13,227
Shareholders' Equity
Issued Capital	1,249,123	1,165,309
Reserves
Foreign Currency Translation Reserve	(261,377)	(227,441)
Share Options Reserve	86,274	82,619
Warrant Reserve	12,969	12,969
Accumulated losses	(212,165)	(193,317)
Total Equity	874,824	840,139
Loss for the period	(18,848)	(19,305)
Total comprehensive income/(loss) for the period	$ (18,848)	$ (19,305)

Parent Entity Financial Infor_4

Parent Entity Financial Information - Additional Information (Details) $ in Millions	12 Months Ended
	Jun. 30, 2023 USD ($)
CALHNI \| Top of range
Disclosure Of Parent Entity Financial Information [Line Items]
Aggregated milestone payments	$ 2.2

Segment Information - Additiona

Segment Information - Additional Information (Details)	12 Months Ended
Segment Information - Additional Information (Details)	Jun. 30, 2023 segment
Disclosure of operating segments [abstract]
Number of operating segment	1

Legal Proceedings - Additional

Legal Proceedings - Additional Information (Details)	Jun. 30, 2023 lawsuit
Legal proceedings provision [abstract]
Number of action lawsuits	1

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Details) $ / shares in Units, € in Millions, $ in Millions

1 Months Ended

12 Months Ended

Mar. 08, 2023

Dec. 21, 2022 $ / shares shares

Nov. 19, 2021 USD ($) $ / shares shares

Oct. 31, 2019 USD ($)

Oct. 12, 2018 USD ($)

Jun. 29, 2018 USD ($)

Jun. 30, 2022 USD ($) shares

Nov. 30, 2021 USD ($)

Feb. 28, 2020 USD ($)

Dec. 31, 2019 USD ($)

Oct. 31, 2018 USD ($)

Jun. 30, 2023 USD ($) segment shares

Jun. 30, 2023 AUD ($) segment

Jun. 30, 2022 USD ($) shares

Jun. 30, 2021 USD ($)

Sep. 30, 2023 USD ($)

Jun. 30, 2023 EUR (€) shares

Dec. 31, 2022 $ / shares shares

Dec. 31, 2017 EUR (€)

Disclosure of summary of significant accounting policies

Number of operating segment | segment

Revenue recognized from up-front payment as deferred consideration

$ 10,000,000

Receipt on non refundable up-front payment upon reaching product regulatory milestone

$ 25,000,000

Number of escalating milestone payments

Research and development tax incentive income(2)

3,506,000

$ 0

Tax incentive income, current

1,200,000

1,100,000

1,200,000

Tax incentive income

Pre launch inventory recognized

$ 28,900,000

$ 22,400,000

28,900,000

Trade and other receivables due for settlement term

60 days

Borrowings

96,634,000

$ 108,763,000

96,634,000

Remeasurement of borrowing arrangements

(678,000)

(382,000)

5,225,000

Variable lease payments

Floating Interest Rate

Disclosure of summary of significant accounting policies

Borrowings

Fixed interest rate

Disclosure of summary of significant accounting policies

Borrowings

$ 106,905,000

$ 116,495,000

$ 106,905,000

Warrants

Disclosure of summary of significant accounting policies

Number of shares warrants granted to purchase (in shares) | shares

1,769,669

2,224,669

1,769,669

2,224,669

Clinical Trials

Disclosure of summary of significant accounting policies

Pre launch inventory recognized

$ 10,000,000

Manufacturing and commercialization

Disclosure of summary of significant accounting policies

Pre launch inventory recognized

$ 7,000,000

$ 3,500,000

$ 7,000,000

13,100,000

Aggregated Turnover Below A$20.0 Millions

Disclosure of summary of significant accounting policies

Percentage of research and development to receive a refundable tax offset

18.50%

Top of range

Disclosure of summary of significant accounting policies

Trade and other payables maturity period

60 days

Top of range | Aggregated Turnover of A$20.0 Million or More

Disclosure of summary of significant accounting policies

Percentage of research and development to receive a refundable tax offset

16.50%

Top of range | Aggregated Turnover Below A$20.0 Millions

Disclosure of summary of significant accounting policies

Amount of annual aggregate turnover

$ 20

Bottom of range

Disclosure of summary of significant accounting policies

Trade and other payables maturity period

30 days

Bottom of range | Aggregated Turnover of A$20.0 Million or More

Disclosure of summary of significant accounting policies

Amount of annual aggregate turnover

$ 20

Percentage of research and development to receive a refundable tax offset

8.50%

Grunenthal

Disclosure of summary of significant accounting policies

Non-refundable upfront payment received

$ 15,000,000

$ 17,500,000

Milestone payment received

$ 2,500,000

Percentage of patients to provide regulatory harmonization, cost efficiencies and streamlined timelines

20%

Cumulative milestone payments reachable amount

$ 1,000,000,000

Revenue from performance obligations satisfied or partially satisfied in previous periods

$ 2,500,000

Revenue recognized relation to patent license agreement

Grunenthal | Top of range | Clinical, Manufacturing, Regulatory and Reimbursement Approval

Disclosure of summary of significant accounting policies

Non-refundable upfront payments receivable

112,500,000

Tasly

Disclosure of summary of significant accounting policies

Deferred consideration milestone consideration recognized

$ 20,000,000

Revenue recognized from up-front payment as deferred consideration

$ 10,000,000

TiGenix NV

Disclosure of summary of significant accounting policies

Royalty income

400,000

300,000

200,000

Milestone revenue in relation to patent license agreement

1,200,000

Regulatory milestone payment receivable | €

€ 1

TiGenix NV | Top of range

Disclosure of summary of significant accounting policies

Milestone revenue relating to non-refundable up-front payment | €

€ 10

J C R Pharmaceuticals Co L T D

Disclosure of summary of significant accounting policies

Royalties receivable under sales-based milestones

$ 8,700,000

7,100,000

8,700,000

7,200,000

Oaktree Capital Management, L.P.

Disclosure of summary of significant accounting policies

Borrowings term

5 years

Borrowings

$ 60,000,000

Borrowings, interest period

3 years

Borrowings principal amortization period

2 years

Percentage of premium for volume-weighted average price

15%

Issuance warrants exercised period

7 years

Remeasurement of borrowing arrangements within finance gains (loss)

(1,600,000)

Finance costs gains (loss) on remeasurement due to additional warrants issued

1,000,000

Finance costs gains (loss) on adjustment of carrying amount on financial liability

600,000

Oaktree Capital Management, L.P. | Refinancing and Expansion of Senior Debt Facility

Disclosure of summary of significant accounting policies

Percentage of share premium price

15%

Warrant exercise term

7 years

Oaktree Capital Management, L.P. | American Depositary Shares

Disclosure of summary of significant accounting policies

Exercise price (in dollars per share) | $ / shares

$ 3.70

$ 7.26

Oaktree Capital Management, L.P. | American Depositary Shares | Refinancing and Expansion of Senior Debt Facility

Disclosure of summary of significant accounting policies

Exercise price (in dollars per share) | $ / shares

$ 3.70

Oaktree Capital Management, L.P. | Warrants

Disclosure of summary of significant accounting policies

Number of shares warrants granted to purchase (in shares) | shares

455,000

1,769,669

Oaktree Capital Management, L.P. | Warrants | Refinancing and Expansion of Senior Debt Facility

Disclosure of summary of significant accounting policies

Number of shares warrants granted to purchase (in shares) | shares

455,000

Oaktree Capital Management, L.P. | Tranche One

Disclosure of summary of significant accounting policies

Borrowings

$ 60,000,000

Oaktree Capital Management, L.P. | Refinancing and Expansion of Senior Debt Facility

Disclosure of summary of significant accounting policies

Borrowings, interest rate

9.75%

Percentage of principal amount payable over two year

40%

Oaktree Capital Management, L.P. | Refinancing and Expansion of Senior Debt Facility | Tranche One

Disclosure of summary of significant accounting policies

Borrowings

$ 60,000,000

Oaktree Capital Management, L.P. | Refinancing and Expansion of Senior Debt Facility | Quarterly Payments

Disclosure of summary of significant accounting policies

Borrowings, interest rate

Oaktree Capital Management, L.P. | Refinancing and Expansion of Senior Debt Facility | Unpaid Interest

Disclosure of summary of significant accounting policies

Borrowings, interest rate

1.75%

NovaQuest Capital Management, L.L.C.

Disclosure of summary of significant accounting policies

Remeasurement of borrowing arrangements within finance gains (loss)

(900,000)

500,000

$ 4,800,000

Remeasurement of borrowing arrangements

$ (900,000)

$ (500,000)

NovaQuest Capital Management, L.L.C. | Fixed interest rate

Disclosure of summary of significant accounting policies

Borrowings principal amount

$ 40,000,000

Borrowings term

8 years

Borrowings, interest period

4 years

Borrowings, interest rate

15%

Borrowings principal amortization period

4 years

NovaQuest Capital Management, L.L.C. | Tranche One | Fixed interest rate

Disclosure of summary of significant accounting policies

Borrowings

$ 30,000,000

Oaktree Capital Management, L.P.

Disclosure of summary of significant accounting policies

Borrowings principal amount

$ 90,000,000

Borrowings, interest rate

9.75%

Oaktree Capital Management, L.P. | Tranche One

Disclosure of summary of significant accounting policies

Borrowings

$ 60,000,000

Borrowings, interest rate

9.75%

Oaktree Capital Management, L.P. | Tranche One | Forecast

Disclosure of summary of significant accounting policies

Borrowings

$ 30,000,000

Oaktree Capital Management, L.P. | Tranche Two

Disclosure of summary of significant accounting policies

Borrowings, interest rate